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ABSTRACT 
The non-Hodgkin's lymphomas (NHL) are a heterogeneous group of malignancies 
characterised by the uncontrolled proliferation of lymphoid cells. The Working Formulation 
divides these neoplasms into low, intermediate and high grade categories according to their 
natural history. Low grade NHL (LG-NHL) is clinically indolent whereas high grade NHL is 
more aggressive. Most LG-NHL patients respond well to chemotherapy, but are rarely cured, 
making death from LG-NHL virtually inevitable. In this study on LG-NHL patients, all patients 
received combination chemotherapy for 6 weeks, which consisted of cyclophosphamide, 
oncovin (vincristine) and prednisone (COP). After this treatment patients received either oral 
cyclophosphamide or alpha-interferon (cx-lFN) as maintenance treatment for a period of two 
years. The ability to predict patients' treatment response at diagnosis would be extremely 
helpful for both the patient and the clinician. This would enable appropriate therapy to be 
instituted at diagnosis, whether it be cyclophosphamide or cx-lFN, which might increase the 
subsequent survival of these patients, as this would prevent patients from receiving treatment 
to which they would not respond. Furthermore, patients who were unlikely to respond to 
either of these two treatments could be targeted for alternative treatment or form part of a 
cl inical research trial. LG-NHL patients were assessed at diagnosis for a number of immune 
parameters. These included:- natural killer activity (NKA), cx-lFN enhanced NKA, mitogen 
and antigen proliferation, lymphokine activated kill against both KS62 and Daudi targets, 
phenotypic analysis of circulating lymphocytes, assessment of IL-2 levels after mitogen 
stimulation of lymphocytes, as well as the determination of plasma IL-2 levels. All these 
above-mentioned parameters were serially monitored over time in an attempt to predict early 
relapse. A statistically significant reduction in percentage of circulating CD3+ and CD8+ 
cells and an increase in percentage NK cells was found in patients at diagnosis as compared 
to normal controls. A reduction in percentage of circulating NK cells over time appeared to 
be a good prognostic indicator and an increase in percentage NK cells a poor prognostic 
indicator in this group of patients, although this was not statistically significant. When the in 
vitro cx-lFN enhanced NKA was indicated as a percentage of NKA, a negative correlation 
appeared to exist between this in vitro response to cx-lFN and the in vivo response, although 
this was not statistically significant (i .e. those patients showing the least cx-lFN enhanced 
NKA were those that responded clinically and those with the highest cx-lFN augmented NKA 
either relapsed or transformed to a higher grade of NHL). By incorporating the percentages 
of circulating lymphocytes present in the peripheral blood, into the multivariate discriminant 
analysis, it was possible to derive formulae to enable the prediction of response to either cx-
lFN or cyclophosphamide. This was a particularly exciting and apparently novel finding. The 
work presented here has therefore established both a possible negative indicator of cx-lFN 
response (a high in vitro cx-lFN response) and a positive indicator (the formula generated in 
the multivariate discriminant analysis using the flow cytometric phenotypic analysis). By 
making using of both of these factors, it would increase the chances of patients being 
selected for appropriate forms of treatment and minimise the chances of patients suffering a 
relapse. The Kaplan-Meier curve indicated that cyclophosphamide treatment was more 
beneficial than n-lFN therapy in this group of patients, although this did not attain statistical 
significance. Verification of all of these above-mentioned findings would need further 
confirmation in a larger study. 
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1. INTRODUCTION 
1.1.0. NON-HODGKIN'S LYMPHOMA 
The non-Hodgkin's lymphomas (NHL) are a heterogeneous group of neoplasms, named after 
Thomas Hodgkins who, in 1832, first described patients with tumours of the "absorbent 
glands". Hodgkin's disease can be distinguished from NHL by the presence of Reed-
Sternberg cells. Reed-Stem.Jerg cells are considered to be the characteristic tumour cells of 
Hodgkin's disease. These cells are large with eosinophilic cytoplasm, striking nuclear 
morphology and a large eosinophilic inclusion-like nucleolus with a well-defined nuclear 
membrane and pale-staining chromatin. Classically these cells have two mirror-image 
nuclei . Also present are large cells of a similar appearance but with a single round nucleus 
and a very large nucleolus, designated mononuclear Hodgkin's cells (Jaffe et al. , 1993; 
Hancock, 1995; Sloane, 1987; Burrichter et al., 1987; Bain et al. , 1996). The term lymphoma 
includes a number of neoplasias in which the malignant process usually involves the lymph 
nodes, spleen, and other lymphoid organs, but occasionally extralymphatic tissue is involved 
(Babier and Stossel , 1994). The term NHL includes more than a dozen neoplasms of the 
lymphoid system (Aisenberg, 1995). NHL's are characterised by the uncontrolled 
proliferation of lymphoid cells, predominantly B cells (Jaffe et al. , 1993; Hancock, 1995). 
Depending on the type and stage of evolution of NHL, malignant cells may be present in the 
peripheral blood, similar to the lymphocytic leukemic pictu:e. There can be considerable 
overlap between lymphomas and leukemias (Babier and Stossel , 1994). All lymphomas are 
of monoclonal origin (Cotran et al., 1989; Ozer et al., 1983; Braylan et al., 1975). Clonality of 
B-cells can be shown by the detection of either 'J... or K light chain expression, rather than a 
mixture of both 'J... or K light chains, which would be shown by normal B-cells. Malignant cells 
present in the haematological malignancies may not multiply at a rapid rate. Multiplication is 
often slower than in normal haemopoietic stem cells. The problem arises as a result of the 
failure of these cells to differentiate, as well as the immortality of these cells. These 
neoplastic cells suppress normal bone marrow cells and may invade normal tissue, impairing 
its function (Babier and Stossel , 1994; Smith, 1996). An oncogene that is associated with 
certain lymphomas is Bcl-2, which contributes to neoplastic expansion primarily by 
prolonging cell survival through its ability to inhibit genetically programmed cell-death 
(apoptosis). Bcl-2 is an example therefore of an oncogene that does not affect cell 
proliferation, but causes an increase in cell survival (Babier and Stossel, 1994; Smith, 1996; 
Magrath, 1997). Oncogenes can be defined as genes that cause cell transformation via the 
production of transforming proteins (Widnell and Pfenninger, 1990). Apoptosis appears to 
be a mechanism for removing cells that are either:- redundant surplus cells; have completed 
their crucial yet temporary role; may be harmful to the organism (in this case lymphoma cells) 
(Osborne and Schwartz, 1995). See Figure 1 for a diagrammatic representation of the cell 
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cycle indicating the influence that the oncogene Bcl-2 has on this cycle. It has been 
proposed that the absence of cell death rather than an increased proliferation of malignant 
cells may be responsible for the development of NHL, particularly low grade NHL (LG-NHL). 
Bcl-2 blocks apoptosis and decreases the normal rate of cell death in follicular lymphomas 
(Shetty et al., 1995). 
NHL is diagnosed on the histological examination of a lymph node biopsy for effacement of 
normal architecture by a monotonous ir filtrate of cells. The cell size is noted and the 
lymphoma is grouped into either a small or large cell class. When the majority of cells 
present are large with vacuolated nuclei and multiple large nucleoli, the lymphoma is 
classified as a large cell lymphoma. The arrangement of these cells is also noted, whether 
they have a tendency to form nodules, follicles, or a diffuse pattern throughout the node. The 
lymphoma is further described morphologically by how closely the cells present resemble 
normal lymphocytes. If the cells closely resemble lymphocytes, the lymphoma is described 
as being well-differentiated, as opposed to being poorly-differentiated, if the cells do not 
resemble lymphocytes. The nuclei of some lymphocytes have predominant infoldings and 
cleavages, and are thus further subdivided into cleaved or uncleaved (Babior and Stossel, 
1994). 
These neoplasms range from low grade, which is clinically indolent, to high grade, which is 
an aggressive form and unless treated, rapidly fatal (Jaffe et al. , 1993; Hnncock, 1995). LG-
NHL represents approximately 25% of all NHL patients (Kwak et al., 1994). LG-NHL patients 
are able to survive for several years irrespective of the implementation of treatment, which 
serves merely to alleviate the unpleasant symptoms (Magrath, 1990). LG-NHL's have a high 
proportion of resting cells and a low proportion of cycling cells. This low proliferative rate of 
LG-NH L's account for the typically long median survival of these patients (Grogan, 1996). 
Most LG-NHL patients respond well to chemotherapy, but patients are rarely cured (Magrath, 
1990; Hancock, 1995). Chemotherapy can be defined as the treatment of malignant stem 
cells by the use of medications and hormones. Due to the fact that chemotherapy usually 
penetrates tissue well , it can be used in the treatment of patients with widely disseminated 
NHL (Babior and Stossel, 1994). LG-NHL's can transform from an indolent to a more 
aggressive form of NHL (Babior and Stossel, 1994). LG-NHL's generally become widely 
disseminated throughout the body and median survival time is 7 -8 years (Magrath, 1990; 
Berkow and Fletcher, 1987; Hancock, 1995; Horning, 1994-a). Two thirds of LG-NHL 
patients survive for 5 years (Aisenberg, 1995). High grade lymphomas generally respond 
well to chemotherapy, with approximately one third of the patients being cured (Hancock, 
1995). 
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Standard therapeutic regimens for LG-NHL have failed to cure these patients, and the 
median survival of LG-NHL patients has remained the same for the past 30 years. The 
reason for this unfavourable outcome in LG-NHL patients may be due to the fact that low 
grade lymphomas have a low mitotic rate and cytotoxic therapy is aimed primarily at rapidly 
proliferating cells. This low mitotic rate accounts for the relatively long natural history of this 
disease, but also explains why cytotoxic treatment is unable to cure these patients. It is clear 
that innovative treatment approaches are necessary. These methods could include:- agents 
which would stimulate apoptosis of lymphoid cells, the use of high dose chemotherapy to kill 
proliferating cells, and biologic therapies to eliminate minimal residual disease (Jaffe et al. , 
1993; Horning, 1994-b). 
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1.1.1. FEATURES OF NHL 
The features of NHL are summarised in Table 1. 
TABLE 1. THE FEATURES OF NHL 
Factor Feature Reference 
Mortality Account for 3-5% of deaths from malignant neoplasias. Magrath, 1990. 
Morbidity Incidence increased by 50% from 1973-1988. Greiner et al., 1995 
Overall incidence in UK = 8 cases per 100 000 per year. Hancock, 1995. 
Age at onset More common in elderly, but occurs in all age groups with a Magrath, 1990; Berkow and Fletcher, 1987; 
slight peak around adolescence. Low-grade 37% = 35-64 Linch, 1990; 
years; 16% <35 years. Rare in children. 
Male:female 6:5 Hancock, 1995. 
ratio 
Aetiology Exposure to hair dye, herbicides, pesticides and fertilisers. Greiner et al., 1995; Carli et al., 1994; 
Epidemiological evidence suggest that farm and meat Kwak et al., 1993; Fritschi and Siemiatycki, 
workers are at greater risk from transmission of oncogenic 1996; Kwak et al., 1994. 
viruses. Grain mill workers and motor vehicle and resin 
product manufacturing workers also appear at greater risk. 
Textile workers also seem to be at higher risk due to 
increased exposure to copper dust and ammonia . People 
employed in the agricultural, forestry and fishing industries and 
the construction and leather industries have a greater risk of 
developing NHL. At increased risk were plant farmers and 
gardeners, painters and plasterers, carpenters, brick and 
stone masons, plumbers, and roofers. Possible exposure to 
chlorophenols or phenoxy acids appeared to be the common 
agent in these occupations responsible for the higher risk of 
NHL. Increased risks were found among metal working, hair-
care, painting and dry-cleaning occupations. 
Clinical Low-grade - usually asymptomatic lymphadenopathy. Berkow and Fletcher, 1987; Jacobs and 
features May present with systemic symptoms. Bird,1983; Linch, 1990. 
Treatment Symptomatic for low-grade. Hancock, 1995.; Magrath, 1990; 
Intensive chemotherapy for high-grade. Ersboll et al., 1985. 
Diagnosis Histological study of excised tissue. Berkow and Fletcher, 1987. 
Survival Low-grade - median 7-f!, years. Hancock, 1995. 
1.1.2. CLASSIFICATION OF NHL 
Much confusion and controversy exists over the classification of NHL. There are a number of 
different categorisation schemes, which results in difficulties when attempting to compare 
clinical therapeutic studies in which different systems have been employed (National Cancer 
Institute, 1982; Ersboll et al. , 1985; Nathwani, 1979; National Cancer Institute, 1985; Pugh, 
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1993). Further problems arise due to the fact that some NHL categories are easier to 
recognise and others more subjective (Harris et al., 1994). Only the well-known and widely 
utilised classification schemes will be discussed here. In this study the Working Formulation 
was used, so a comparison will be made between that and other schemes to facilitate any 
correlation between trials. 
The Rappaport Classification, proposed in 1956 and modified in 1966, has been the most 
commonly utilised in the United States (Table 2). This classification combines cytological 
appearance of cells with their growth pattern as either nodular aggregates or a diffuse 
infiltration throughout the node (Rappaport et al. , 1956; Byrne, 1977; Nathwani et al., 1978; 
National Cancer Institute, 1985). This classification scheme was proposed prior to the 
knowledge of lymphocyte subsets, their activation and their specific anatomic location within 
the lymph nodes (Cotran et al. , 1989; Lukes and Collins, 1974-b). 
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TABLE 2. MODIFIED RAPPAPORT CLASSIFICATION (1966) 
(Magrath, 1990; Berard, 1987; Ezdinli et al., 1979). 
Working 
Classification Formulation Description of terms 
related 
category 
Nodular Tumour cells dumped into recognisable nodules thrOlJ! hout the 
lymph node. Better prognosis than diffuse. 
Lymphocytic, wen differentiated A Well differentiated - Resembled normal lymphocytes in size and 
morphology. More differentiated the cell type, the greater the 
survival advantage than patients with large immature cell types. 
Lymphocytic, poorly differentiated B Poorly differentiated - Lymphocyte-like cells, but containing 
irregular and angulated nuclei. 
Mixed, lymphocytic and histiocytic C Mixture of lymphocytes and between 30 - 50% large tumour cells . 
Histiocytic D Composed of greater than 50% large tumour cells containing 
abundant cytoplasm. 
Diffuse No follicles present in lymph node. Proliferating cells diffusely 
infiltrate or efface the architecture of the node. 
Lymphocytic, well differentiated without plasmocytoid A Well differentiated - Resembled normal lymphocytes in s ize and 
features morphology. More differentiated the cell type, the greater the 
survival advantage than patients with large immature cell types. 
Lymphocytic, well differentiated with plasmacytoid A 
features 
Lymphocytic, poorly differentiated E Poorly differentiated - LymphocytEHike cells, but containing 
irregular and angulated nuclei. 
Lymphoblastic, convoluted I 
Lymphoblastic. non-convoluted I 
Mixed, lymphocytic and histiocytic F Mixture of lymphocytes and between 30 - 50% large tumour cells. 
Histiocytic without sclerosis G 
H istiocytic with sclerosis G 
Burkitt's tumour J 
Undifferentiated J 
Malignant lymphoma, unclassified 
Composite lymphoma 
See Table 5 for description of Working Formulation and related categories. 
In 1973, the Lukes-Collins classification was proposed and modified in both 1974 and 1976 
(Table 3) (Lukes and Collins, 1974-a; Lukes and Collins, 1974-b; Lennert et al., 1975; 
Nathwani et al. , 1978; Lennert et al. , 1983). This scheme attempted to overcome the 
shortcomings of the Rappaport classification (Cotran et al., 1989). Lukes and Collins 
categorised the NHL's according to their cell of origin into tumours of t:,ree different cell 
types:- (1) T cells, (2) B cells, or (3) histiocytes (Cotran et al., 1989; Lukes and Collins, 
1974-a; Lukes and Collins, 1974-b; Lukes, 1971 ; Jaffe et al., 1993). A major disadvantage of 
this classification system is the lack of correlation with prognosis. The cumbersome 
terminology of this classification scheme is also a limitation (Dorfman, 1977). 
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TABLE 3. LUKES AND COLLINS CLASSIFICATION (1974) 
(Magrath, 1990). 
Lukes - Collins classification 
Undefined cell type 
T-cell , type , small lympt-ocytic 
T-cell , type, Sezary-mycosis fungoides (cerebriform) 
T-cell type, convoluted lymphocytic 
T-cell type , immunoblastic sarcoma (T-cell) 
B-cell type, small lymphocytic 
B-cell type, plasmacytoid lymphocytic 
Follicular centre cell , small cleaved 
Follicular centre cell , large cleaved 
Follicular centre cell , small non-cleaved 
Follicular centre cell , large non-cleaved 
lmmunoblastic sarcoma (B-cell) 
Subtypes of follicular centre cell lymphomas 
1. Follicular 
2. Follicular and diffuse 
3. Diffuse 
4. Sclerotic with follicles 
5. Sclerotic without follicles 
Histiocytic 













See Table 5 for description of Working Formulation and related categories. 
A European group in 1974 proposed the "Kiel classification", due to the fact that the concepts 
were based chiefly on propositions by Lennert and co-workers from the University of Kiel , 
West Germany (Gerard-Marchant et al., 1974; Lennert et al., 1975; Nathwani, 1979; Lennert 
et al. , 1983). This categorisation has undergone several modifications both in 1975 and 
again in 1978 (Table 4). The Kiel classification is widely accepted in many European 
countries, which poses a dilemma in the comparison of therapeutic results across the Atlantic 
(Ersboll et al., 1985; Lennert et al. , 1975; Nathwani, 1979). NHL's are divided into either low 
or high grade malignancy. Low grade malignancies end with the suffix "-cytic or -cytoid" and 
high grade tumours, the suffix "-blastic".(Gerard-Marchant et al. , 1974; Lennert et al., 1975; 
Ersboll et al., 1985). In the Kiel classification, criteria are presented which are both 
confusing and contradictory and the majority of pathologists find great difficulty in adopting 
this scheme for regular diagnostic purposes (Byrne, 1977). 
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TABLE 4. KIEL CLASSIFICATION (1974) 
(Magrath, 1990). 
Kiel classification 
Low-grade malignancy (ends with suffix "-cytic or -cytoid") 




Centroblastic-centrocytic, follicular without sclerosis 
Centroblastic-centrocytic, folticular with sclerosis 
Centroblastic-centrocytic, follicular and diffuse, without sclerosis 
Centroblastic-centrocytic, follicular and diffuse, with sclerosis 
Centroblastic-centrocytic, diffuse 
Low-grade malignant lymphoma, unclassified 
High-grade malignancy (ends with suffix "-blastic") 
Centroblastic 
Lymphoblastic, Burkitt's type 
Lymphoblastic, convoluted cell type 
Lymphoblastic, other (unclassified) 
lmmunoblastic 
High-grade malignant lymphoma, unclassified 














See Table 5 for description of Working Formulation and related categories. 
A further classification system, the Working Formulation, was devised with a strong clinical 
bias (Cotran et al. , 1989; National Cancer Institute, 1982; National Cancer Institute, 1985). 
This scheme was intended to merely clarify the confusion and not as a new classification. 
The Working Formulation is however widely used as a classification scheme mostly in 
America. This poses a problem in comparing different clinical trials, as the European 
pathologists favour the Kiel classification. By using the Working Formulation, pathologists 
and clinicians world-wide may continue using terminology from any classification and by 
using this formulation, it is possible to translate terminology from one scheme to another, 
thereby assisting in comparisons of clinical therapeutic trials (National Cancer Institute, 
1982; National Cancer Institute, 1985; Pugh, 1993). The Working Formulation is entirely a 
morphological classification, based on clinicopathologic correlative studies and without any 
immunological methods being employed (National Cancer Institute, 1982; Berard et al. , 
1987). NHL's are separated into three different groups; low, intermediate and high grade, 
which correlate with natural history and prognosis and aids in clinical decision making 
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(Magrath, 1990; Cotran et al., 1989; Berkow and Fletcher, 1987; Smith, 1996). Each of these 
above mentioned prognostic categories contain various morphological groups, making use of 
a combination of the Rappaport and Lukes-Collins terminology (Cotran et al. , 1989; Ersboll et 
a/. , 1985; Sommers and Rosen, 1983). The Working Formulation, however, does not take 
into consideration immunologic data and this has short-comings when it is used as an 
alternative classification. The Working Formulation does not distinguish between T and B 
lymphoid systems, or the stages of differentiation within each system. This results in the 
grouping together of biologically different entitias and the separation of closely related ones 
(Pugh, 1993). See Table 5 for description of Working Formulation and related categories. 
Even more recently, in 1994, a Revised European-American Classification (REAL 
classification) was proposed (Table 5). The classification system was given this name, as it 
seeks to revise and co-ordinate the currently used European and American lymphoma 
classifications. The REAL classification builds on the Kiel classification, simplifying some 
aspects and including some lymphomas that were omitted in the Kiel classification (e.g. 
MALT lymphomas). It was felt that the understanding of lymphomas, as well as the 
techniques available immunologically and in molecular biology over the past 15 to 20 years, 
has made it necessary to revise the classification scheme, as a purely morphological basis is 
no longer sufficient. In this scheme, the lymphomas are divided into three major categories: 
B-cell neoplasms, T-cell and postulated natural killer neoplasms, and Hodgkin's disease. 
The NHL's are also divided according to prognosis depending on the clinical behaviour of a 
tumour. The use of immunophenotyping and special staining techniques as well as 
molecular genetic studies are also included (Harris et al. , 1994; Chan et al. , 1994; Bain et 
al. , 1996; Pittaluga et al. , 1996). An advantage of this scheme is that it employs commonly 
used terminology with minimal introduction of new terms. This scheme has drawbacks in that 
many of the methods employed are not available at all medical centres. This classification 
scheme appears to be unnecessarily complex and does not correlate clinically as is the case 
with other classification systems. The REAL classification does not define prognostic 
Qroups. It also appears to be more scientifically correct than clinically useful and needs to be 
formally tested for reproducibility (Meijer et al. , 1995; Aisenberg, 1995; loachim, 1996; Mason 
and Gatter, 1995; Rosenberg, 1994; Bonadonna, 1995). 
Table 5 compares the REAL classification and the Working Formulation, as well as 
describing and giving the relevant category of the Working Formulation. This aids in the 
comparison of the Working Formulation with all the other classification schemes previously 
described. 
21 
TABLE 5. COMPARISON OF WORKING FORMULATION AND REAL 
CLASSIFICATION 
(Hiddemann and Unterhalt,1994). 
Working Formulation REAL Classification 
Low.grade lymphomas 
Small lymphocytic (A) lymphocytic 
L ymphoplasmocytoid 
Marginal zone 
Follicular small cleaved (B) Follicle centre, follicular 
Follicular mixed (C) (small and mixed) 
Intermediate-grade lymphomas 
Follicular large (D) Follicle centre, large 
Diffuse small cleaved (E) Mantle cell 
Diffuse mixed (F) Follicle centre, diffuse (small) 
Diffuse large cell (G) 
High.grade lymphomas 
lmmunoblastic, large cell (H) Diffuse large B cell 
lymphoblastic, convoluted and 8-precursor large B cell 
non-convoluted (I) lymphoma/leukemia 
lymphoblastic, small-non-cleaved (J) 
Th~ Ann Arbor Staging System, which was originally described for Hodgkin's disease, is also 
used in NHL (Table 6). The biologic characteristics of Hodgkin's disease and NHL, however, 
differ as NHL does not usually follow an orderly progression via adjacent nodal groups and is 
usually at an advanced stage at diagnosis. The Ann Arbor Staging System is therefore found 
to have little prognostic value in NHL, although it continues to be used in staging NHL 
patients (Linch, 1990; Jacobs and Bird, 1983; Rosenberg et al., 1971 ; Smith, 1996; Denham 
et al., 1996). 
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TABLE 6. THE ANN ARBOR STAGING 
(Magrath, 1990). 
Stage I Involvement of a single extranodal organ or site 
(1E) 
Stage II Involvement of two or more lymph node regions 
on the same side of the diaphragm, or 
localised involvement of an extranodal site or 
organ (2E) and of one or more lymph nod~ 
regions on the same side of the diaphragm 
Stage Ill Involvement of lymph node regions on both 
sides of the diaphragm, which may also be 
accompanied by localised involvement of an 
extranodal organ or site (3E) or spleen (3S) or 
both. (3SE) 
Stage IV Diffuse or disseminated involvement of one or 
more distant extranodal organs with or without 
associated lymph node involvement 
Category A Asymptomatic 
Category B Symptomatic (Fever > 38°C, night sweats, 
and/or weight loss > 10% of body weight in the 
six months preceding admission are defined as 
systemic symptoms) 
The majority ol LG-NHL are at stage Ill or IV when detected, with only 15 to 20% being 
diagnosed at stages I and II (Berkow and Fletcher, 1987; Hiddemann and Unterhalt, 1994; 
Vose et al., 1991 ). By the time sufficient neoplastic cells have accumulated in a patient to 
produce symptoms, more than 90% of NH L's are already disseminated (Magrath, 1990). 
A major problem in any study involving LG-NHL patients, is that years of follow-up are 
necessary before any valuable results can be shown, due to the long natural history of this 
disease (Witzig et al. , 1995). 
1.1.3. CLINICAL FEATURES/ASPECTS OF NHL 
The incidence of NHL has increased by 150% in the USA during 1950-1985. Incidence rates 
have increased in all age groups (except the very young), all race groups, over all 
geographic areas of the USA, and in both sexes. A particular observation has been the 
marked increase in older age groups. The incidence of NHL continues to rise world-wide. 
This increase is independent of the acquired immune deficiency syndrome (AIDS) epidemic. 
Reasons for this higher incidence include the fact that NHL was often misdiagnosed as 
another malignancy, as well as the fact that some NHL were not previously classified 
correctly. These factors can still not account for such a dramatic increase in the incidence of 
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this disease. Although the rise in the incidence of NHL is apparent over all ages, the most 
striking increases are among the older age groups. As the greatest increase occurs in the 
elderly, this may disprove the theory that some occupational groups are at an increased risk 
of developing NHL, as the effect should surely be apparent in younger people. An increased 
exposure to herbicides has been suggested as a cause for this escalation in developed 
countries. Exposure to hair dye, herbicides, pesticides and fertilisers has also been 
implicated. Epidemiological evidence suggest that farm and meat workers are at greater risk 
from transmission of oncogenic viruses. Grain mill workers and motor vehicle ar.d resin 
product manufacturing workers also appear at greater risk, as too are textile workers, who 
seem to be at higher risk due to increased exposure to copper dust and ammonia. People 
employed in the agricultural , forestry and fishing industries and the construction and leather 
industries have an increased risk of developing NHL. Plant farmers and gardeners, painters 
and plasterers, carpenters, brick and stone masons, plumbers, and roofers are at increased 
risk of NHL which is possibly due to exposure to chlorophenols or phenoxy acids which 
appears to be the common agent in these occupations. Increased risks were also found 
among metal working, hair-care, painting and dry-cleaning occupations. A recent article 
published by McMichael and Giles (1996) suggests that the increase in the incidence of 
NHL may be attributed to exposure to ultraviolet radiation which causes systemic immune 
suppression. The incidence of NHL appears to be affected more by systemic immune 
suppression than that of any other malignancy. Autoimmunity has also been recognised as a 
factor in lymphomagenesis Viruses also play an etiological role in lymphomagenesis, 
especially Epstein-Barr virus and human T-cell leukaemia virus-1 . Hepatitis C virus has also 
been implicated in lymphoma. It appears therefore, that overstimulation as well as 
suppression of the immune system may predispose patients to lymphoma (Chappuis and 
Sappino, 1995; Aisenberg, 1995; Greiner et al., 1995; McMichael and Giles, 1996; Hjalgrim 
et al. , 1996; Carli et al. , 1994; Kwak et al., 1993; Fritschi and Siemiatycki , 1996; Kwak et al. , 
1994; Kwak and Longo, 1996; Gale et al. , 1994). 
LG-NHL's are usually first recognised by painless enlargement of one or more peripheral 
lymph nodes and progress slowly. These lymphomas may cause few problems for the patient 
initially. The enlargement of internal lymph nodes may cause symptoms by encroaching on 
internal organs. As a result of the generalised distribution of lymphoid tissue throughout the 
body, practically any organ can become affected should NHL arise in or near it. Bone 
marrow infiltration is frequent in lymphoproliferative disorders. When the bone marrow is 
extensively involved, the haemoglobin concentration and platelet and neutrophil counts may 
be reduced. In NHL's of B-cell lineage, bone marrow infiltration is more common in LG-
NHL's than in high grade NHL's. Bone marrow infiltration is observed more often in B-cell 
lymphomas than in T -cell lymphomas. The clinical importance of bone marrow involvement 
is dependent on the category of NHL. Usually the prognosis of LG-NHL's patients with bone 
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marrow involvement remains unaffected (Babior and Stossel, 1994; Bain et al. , 1996; 
Grogan, 1996). 
Prognostic factors in LG-NHL (summarised in Table 7) as described by some authors, 
include: tumour burden - determined by factors such as Ann Arbor stage, bone marrow 
involvement, J32microglobulin and number of extranodal sites; host factors - including age, 
sex, systemic symptoms, haemoglobin; presence of B symptoms (fever, night sweats, 
unexplai11ed weight loss >10%) and response to treatment. Based on these factors, 
prognostic indices have been formulated (Horning, 1994-a; Shipp et al., 1993; Kwak et al., 
1993; Coiffier et al. , 1993; Pasquini et al., 1994). The International Prognostic Index 
considers age, performance status (according to the Eastern Cooperative Oncology Group 
as discussed in Section 1.1.5.1.), stage, extranodal involvement and elevated serum lactate 
dehydrogenase, but does not include tumour cell proliferation rate (Joensuu et al., 1994; 
Hermans et al., 1995). Witzig and co-workers (1995), recommend that a measure of tumour 
cells in the $-phase of the cell cycle be included in this prognostic index (see Figure 1 for a 
diagrammatic representation of cell cycle). The S-phase of the cell cycle is the DNA 
synthesis phase, where DNA content doubles in preparation for cell division. The 
proliferative rate of NHL can be measured by estimating the proportion of cells in the DNA 
synthesis phase. DNA binding dyes, such as propidium iodide are used, and DNA content 
histograms generated by flow cytometry. The percentage of $-phase fraction can then be 
determined using computer software. Al ,ernatively, cell proliferation can also be determined 
by staining for the nuclear antigen Ki-67, which is a monoclonal antibody that marks a 
nuclear protein present in cycling cells. The prognostic value of the $-phase fraction varies 
in different studies, but it has been shown that LG-NHL patients demonstrating tumours with 
less than or equal to 5% Ki-67 positive cells, had a statistically significant better chance of 
survival (Witzig et al. , 1995; Miller TP et al. , 1994; Armitage, 1993). The mean S-phase 
fraction for the different grades of NHL, according to the Working Formulation, were 
determined in a study by Joensuu and co-workers (1994). The mean S-phase fraction for 
LG-NHL was found to be 4.8%, for Intermediate grade NHL, 10.3% and for High grade NHL, 
11 %. These groups could be further divided prognostically into subgroups by the use of 
these S-phase fractions and the comparison to the median for each group i.e. Low grade, 
Intermediate grade, or High grade. 
Parker and co-workers (1994), found that LG-NHL patients with lymphocyte counts below 1 x 
109 /I prior to the commencement of treatment, demonstrated worse survival than patients with 
higher lymphocyte counts. The majority of patients presented with lymphocyte counts 
between 1-3 x 109/1 , however patients with lymphocyte counts of greater than 3 x 109/1 
showed similar survival. In this same study, it was shown that serum immunoglobulin (lg) 
levels correlated with survival. Using a cut-off point of 1 Ogll for lgG, it was found that 
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patients with< 109/I showed significantly worse survival than patients with lgG of> 109/1. It 
was speculated that this finding was as a result of disease progression rather than a pre-
existing immunodeficiency. This is possibly due to the fact that the malignant B cells do not 
produce immunoglobulin and as their numbers increase relative to normal B cells this causes 
a decrease in the serum immunoglobulin. 
Early detection of relapse following a response in NHL patients is important as this might 
increase the subsequent survival of the patient. In a study conducted by Weeks and 
colleagues (1991 ), only 6% of relapses were detected before the appearance of overt 
symptoms. This was despite diligent serial follow-up measures which included radiographic 
studies and gallium scans. In this same study only serum lactate dehydrogenase 
successfully detected preclinical relapse with a sensitivity of 42% and a specificity of 85% 
(Kwak et al., 1993). Clearly a more sensitive method for detection of relapse is necessary. 
TABLE 7. PROGNOSTIC FACTORS IN LG-NHL AT DIAGNOSIS 
(Horning, 1993). 
Clinical characteristic 
Limited Ann Arbor stage 
Age(> 60-70 years) 
Male gender 
Systemic symptoms 
Good performance status 
(according to the Eastern Cooperative Oncology Group 
criteria as discussed in section 1 .1 .5 .1.) 
~ 2 extranodal sites 
Bulky tumour 
Hepatosplenomegaly 
> 20% bone marrow involvement 
Normal hemaglobin 
Elevated LOH 














(LOH= lactic dehydrogenase) 
1.1.4. PATHOPHYSIOLOGY OF LOW-GRADE 8-CELL NHL 
Malignant B cells display a lack of differentiation as a result of genotypic transformation, 
probably caused as a result of structural chromosome abnormalities affecting genes involved 
in cell cycle control (such as Bc/-2). Mutations have been demonstrated in lymphomas which 
could deregulate B-cell development. Cytokines do not appear to play a primary role in 
lymphomagenesis, however they may provide stimuli for malignant clone proliferation. In 
vitro studies have found secretion of cytokines such as tumour necrosis factor (TNF) alpha, 
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interleukin (IL) 6 and 8-cell growth factor (IL-4) by malignant B cells. T-cell cytokines such 
as IL-2, IL-4 and IL-10 enhanced the proliferation in vitro (Schuler et al., 1995). IL-6 appears 
to be a growth factor in vitro for some lymphomas (Kwak et al., 1994). Low-grade malignant 
B cells are difficult to culture in vitro thus highlighting the necessity of growth stimulation 
provided by cytokines and direct cell-cell interactions with either T lymphocytes or other 
cells. Malignant B cells accumulate in lymphoid and extralymphatic tissue, which could be as 
a result of an inhibition of programmed cell death (apoptosis). See Figure 1 for a 
diagrammatic representation of the cell cycle indicating the influence that the oncogene Bcl-2 
has on this cycle. In vitro inhibition of malignant B cell apoptosis has been described for IL-
4, interferon (IFN) gamma (y) and IFN alpha (a) (Schuler et al., 1995). 




(Go) __ __,..,_ Differentiated End Cell 
/ /-- competenre factors 
(G1) 
RNA and protein synthesis 
Death (Apoptosis) 
....__ Progression factors 
....__ Start 
FIGURE 1. A diagrammatic representation of the cell cycle. 
The cell cycle can be divided into four phases: G1 (G = gap), S, G2 and M. 
G1 phase. Immediately after mitosis, cells enter the G1 phase. The cell synthesises and accumulates 
RNA, enzymes and proteins necessary for DNA synthesis. Cells either progress irreversibly into DNA 
synthesis (S phase) or become resting cells and enter Go phase. These cells may either remain in Go, 
return to the cell cycle, or become differentiated end cells, which are incapable of cell division. The 
proposed role of the oncogene, be/, is clearly indicated. 
S phase. The S phase starts as soon as DNA synthesis begins. DNA content doubles in preparation 
for cell division. Thereafter cells enter the G2 phase. 
G2 phase. This is the pre-mitotic phase. DNA synthesis ceases, but specialised protein and RNA 
synthesis continues. Microtubular precursors of the mitotic spindle are synthesised. Cells shift from G2 
to M phase. 
M phase. This is the mitotic phase. Protein and RNA synthesis cease abruptly. Genetic material is 
segregated in an orderly manner. Cell division occurs and the two daughter cells enter either G1 or Go 
phase (Babior and Stossel, 1994; Widnell and Pfenniger, 1990). 
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1.1.5.0. TREATMENT OF NHL PATIENTS 
Treatment of NHL has changed very little over the past decades (Ersboll et al., 1985; 
Hiddemann and Unterhalt, 1994). As mentioned previously, LG-NHL patients are able to 
survive for several years whether or not they undergo treatment. Treatment serves merely to 
alleviate the unpleasant symptoms of NHL (Macgrath, 1990). The treatment of choice for 
NHL patients diagnosed at stage I and II is irradiation, although, as mentioned previously, 
patients are rarely diagnosed at these stages (Hiddemann and Unterhalt, 1994). Treatment 
of stage Ill and IV LG-NHL patients remains controversial, with a ''watch and wait" policy 
being recommended by some since aggressive combination chemotherapy has not been 
shown to significantly impact the overall survival of patients (Flecknoe-Brown, 1995; 
Hiddemann and Unterhalt, 1994; Vose et al., 1991). LG-NHL are thus incurable using 
standard chemotherapy regimens, because although most NHL patients respond well to 
current chemotherapy this response is not sustained (Schuler et al. , 1995). Attaining a 
response in these patients with chemotherapy is not a major clinical hurdle; rather, 
maintaining the remission is the major clinical challenge as relapse is fairly common and 
treatment is not curative and does not affect median survival. The continuous relapse 
pattern makes death from LG-NHL virtually inevitable (Macgrath, 1990; Parkinson et al., 
1993; Rohatiner, 1991 ; Gaynor and Fisher, 1991 ). The goal when treating LG-NHL patients, 
is to selectively destroy the tumour stem cells with minimal damage to healthy stem cells. 
Surgery is usually not a viable option in the treatment of LG-NHL patients, due to the fact that 
tumour cells are usually disseminated at diagnosis (Babier and Stossel, 1994). Almost all 
LG-NHL patients have relapses at a rate of about 15% per year (McLaughlin et al., 1993). It 
is clear that innovative treatment approaches are necessary in the treatment of LG-NHL 
patients. These methods could include agents which would stimulate apoptosis, in 
conjunction with the use of high dose chemotherapy to kill proliferating cells and biologic 
therapies to eliminate minimal residual disease (Jaffe et al., 1993). 
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1.1.5.1. TOXICITY AND RESPONSE TO TREATMENT 
The Eastern Cooperative Oncology Group (ECOG) have presented criteria for the 
standardisation of toxicity and response to treatment. ECOG stresses that such a 
standardisation is important for researchers conducting clinical trials. Extremely detailed 
criteria have been proposed by this group, but a brief summary follows. A scale to evaluate 
toxicity from 0-5 has been formulated as: 
0 = none 
1 = mild 
2 = moderate 
3 = severe 
4 = life-threatening 
5 = lethal. 
The ECOG performance status ranges from 0-5 as follows: 
0 = Fully active. 
1 = Restricted in physical activity. Able to carry out light work. 
2 = Ambulatory and capable of self care. Unable to work at all. Up and about 50% of the 
day. 
3 = Capable of limited self care. Confined to bed or chair for more than 50% of the day. 
4 = Completely disabled. Incapable of self care. Confined totally to bed or chair. 
5 = Dead. 
Response criteria are defined by ECOG as: 
1. Complete response - disappearance of all clinically detectable malignant disease for at 
least 4 weeks. Lymphoma patients who at diagnosis presented with abnormal 
lymphangiograms and who have stable and marked decrease in size of 
lymphangiographically abnormal nodes are considered complete responders if all other 
measurable, evaluable, and pathologically demonstrable disease is in complete 
response. 
2. Partial response - greater than or equal to 50% reduction in tumour area for at least 4 
weeks, as well as no increase of >25% in the size of any malignant area. No new 
appearance of malignancy. 
3. Stable disease - no significant change in measurable or evaluable disease for at least 4 
weeks. 
4. Progressive disease - significant increase in the size of lesions that were present at the 
start of therapy or after a response. Appearance of new malignant sites. Stable disease, 
but combined with a decline in ECOG performance status of greater than or equal to 1 
level. 
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5. No evidence of disease - lack of clinically determined malignant disease in 
nonmeasurable, nonevaluable patients. 
6. Onset of response - time between initiation of treatment and the onset of either partial 
response or complete response. 
7. Duration of response - time from onset of partial response (even if patient subsequently 
has a complete response) until clear evidence of progressive disease. 
8. Overall survival is calculated from the first day of treatment to death (whatever the 
cause) (Coiffier et al., 1993; Oken et al. , 1982). 
The appearance of second neoplasms after treatment for NHL has occasionally been 
reported. Patients undertaking therapy may therefore be at an increased risk of developing 
second neoplasms (Kwak et al. , 1993). 
1.1.5.2. CHEMO-IMMUNOTHERAPY 
For chemotherapy to be successful , it must eradicate all tumour cells. It is usually not 
possible to eradicate all tumour cells, as some cells are resistant to the drug, and there are 
also the constraints of a maximum tolerated dose. lmmunotherapy is the stimulation of the 
hosts own anti-tumour immunity by means of treatment. The term "biological response 
modifier" (BRM) is often used to refer to these approaches to immunotherapy. Therapy could 
include IFN, which stimulates the host's own defence mechanism and is considered a BRM 
(Foon, 1989). BRM's are agents and approaches whereby the mechanism of action involves 
the patient's own biological response. BRM's act by:- (1) increasing the host's defenses by 
administering natural biologicals (or synthetic equivalents) as effectors or mediators of an 
antitumour response, or (2) increasing the individual's own antitumour responses, through 
either enhancement or restoration of effector mechanisms, or by decreasing the 
unfavourable component of the host's reaction, or both, or (3) enhancement of the patient's 
responses to modified tumour cells or vaccines which may stimulate a better response for 
example by making the tumour cells more susceptible to killing (Geerligs et al., 1993). 
Toxicities usually differ between chemotherapy agents and immunostimulating agents, 
therefore a combination should increase the therapeutic index. There are differences 
between the response to chemotherapy and immunotherapy: (1) Unless patients 
demonstrate a complete response, while using chemotherapy, they do not experience 
prolonged survival. Patients exhibiting even a partial response, while using immunotherapy, 
usually experience prolonged survival; (2) The effect of chemotherapy will only last as long 
as the treatment, whereas with immunotherapy, it may continue for weeks or even months 
after completion of treatment; (3) The response to chemotherapy is usually directly dose-
related, but this is not as marked with immunotherapy, and (4) chemotherapy appears more 
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effective for bulky disease, whereas immunotherapy is probably more effective for minimal 
residual disease (Kedar and Klein , 1992). 
Alpha Interferon (a-lFN) and cytotoxic drugs e.g. cyclophosphamide and vinca alkaloids 
appear to have a synergistic or additive effect when administered to LG-NHL patients (Solal-
Celigny et al. , 1993; Rohatiner, 1991 ). 
The aim, in a clinical trial would therefore t -e to reduce the tumour load using chemotherapy, 
prior to the use of immunotherapy (Kedar and Klein, 1992). 
1.1.6.0. ALPHA INTERFERON 
Interferons are a group of naturally occurring proteins and glycoproteins, first described by 
Isaacs and Lindenmann in 1957, that have large molecular weights and demonstrate a 
number of biological activities, including antiviral, antitumour activity and regulation of the 
immune system. Several types of IFN exist that differ in amino acid composition and 
carbohydrate content. For several years IFN was regarded only as a mediator of viral 
interference (hence the name, from "to interfere") (Geerligs et al. , 1993; Crowther, 1991 ). 
IFN's are secreted by cells following exposure to a variety of biologic and chemical stimuli 
(Louie et al. , 1981 ; McLaughlin, 1993). IFN's have been classified as a-interferon, B-
interferon and y-interferon. a-IF N's are produced by leukocytes, y-lFN by T lymphocytes and 
B-IFN by fibroblasts and epithelial cells (Crowther, 1991 ; Gilewski and Richards, 1990). 
IFN's are also responsible for growth and differentiation of normal B lymphocytes and 
demonstrate a direct antiproliferative effect against tumour cells and stimulatory effects on 
antitumour cells. IFN's also cause induction or augmentation of expression of membrane 
antigens on tumour cells which facilitates immune recognition by the host. It is unclear as to 
which of these effects are important in antitumour activity in vivo (Foon, 1989; McLaughlin, 
1993; Geerligs et al., 1993). In animal experiments, IFN's used alone cause tumour 
regression with subsequent prolonged survival, but seldom result in cures. IFN's were the 
first human recombinant proteins used in the treatment of human cancer. a-lFN has an 
established role in the management of LG-NHL patients (Crowther, 1991 ). 
IFN is known to prolong G1 , G2 and S phases of the cell cycle (see Figure 1 for 
diagrammatic representation of the cell cycle), resulting in an overall lengthening of the 
cycle. It has been suggested that IFN has its effects predominantly on resting cells in the GO 
phase. The antiproliferative activity of IFN is probably responsible for inhibition of 
lymphocyte blastogenesis (Quesada, 1983). 
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a.-lFN is actually a family of over 30 subtypes and is produced by leukocytes (B-cells, T-cells, 
NK cells and macrophages) as a result of exposure to B-cell mitogens, viruses, foreign cells, 
or tumour cells (Foon, 1989; McLaughlin, 1993; Geerligs et al. , 1993). a.-lFN is stable at a 
pH of 2 (Quesada, 1983). 
a.-lFN is the only IFN that has been widely used in the treatment of cancer patients, however 
it remains unclear whether patient responses are due to a.-lFN's antiproliferative or 
immunomodulatory effect. It seems likely that a combi1 ,ation of mechanisms are involved in 
these anti-cancer effects that have been demonstrated. The immunomodulatory effects of a.-
lFN could possibly stimulate the rejection of tumour cells by the host. The stimulation of NK 
activity by a.-lFN may also play an important role. The results could also be mediated by the 
induction of a cascade of cytokines or growth factors (Foon, 1989; Crowther, 1991 ). 
Early trials were conducted using non-recombinant a.-lFN, obtained from virus stimulated 
buffy coat leukocytes. The purity of these preparations was about 1 % (106 U/mg protein) 
(Foon, 1989). See Table 8-A for a summary of clinical trials using non-recombinant a.-lFN 
therapeutically. IFN is now produced by recombinant DNA technology and is available for 
therapy. This has the obvious advantage of purity and consistency in IFN activity (Parkinson 
et al. , 1993; Gaynor and Fisher, 1991 ). In early clinical trials using crude natural and 
recombinant forms of a.-lFN a response rate of 33-50% could be demonstrated in LG-NHL 
patients (Smalley et al. , 1992). Using recombinant a.-lFN, a response of approximately 50% 
in LG-NHL patients was achieved, of which most was only partial , however 5-10% did 
achieve complete response (Foon, 1989). See Table 8-B for a summary of clinical trials 
using recombinant a.-lFN therapeutically. 
It is a well established fact that a.-lFN enhances the cytolytic capacity of NK cells in vitro 
(Kedar and Klein, 1992). Due to this fact, it was envisaged that the in vivo treatment of 
patients with a.-lFN would augment NK mediated cytotoxicity in vivo in cancer patients 
against tumour cells. 
a.-lFN appeared to be a very promising form of treatment for use in tumours with low and 
potentially easily controlled proliferative rates, e.g. LG-NHL. Clemens stated in 1988, that a.-
lFN had definite therapeutic activity in LG-NHL patients. a.-lFN is a much less impressive 
agent for patients with either intermediate or high-grade lymphomas. Resistance to 
chemotherapy does not mean that tumours are resistant to a.-lFN. In fact patients who have 
relapsed while undergoing chemotherapy have responded to treatment with a.-lFN. a.-lFN has 
been used, either alone, or in combination with chemotherapy. An additive or synergistic 
effect has been observed between a.-lFN's and various cytotoxic drugs in both in vitro and in 
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vivo studies. (Gaynor and Fisher, 1991 ; Foon, 1989; McLaughlin 1993; Gilewski and 
Richards, 1990; Cavalli 1988; Ozer et al., 1983; Foon et al., 1984). Two different types of 
recombinant a.-lFN are currently in use: alpha23 (Roferon ®) and alpha2b (lntron A ®}, 
differing by an amino acid substitution at position 23 (Gilewski and Richards, 1990; Coiffier, 
1993). The combination of both chemotherapy and a.-lFN may lead to more complete and 
durable clinical responses since a.-lFN alone does not cure. Trials have therefore focused 
on combining therapies without increasing toxicity (Coiffier, 1993; Oken, 1992). This was 
confirmed with animal model experiments in which implementation of IFN treatment following 
chemotherapy induced both remission and prolonged survival. See Table 9 for a summary of 
clinical trials using a.-lFN therapeutically in combination with chemotherapy. It seems 
appropriate to treat only those patients who have achieved a complete response after 
chemotherapy with a.-lFN. This regimen is in accordance with that of Kedar and Klein 
(1992), who suggested a reduction in the tumour load by surgery followed by chemotherapy 
or radiation prior to the commenceme,1t of a BRM. Accumulating evidence seems to indicate 
that a.-lFN may prolong the disease-free interval and possibly the overall survival when 
administered after initial cytoreductive treatment (reduction in tumour by the use of cytotoxic 
drugs) (Hiddemann et al., 1994). The continued use of a.-lFN as maintenance treatment after 
patient response may improve remission duration and hence possibly survival , but it is 
unlikely to cure patients (Rohatiner, 1991 ). This strategy of treating the patient with 
chemotherapy, followed by maintenance a-lFN maximises the effects of a.-lFN at a time when 
the patient has minimal residual disease and biological agents are expected to be most 
effective. It is also at the stage following immunosuppressive therapy when the 
immunrestorative effects of a.-lFN would be most beneficial. Unfortunately the use of a.-lFN 
as maintenance treatment requires extended periods of treatment (McLaughlin, 1993). Kwak 
and co-authors (1994) comment that the a.-lFN treatment appears to be simply keeping the 
residual disease at a subclinical level , because nearly all a.-lFN treated patients relapse 
within a year of discontinuation of treatment. 
Data from Italy, Britain and the European Organization for the Research and Treatment of 
Cancer group, indicate that a.-lFN treatment served to prolong the period of disease free 
survival , after either cytoreductive cherr.otherapy or combination chemotherapy. The 
combination chemotherapy consisted of cyclophosphamide, oncovin (vincristine) and 
prednisone (COP). The duration of this beneficial effect was limited to the period of a-lFN 
treatment, usually 12 months (Hiddemann and Unterhalt, 1994). Contrary to this, however, 
Schuler et al. , 1995, state that no additional benefit is gained by combining a.-lFN with 
chemotherapy when compared to chemotherapy alone (Horning, 1994-b). 
Kwak and Longo (1996), feel that due to the long natural history of LG-NHL, a longer follow-
up period is necessary, to ascertain whether the survival advantage for a.-lFN treated 
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patients is maintained or lost, when compared to patients treated with chemotherapy alone. 
a-lFN treatment appears to keep subclinical levels of the disease under control, but patients 
experience chronic a-lFN toxicity especially fatigue and depression, without any 
improvement in survival (Kwak and Longo, 1996). 
Absorption and clearance of a-lFN is fairly rapid following subcutaneous injection. Peak 
serum concentrations are found after 6-8 hours and clearance usually takes approximately 
24 hours (Quesada, 1983). 
TABLE 8-A. SUMMARY OF SINGLE AGENT NON-RECOMBINANT a-lFN CLINICAL 
TRIALS 
Type of NHL Type of a-lFN Dose and site Response (%) No of patients Reference 
Non-recombinant a-lFN's 
LG-NHL human leukocyte 5X10" Ui.m.2X PR - 3 (100) 3 Merigen et al., 
IFN 106 reference daily 1978 
units/mg protein 
LG-NHL human leukocyte 5 X 10" U i.m. 2 X CR - 1 (13) 8 Louie eta/. , 1981 
IFN 106 U/mg daily PR - 3 (38) 
protein MR - 3 (38) 
NE - 1 (13) 
LG-NHL human leukocyte 1-9X10° U CR - 0 28 Homing et al., 
IFN 106 U/mg i.m. 1 X daily PR - 3 (11) 1985. 
protein MR - 3 (11) 
Results have only been shown on tnals rnvolvrng LG-NHL patients. Where a combination of different 
categories of patients were treated, results have been indicated in LG-NHL patients only. 
See section 1.1.5.1 . for a detailed description of response criteria . 
CR = complete response PR 
MR = minimal response NE 






TABLE 8-B. SUMMARY OF SINGLE AGENT RECOMBINANT a-lFN CLINICAL TRIALS 
Type of NHL Type of a-lFN Dose and site Response (%) No of patients Reference 
Recombinant a-lFN's 
LG-NHL IFN-a2 1 - 100 X 10°U CR-0 3 Ozer eta/., 
(refractory to ~ 108 U/mg i.m. PR - 1 (33) 1983 
standard protein 1 Xweekly MR - 1 (33) 
treatment) SD - 1 (33) 
LG-NHL a-lFN 50 X 10° U i.m. 3 CR-4 (17) 24 Foon et al., 
Previously treated X weekly PR - 9 (38) 1984 
- now 
unresponsive 
LG-NHL IFN alfa2. Low dose Low dose 39 Van der Molen 
Previously treated (Roferon) 3 X10
6 U s.c. CR - 0/19 eta/., 1990 
- now daily PR - 5/19 (26) 
unresponsive High dose SD - 3/19 16) 
50 X 106 U i.m. 2 PD - 10/19 (53) 
X weekly High dose 
CR - 2/20 (10) 
PR - 5/20 (25) 
SD - 6/20 (30) 
PD - 7/20 (35) 
Results have only been shown on tnals involving LG-NHL patients. Where a combination of different 
categories of patients were treated, results have been indicated in LG-NHL patients on:y. 
See section 1.1.5.1. for a detailed description of response criteria. 
CR = complete response PR 
MR = minimal response SD 
PD = progressive disease i.m. 









TABLE 9. SUMMARY OF COMBINATION a-lFN CLINICAL TRIALS 
Type of NHL Type of 1-IFN Dose and site Response (%) No of patients Reference 
Combination trials - non-recombinant 1-IFN 
LG-NHL Human leukocyte 6X 10° U i.m . CR- 3 (43) 7 Clark et al., 1989 
(advanced) 1-2 X 106 Ulmg +CLB PR - 1(14) 
Heavily pre- protein NR - 2 (29) 
treated 
Combination trials - recombi1.ant a-lFN's 
LG-NHL IFN alfa2b 2 X 10° U s.c. CR- 8 (19) 43 Ozer et al., 1987 
(lntron A) alternate days PR - 23 (53) 
+ cyclo MR - 8 (19) 
PD - 4 (9) 
LG-NHL IFN alfa2b 3 X 10° U s.c. CR-2 (20) 10 Chisesi et al., 
(advanced) (lntron A) 3 X weekly PR-6 (60) 1987 
+CLB NR - 1 (10) 
SD - 1 (10) 
LG-NHL and IG- IFN alfa2a COPA COPA COPA - 127 Smalley et al., 
NHL (Roferon A) Qf CR-29% IFN+COPA -1 22 1992 
IFN+COPA PR - 57% 
6 X 106 U i.m. IFN+COPA 
5 X days/month CR- 32% 
PR - 54% 
Results have only been shown on trials involving LG-NHL patients. Where a combination of different 
categories of patients were treated, results have been indicated in LG-NHL patients only. The trial 
conducted by Smalley et al, in 1992, was conducted on both low and intermediate grade patients. No 
distinction was made between the different grades when results were discussed, therefore these 
results cannot be separated into low and intermediate grade patients. 
See section 1.1.5.1 . for a detailed description of response criteria. 
CR = complete response PR = partial response 
MR = minimal response SD = stable disease 
NR = no response PD = progressive disease 
i.m. = intra-muscular s.c. = sub-cutaneous 
CLB = chlorambucil cyclo = cyclophosphamide 
COPA = cyclo, vincristine, prednisone and doxorubicin 
1.1.6.1. a-lFN TOXICITY 
a-lFN toxicities are directly dose-related and consist of flu-like symptoms such as fever, 
chills, rigors, headache, malaise, nasal congestion, myalgias, anorexia and fatigue and 
psychiatric disorders such as confusion/involution, depression, and also impotence, nausea, 
vomiting, xerostomia, mild alopecia, nail changes, development of a metallic taste sensation, 
paraesthesias, rash, liver injury, pulmonary embolism, pulmonary oedema, sarcoidosis, 
modest myelosuppression, hypotension and tachycardia. The most commonly described 
side-effects are flu-like in nature. At high doses, the interferons are neurotoxic and 
demonstrate a variety of side-effects, including behavioural changes. Various ocular side-
effects have also been documented. Bone marrow depression causing neutropenia and 
thrombocytopenia is a serious form of toxicity. This must be borne in mind when cx-lFN is 
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used in association with cytotoxic chemotherapy. It is imperative that patients being treated 
with a.-lFN are warned and monitored for side-effects that may or may not be reversible 
(Parkinson et al. , 1993; Tang, 1995; McLaughlin et al. , 1993; Horning et al. , 1985; Ozer et 
a/. , 1983; Kuzel , et al. , 1990; Crowther, 1991). In one trial , a patient with a history of 
coronary-artery disease had a massive myocardial infarction and died after the first dose of 
a.-lFN. It is recommended therefore that patients with clinically important cardiac disease not 
receive a.-lFN treatment (Foon et al. , 1984). 
With long term treatment of a.-lFN, which is recommended by most authors, the minor side 
effects gain importance, because phenomena such as chronic fatigue may substantially 
impair the quality of life. The majority of patients treated with a.-lFN are relieved to have 
even completed one year's maintenance therapy (Ziegler-Heitbrock and Thiel , 1990; 
Crowther, 1991 ). 
1.1.7. TREATMENT OF PATIENTS IN THIS STUDY 
In an attempt to maximise the response for the patients on this trial , they were initially placed 
on combination chemotherapy of COP consisting of:- cyclophosphamide (intravenous) + 
vincristine (intravenous) + prednisone (oral) to reduce the bulk of tumour cells. This is a 
relatively non-toxic drug combination (Gaynor and Fisher, 1991 ). Following this regimen, and 
if patients responded to this treatment, the patients were selected to receive either 
maintenance a.-lFN or maintenance chemotherapy. Maintenance chemotherapy consisted of 
oral cyclophosphamide for a period of 2 years. a.-lFN was given at a dose of 3 X 10
6 units by 
subcutaneous injection three times a week, as a form of maintenance therapy. A relatively 
low dose of a.-lFN was selected to avoid intolerable toxicity and to obtain an acceptable rate 
of compliance. Synonymous with results in myeloma, hairy-cell leukaemia and chronic 
myeloid leukaemia, it appears that a prolonged exposure to a.-lFN is most beneficial. 
Patients in this study group were therefore treated with maintenance a.-lFN for a period of 
two years (Rohatiner, 1991 ). The a.-lFN was given after the chemotherapy in an attempt to 
eliminate any remaining tumour cells. Maintenance immunotherapy is appealing due to the 
fact that lymphoma patients often have underlying immune dysfunction (McLaughlin et al. , 
1993). 
The rationale for using a.-lFN as maintenance treatment was that BRM's are felt to be most 
effective in the elimination of minimal residual disease. Long term treatment with an a.-lFN 
was assumed to be less likely to be associated with chronic marrow toxicity such as 
myelodysplasia. It was anticipated that there would be enhancement of the immune system 
and that some patients would remain in prolonged complete response (McLaughlin et al., 
1993; Crowther, 1991 ). Recent results published by the European Organization for the 
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Research and Treatment of Cancer lymphoma study group report a longer period of disease-
free survival in patients treated with a-lFN as maintenance therapy after initial treatment 
consisting of COP. These results appear to be confirmed by an Italian and British study 
(Hiddemann and Unterhalt, 1994). 
1.1.8. ADVERSE HAEMATOLOGICAL COMPLICATIONS OF CHEMOTHERAPY 
In patients treated with chemotherapy, no direct effect is observed on mature cells in either 
the blood or bone marrow, with the exception of the lymphocyte. As a result of this, the life 
span of peripheral blood cells determine when a particular cytopenia will develop. 
Neutrophils survive for about 10 hours, platelets for about 10 days and red blood cells for 
about 120 days. Cytotoxic agents can be categorised as:- cell cycle phase specific, when 
cells in a particular phase of the cell cycle are targetted, or:- phase non-specific, when no 
particular phase of the cell cycle are targetted (see Figure 1 for a diagrammatic 
representation of the cell cycle). Cycle-nonspecific drugs may kill cells that are not actively 
dividing and are effective in tumours in which the growth fraction is low. Phase-specific 
agents exert their anti-neoplastic activity in a particular phase of the cycle, and such drugs 
are more effective among tissues that exhibit a high growth fraction. The COP regimen used 
for treating NHL patients on this study is considered a relatively non-aggressive form of 
treatment (Bodensteiner and Doolittle, 1993; Dorr and Fritz, 1982). A combination of drugs, 
usually with different killing mechanisms are selected. This treatment protocol maximises the 
killing of tumour stem cells and prevents tumour resistance to a single form of therapy. 
Cyclophosphamide is not in itself an alkylating agent, but is converted by the liver into an 
alkylating compound which is phase non-specific (Bodensteiner and Doolittle, 1993; Dorr and 
Fritz, 1982; Babier and Stossel , 1994). Cell cycle-nonspecific drugs such as 
cyclophosphamide will destroy all haemopoietic cell production. Only the pool cells and 
post-mitotic maturing cells in the bone marrow will be spared. Cyclophosphamide treatment 
is usually well tolerated. Vincristine is one of the active principles of the vinca alkaloids and 
is a M-phase-specific drug. The degree and duration of bone marrow suppression depends 
on the type of agent used. Cell cycle-specific agents tend to cause early myelosuppression 
with rapid marrow recovery compared with non-phase-specific agents. The mode of action 
and toxicity of prednisone appears similar to that of other alkylating agents. The prednisone 
regimen for NHL generally produces less severe haematological toxicity than for other 
neoplasms. Toxicity includes myelosuppression which is characterised by dose-dependent 
leukopenia and thrombocytopenia. There also appears to be no cross-resistance between 
prednisone and the other alkylating agents such as cyclophosphamide (Bodensteiner and 
Doolittle, 1993; Dorr and Fritz, 1982; O'Reilly and Connors, 1992). 
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When using peripheral blood counts to monitor dosage and frequency of chemotherapy, it is 
essential to remember that changes in the peripheral blood cell counts lag behind changes in 
the bone marrow production pools. If the leukocyte count remains in the normal range for 
patients treated with chemotherapy, this should be increased, until treatment causes mild 
myelosuppression. This is to ensure that a sufficient amount of the drug is being absorbed 
(Bodensteiner and Doolittle, 1993; Dorr and Fritz, 1982; O'Reilly and Connors, 1992). 
1.2.0. NATURAL KILLER CELLS 
1.2.1. MORPHOLOGY AND COMPOSITION OF NK CELLS 
Human natural killer (NK) cells are a small population of lymphoid cells of distinct lineage 
which differ from T and B lymphocytes in that they do not express receptors for surface 
immunoglobulin or T cell antigen receptors (TCR). NK cells account for approximately 10-
15% of peripheral blood mononuclear cells (PBMC). At least 70% of human PBMC large 
granular lymphocytes (LGL) have been shown to have NK activity (Reynolds and Wiltrout, 
1989). Both cell number and cytotoxicity varies among normal individuals (Gong et al. , 1994: 
Lotzova, 1991 ; Moretta et al. , 1994-a). NK cells are generally larger than resting T or B 
lymphocytes and display the typical LGL morphology, containing intracytoplasmic azurophilic 
granules and have a high cytoplasmic to nuclear ratio (Roitt et al., 1987; Moretta et al., 1994-
a). NK cells may also be of medium size and agranular, but this may be related to the NK 
cell stage of differentiation (Lotzova, 1993). Granules appear to play a role in cytolytic 
activity, as granular content correlates with cytolysis (Shibuya et al. , 1993, Lebow et al. , 
1993). Using electron microscopy, the LGL appear as medium sized lymphocytes with round 
or indented nuclei , condensed chromatin, prominent nucleoli and extended golgi 
apparatuses. 
1.2.2. FUNCTION OF NK CELLS 
NK cells are so named, because they have spontaneous or natural cytotoxicity against cells 
infected with bacteria and viruses or tumour cells, without prior in vitro or in vivo activation. 
These cells are therefore important in innate immunity (Caldera et al., 1992; Kos and 
Engleman, 1996). The cytolytic function of NK cells has been described as natural killer 
activity (NKA) and differs from the immunologically specific lytic activity of cytotoxic T 
lymphocytes (CTL) in that it is not major histocompatibility complex (MHC) restricted, and 
does not follow immunology rules of selectivity, specificity and memory (Reynolds and 
Wiltrout, 1989). 
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Not all NK cells bind to targets and of those that do bind not all are cytotoxic (Lebow et al. , 
1993). NK cells have been proposed as the first line of defense against tumour cells 
(Caldera et al., 1992). These cytotoxic effects can be observed against a variety of tumour 
cells, both non-immunogenic as well as immunogenic (Reynolds and Wiltrout, 1989). 
Often it is necessary for the target cell to be precoated with specific lgG prior to the killing of 
the target cell. This lytic process is known as antibody-dependent cellular cytotoxicity 
(ADCC) (Abbas et al. , 1994). NK cells, together with the humeral in1mune system, are 
responsible for the elimination of target cells via ADCC (Metes et al. , 1994 ). 
NK cells are rapidly recruited to sites of inflammation by their ability to respond to 
chemokines and inflammatory mediators. NK cells also express many adhesion receptors 
which facilitate margination, extravasation and migration of these cells (Palmieri and Santoni , 
1997). 
NK cells may also play a large role in maintaining the homeostasis of the haemopoietic 
compartment. This hypothesis was confirmed by in vitro human studies that indicated NK 
cells displayed control over the colony-forming potential of both erythroid and myeloid 
precursors. Evidence also appears to imply that proliferation, differentiation, and functions of 
some members of the lymphoid compartment could be controlled by NK cells. The exact 
mechanisms by which NK cells regulate this activity is unclear, although some of these 
effects appear to be related to cytokine production (Lotzova, 1993; Perussia, 1991 ; 
Trinchieri, 1992). 
1.2.3. NK CELLS AND TISSUE DISTRIBUTION 
NK cells have been identified in various tissue compartments other than the peripheral blood, 
e.g. lungs, red pulp of the spleen, intestinal mucosa, liver and peritoneal cavity. NK 
cytotoxicity has also been detected in human tonsils. NKA levels are highest in peripheral 
blood and spleen. In some tissue, it is necessary to activate cells before cytotoxicity is 
detected. NK cells are present in small numbers in lymph nodes, although they do not travel 
through the lymphatic circulatory system. NK cells do not recirculate between blood and 
lymph as T cells do (Lotzova, 1991 ; Warren, 1996). Spontaneous NKA in lymph nodes is 
relatively low, but this cytolytic activity can be stimulated. Stimulation of NKA and 
maintenance of these levels, may contribute to the treatment of cancer patients (Reynolds 
and Wiltrout, 1989). 
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1.2.4. CONTROL OF NK FUNCTION BY NON-LYMPHOID CELLS 
Since red blood cells (RBC) form the most abundant component of peripheral blood, NK cells 
as well as other lymphocytes are continually in contact with RBC's during circulation. RBC's 
have been found to enhance NK cytotoxicity in vitro. This enhanced cytotoxicity was 
observed with two target cell lines viz. the erythroleukemic cell line, KS62 and the histiocytic 
cell line, U937. Only intact RBC's and not RBC lysates were found to enhance C}totoxic 
activity. Evidence suggests that a unique RBC protein may be responsible for this 
augmentation (Shau et al., 1993). 
Polymorphonuclear neutrophils account for the most abundant leukocytes in the peripheral 
blood. Polymorphonuclear neutrophils have been found to inhibit NK cytotoxicity in vitro. In 
the presence of TNF, which is a potent polymorphonuclear neutrophil stimulator, this 
suppression was found to be even greater. Cell-cell contact was necessary for this 
inhibition, a phenomenon that was observed for intact and viable polymorphonuclear 
neutrophils only (Shau et al. , 1993). 
It seems likely that both RBC's and polymorphonuclear neutrophils play an important role in 
the regulation of NK function in vivo (Shau et al. , 1993). 
1.2.5. NK CELLS AND SURFACE MARKER EXPRESSION 
There is currently much research being undertaken into NK cells and antigen expression. 
Some of these NK cell receptors are essential in cytotoxicity, while others are important in 
adhesion, or as cytokine receptors (Yokohama, 1995). 
NK cells are characterised by expression of Cluster of Differentiation antigen (CD) CDS6 and 
CD16 (predominantly but not exclusively present in NK cells - this marker can also be found 
on macrophages, neutrophils and a subset of eosinophils) and lack of CD3 expression. CD3 
is always expressed in association with the TCR. NK cells do not express the al~ or y/8 
genes of the TCR, however, they may express thee- or (,- chain of the CD3 molecule. 
CDS6 is a typical but not exclusive NK cell molecule. This molecule is also present on T cell 
subsets and neural and muscle tissues. NK cells express a low-affinity receptor for the Fe 
portion of lgG, called FcyRIII or CD16. NK cells are capable of binding to lgG immune 
complexes via CD16 molecules on their surface. This interaction activates the NK cell lytic 
mechanism and induces production of lymphokines by the activated cells. Functionally CD16 
is important for mediation of antibody-dependent cellular cytotoxicity. 
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NK cells can be distinguished from T cells by their lack of expression of CD3, CD4 and CD5 
cell surface molecules and of T cell receptor chains a ,~,y,o. In addition NK cells display in 
vitro cytotoxic activity against NK-sensitive targets such as the erythroleukaemic human cell 
line, K562 (Moretta et al. , 1994-a; Gong et al. , 1994; Spits et al. , 1995; Trinchieri and 
Valiante, 1993; Lotzova, 1993; Pollack, 1993). CD2, the low-affinity rosette receptor, is also 
present on most mature NK cells and may also be important in target cell interaction 
(Lotzova, 1991 ; Trinchieri , 1992). NK cells may also express CD8 and CD57 (Warren, 
1996). NK cell progenitors in vitro that lack CD56 expression also lack cytotoxic activity 
against NK sensitive targets. On further culture these CD56- cells gained both CD56 
expression and cytotoxicity. There appears to be therefore an association between the 
cytotoxic activity of NK cells and the expression of CD56 (Spits et al., 1995). CD56 may also 
be important in NK cell interaction with targets (Lotzova, 1993). 
CD7, a 40 kilodalton (kDa) glycoprotein present on mature NK cells may play a role in 
adhesion and cell activation (Miller JS et al., 1994 ). 
Resting NK cells do not express HLA-DR antigens (class II MHC), but when activated they 
often express HLA-DR and transferrin receptors. 
NK cells activated by IL-2 or a-lFN express CD69 activation antigens and increased 
expression of this marker correlates with cytolytic activity. CD69 is upregulated in binder and 
killer cells compared to free cells (Bonavida et al. , 1993; Jewett and Bonavida, 1995). 
1.2.6. NK CELL DEVELOPMENT 
It has been establ ished that a functional thymus is not necessary for maturation of NK cells, 
however it is possible that NK differentiation could occur in the thymus (Moretta et al., 1994-
a; Spits et al. , 1995; Moretta et al. , 1994-b ). 
It is possible that the thymus is colonised by multipotential haemopoietic progenitor cells that 
are distinct from stem cells. These progenitor cells have the potential to develop into 
haemopoietic non-T cells within the thymus. Athymic mice have normal numbers of NK cells 
in the peripheral blood (Spits et al. , 1995). It is likely that the bone marrow is the main site 
for the development and differentiation of NK cells, although both NK cell number and 
cytotoxicity in the bone marrow of healthy donors is low (Spits et al., 1995; Lotzova 1991 ; 
Haller et al. , 1977). See Figure 2 for a diagrammatic representation of production and 
differentiation of NK cells. See Table 10 for morphological characteristics of development of 
the NK lineage. 
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A description for the development of NK cells now follows. Large proliferating progenitor NK 
cells in the bone marrow, give rise to less rapidly proliferating precursor NK cells. The 
presence of stromal cells and growth factors is essential for this to take place. Precursor NK 
cells exhibit some phenotypic and morphological characteristics of NK cells. These 
precursor cells divide and differentiate in the bone marrow into phenotypically recognisable 
primary NK cells. It is important to note the progressive decrease in cell size and the 
acquisition of typical f\K cell surface antigens as differentiation proceeds. These primary NK 
cells are relatively small lymphocytes (about 8 µm) and are agranular as compared to mature 
NK cells. Primary NK cells are not in cell cycle and have low lytic activity and express the 
phenotype of resting NK cells. Primary NK cells are able to respond to both interferon and 
IL-2, but not as well as mature NK cells. These cells leave the bone marrow and undergo 
further maturation in peripheral sites. Peripheral NK cells are activated by agents such as 
interferon to undergo prol iferation in response to stimuli . It should be noted that although 
peripheral NK cells are highly activated by interferon, less mature NK precursors seem to be 
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Production and differentiation of NK cells 
(based on data from the mouse) (Pollack, 1993). 
Pre = precursor Pro = progenitor NK1 .1 = NK equivalent to either CD16 or CD56 in humans 
The presence of IL- 2 is required for in vitro or in vivo culture of bone marrow derived NK 
cells, suggesting that NK progenitors have IL-2 receptors (IL-2R) (Miller et al. , 1992; Lotzova 
et al., 1993; Silva et al., 1994; Lotzova et al., 1991 , Shibuya et al. , 1993). 
It is possible that NK cells may develop in other organs such as spleen, liver, or blood, but as 









MORPHOLOGICAL CHARACTERISTICS OF THE DEVELOPMENT OF 
THE NK LINEAGE 
(based on data from the mouse) (Pollack, 1993). 
PRO-NK PRE-NK PRIMARYNK PERIPHERAL NK 
large large-medium small varies 
75 25 0 varies 
+ ++to++++ 
+ + + 
(+) + 
progenitor pre = precursor 
Both cytolytic NK cells and/or T cells have been generated from CD34+ or CD34- bone 
marrow cells, depending on the in vitro conditions (Shibuya et al., 1993; J.S. Miller JS et al., 
1994; Miller et al. , 1992; Lotzova et al. , 1993). See Figure 3 for the development of T and 
NK cells. It appears therefore, that CD34+ cells are primitive progenitors for either NK cells 
or T cells and as these cells differentiate, they lose the CD34 expression. These NK cells 
then acquire expression of CO2, CD16 and CDS6 antigens (which are usually found on 
mature NK cells) as well as gaining cytolytic activity (Spits et al. , 1995; Lotzova and Savary, 
1993). The CD34+ population display the typical blast morphology and the mature NK cells 
the LGL morphology, with a progressive decrease in cell size as maturation takes place 
(Lotzova and Savary, 1993; Pollack, 1993). Bone marrow NK cells have a rapid turnover 
time (Pollack, 1993). NK cells have also been cultured from CD34+ populations depleted of 
the CD34+, CD33+ subset, which represents the committed myeloid progenitor, indicating 
that these cells are not required for NK cell generation (Lotzova and Savary, 1993). 
It is possible, that in addition to IL-2, other cytokines are necessary in the development of NK 
cells and that as these progenitor cells differentiate, they in turn provide other essential 
cytokines. It has been shown that TNF-alpha enhances the IL-2 driven production of NK 
cells (Lotzova and Savary, 1993). 
NK cells have not been found to lyse normal autologous cells which appears to indicate that 
an NK cell receptor can identify at least one self MHC class I allele. The molecular 
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Model of T and NK cell development in the thymus (Spits et al., 1995). 
progenitor cyCD3 = cytoplasmic CD3 
1.2.7. CYTOKINES AND NK CELL DEVELOPMENT 
Table 11 summarises the effects of cytokines and growth factors on production of NK cells 
from bone marrow. IL-2 (produced exclusively by activated T-cells), is a potent stimulator of 
NK cells, causing not only proliferation, but cytokine production and increased cytotoxicity 
(Naume and Espevik, 1994; Warren, 1996). Various cytokines appear to play either positive 
or negative regulatory roles during the production of NK cells (Pollack, 1993). IL-3 appears to 
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inhibit the IL-2 driven generation of NK cells from bone marrow in vitro (Pollack, 1993). IL-4 
either inhibits or stimulates the production of NK cells, depending on the co-stimulus used 
and the activation state of the NK cells (Pollack, 1993; Naume and Espevic, 1994). The 
reported effect of IL-6 on NK cells has been contradictory, but this cytokine appears to have 
stimulatory effects on NK cells. IL-6 also induces adhesion molecules, TNF-alpha and TNF-
beta cytokine production, and moderate proliferation in NK purified cells (Naume and 
Espevik, 1994; Ortaldo et al., 1995). Controversy exists as to the role of IL-7 in the 
development of NK cells. Pollack (1993) states that IL-7 does not appuar to play a crucial 
role in the development of NK cells, whereas Spits and co-workers feel that evidence points 
to IL-7 as being involved in the development of NK cells (Spits et al. , 1995). Ortaldo and co-
authors (1995), report that IL-7 activates NK cytotoxicity. IL-12, also known as NK cell 
stimulatory factor or cytotoxic lymphocyte maturation factor, which is produced by monocytes 
and B cells, has several effects on NK cells including:- stimulation of proliferation, increase in 
IFN-y production, enhancement of adhP.sion molecule expression, increase in granule 
content and augmentation of cytotoxicity (Klein and Mantovani, 1993; DeBlaker-Hohe et al., 
1995; Naume and Espevik, 1994). a-lFN and y-lFN has been found to activate NK 
cytotoxicity (Ortaldo et al. , 1995). IL-15 can support human NK survival in vitro in the 
absence of serum or any other growth factors, possibly by the prevention of early apoptosis. 
11-15 appears, at least in part, to be able to mimic the bone marrow environment in NK cell 
differentiation. IL-15 is also able to activate cytotoxic activity and cytokine production by 
human NK cells, as well as inducing proliferation of NK cells. Furthermore, as IL-15 appears 
to be constitutively expressed in various cells, including monocytes/macrophages, it may play 
an important role in the regulation of NK cell function. The 3-0 structure of IL-15 is similar to 
that of IL-2 and both of these cytokines display similar functions in their ability to activate 
both T and NK cells (Carson et al. , 1997; Leclercq et al., 1996; Salvucci et al., 1996; 
Puzanov et al., 1997). Murine IL-15 caused the maturation and differentiation of nonlytic 
murine NK cells in vitro (Puzanov et al. , 1996). 
NK precursors appear refractory to the stimulatory effects of a-lFN or f3-IFN in vitro, whereas 
mature PBMC derived NK cells can be highly activated by IFN. Both y-lFN and TNF-a 















EFFECTS OF CYTOKINES AND GROWTH FACTORS ON PRODUCTION 
OF NK CELLS FROM BONE MARROW 
(based on data from the mouse) (Pollack, 1993). 
IN VIVO IN VITRO EFFECTS ON NK CELL PRODUCTION 
+ increases number of ASGM,. cells (NK cells) and NKA in bone 
marrow 
+ induces generation of NK cells from BMC 
+ augments IL-2 induced production in combination with TNF 
+ no effect alone; augments IL-2 dependent generation of NK 
+ decreases frequency of IL-2 responsive precursors 
+ decreases IL-2 dependent generation of NK cells when added 
earty 
enhances IL-2 dependent generation of NK cells at low doses of 
IL-2 
+ decreases generation of NK cells at high doses of IL-2 
increases generation of NK cells at low doses of IL-2 
+ no effect 
+ no effect 
+ no effect 
+ IFN-a/P has no effect on precursors; little effect on primary NK 
cells 
IFN-y augments response to IL-2 
anti-lFN blocks IL-2 induced differentiation of BMC 
+ augments IL-2 dependent generation of NKA 
+ inhibits IL-2 dependent generation of NK cells 
+ preculture in TNF augments response to IL-2; anti-TNF blocks 
NKA = NK activity BMC = bone marrow cell 
CSF = colony-stimulating factor 
GM-CSF = granulocyte/macrophage colony-stimulating factor * Although NK cells in the peripheral blood can be highly activated by IFN, less mature NK cells 
appear refractory to IFN. 
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1.2.8. THE COMPOSITION OF NK CELL GRANULES 
Granules isolated from cytotoxic lymphocytes have been found to be cytolytic towards some 
nucleated cells, as well as to RBC's. It has been hypothesised that these granules are 
involved in NK cell-mediated killing (Lowin et al. , 1994). 
All activated CTL's and cytolytic NK cells contain approximately 30-50 lytic granules. Based 
on electron microscopic studies there appears to be three types of granules which have been 
designated type I, type II and intermediate. Proteins present in killer cells can be divided into 
three groups, perforin, granzymes and T1-A (Griffiths and Argon, 1995). Perforin (cytolysin 
or pore-forming protein) is a 70 kDa membraneolytic protein and the granzymes (granule 
enzymes) are serine esterases. The third group of protein, a poly(A)-binding protein, is TIA-
1 and its relative TIAR which are RNA binding proteins, and could be a natural target of 
granzymes (Radosevic et al. , 1995-a; DeBlaker-Hohe et al. , 1995; Yagita et al. , 1992; Berke, 
1994; Griffiths and Argon, 1995; Greenberg and Litchfield, 1995; Lowin et al. , 1994; Liu et 
al., 1995). 
Four human granzymes have been identified (granzyme A, B, Hand possibly 3) (Lowin et al. , 
1994). Granzymes A and B have been described and cloned. Granzyme A possesses 
trypsin-like specificity. Granzyme B is the most abundant granzyme present in cytoplasmic 
granules and binds proteins (Smyth and Trapani , 1995). Granzyme B is most likely involved 
in a proteolytic cascade leading to apoptosis (Lowin et al. , 1994). Another function of 
granzymes could be cytostasis:- the prevention of cellular proliferation without death (Lowin 
et al. , 1994). 
Another component of the granules are proteoglycans which are not restricted to killer 
lymphocytes, and may serve a role in the compression of proteins inside the granules to form 
a higher density. Proteoglycans may also prevent autolysis, by enveloping granular 
proteases. Chondroitin sulfate is the predominant proteoglycan in these lytic granules and 
appears to play important structural roles and also maintain the proteins in an inactive state 
until a pH change occurs as a result of granule exocytosis (Griffiths and Argon, 1995; Lowin 
et al. , 1994; Berke, 1994; Trapani and Smyth, 1993). 
Lysosomal/endosomal enzymes, receptors and membrane proteins are also present in lytic 
granules. Soluble lysosomal hydrolases and lysosomal membrane proteins reside in the 
granules (Griffiths and Argon, 1995; Lowin et al. , 1994; Berke, 1994; Trapani and Smyth, 
1993). 
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Calreticulin, a calcium-binding 46 kDA protein, is also present and is possibly involved in the 
binding of calcium. Calreticulin may also play an important role as a Ca2+ buffer and in the 
protection of perforin, which is inactivated by low concentrations of calcium. It has been 
proposed by Bleackley and co-workers (1995), that calreticulin may be important in 
accompanying perforin to the granules in two ways; as a chaperone ensuring that perforin 
remains inactive; in protecting perforin from coming in contact with free Ca2+. These authors 
also propose that calreticulin may be important in ensuring that sufficient amounts of Ca2+ are 
available on granule exocytosis (Griffiths and Argon, 1995; Lowin et al. , 1994; Berke, 1994; 
Trapani and Smyth, 1993; Bleackley et al. 1995). 
Lytic granules clearly function as secretory organelles both storing and secreting the lytic 
proteins in a highly specific manner (Griffiths and Argon, 1995; Lowin et al., 1994; Berke, 
1994; Trapani and Smyth, 1993). 
All NK cells are positive for perforin (97-99%) when staining with an anti human perforin 
monoclonal antibody (Konjevic et al., 1995). Perforin expression has been found to correlate 
with cytotoxicity. In the circulating nonactivated lymphocyte population, perforin and 
granzymes are only expressed in NK cells and gamma/delta T cells. Reduced cytolysis is 
the result of treatment with granzyme inhibitors. DNA breakdown is also inhibited by the use 
of serine esterase inhibitors. Granzymes appear to act within the target cell as either 
activators of cellular degradation, or directly in DNA fragmentation. Granzyme A binds to 
nuclear proteins, particularly nucleolin (Lowin et al. , 1994). 
Not all molecules present in these granules are involved directly in cytolysis, but could serve 
a role in maintaining the granule structure, as well as control in activation of lytic molecules 
to prevent autolysis (Lowin et al. , 1994). 
1.2.9. NK CELLS AND THE MECHANISMS OF CYTOTOXICITY 
The exact mechanisms by which NK cells recognise and kill their targets has still not been 
totally clarified and remains the subject of intense research and debate (Berke, 1995). In 
principle the cytolytic function consists of three distinct steps:- Recognition and binding of 
tumour cells, resulting in stable lymphocyte-target conjugates; Subsequent delivery of lethal 
hit and dissociation and; Recycling of the lymphocyte while the target undergoes lymphocyte-
independent lysis (Lotzova, 1993; Bonavida, et al. , 1993). Binder and killer cells appear to 
be poor recyclers (Bonavida, et al., 1993). Berke (1994) states that NK cells are capable of 
recycling, but, unlike most CTL, which are able to lyse targets for at least two or more cycles 
without necessitating reactivation, NK cells require reactivation with lymphokines. One of the 
most important steps during cytotoxicity is the conjugate formation between target and NK 
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cell. This is mediated by receptor-ligand interactions between lymphocyte adhesion 
molecules and target cell ligands and allows the NK cell to recognise whether or not the 
target is to be killed. Secretion of granules into the limited area of cell contact ensures a 
high degree of target specificity during the killing process (Radosevic et al. , 1995-a; 
Radosevic et al. , 1995-b). 
There appear to be two mechanisms of cytotoxicity:- The perforin-dependent pathway (Figure 
4) mediated by the secretion of perforir , ( calcium ions are required for both the release of 
perforin from killer lymphocytes and for its pore-forming activity); The non-secretory pathway 
which is Fas-dependent, resulting in apoptosis (Kagi et al. , 1995; Liu et al. , 1995). The 
literature reports researchers with diametrically opposed views on whether or not NK cells kill 
by osmotic lysis (secretory) and/or apoptosis (non-secretory). Greenberg and Litchfield 
(1995), state that it is possible in NK mediated cytolysis that target cells demonstrate 
features consistent with both apoptosis and necrosis. Palmieri and Santoni (1997) agree 
with these previous authors, that in response to target recognition, NK cells display both 
secretory and non-secretory lytic methods. Lowin and co-workers (1994), state that NK cells 
kill target cells, not as a result of osmotic lysis, but rather as a result of apoptosis, but these 
authors also quote other researchers who have demonstrated cytotoxicity by osmotic lysis. 
Other authors feel that it is possible that in NK mediated cytotoxicity, Fas-based killing plays 
a role as well as the perforin/granule exocytosis model , because in experiments using 
perforin-free NK cells, target cells were lysed. These authors also feel that due to the 
heterogeneity of NK cells, it is possible that different lytic mechanisms play a role in 
cytotoxicity (Berke, 1994; Lowin et al. , 1994). Radosevic and co-authors state that cytolysis 
occurs in the absence of calcium, which is necessary for perforin activity and that cytolysis 
can also occur without visible degranulation (Radosevic et al., 1995-b). Other authors 
estimate that Fas-based killing accounts for approximately 25% of the lysis in short-term 
assays (Lowin et al. , 1994). Perforin has also not been detected in the medium following 
cytotoxic assays (Berke, 1994). Perforin has been proposed as playing a central role in 
cytotoxicity due to circumstantial evidence. Ring-like lesions have been found in the lipid 
bilayer on target cells after NK cytotoxicity. Cytoplasmic granules, isolated from NK cell 
lines, were found to be cytotoxic to a number of target cells by producing pores on the target 
cell membranes in precisely the same manner as intact NK cells. Perforin has been isolated 
from cytoplasmic granules both in vitro and in vivo (Yagita et al., 1992; Smyth et al., 1994). In 
experiments using perforin-knockout mice, it has been found that perforin is necessary for 
the primary lytic mechanism, but that perforin alone is incapable of causing DNA 
fragmentation. Granzyme B has been shown to be essential in inducing DNA degradation in 
target cells (Greenberg and Litchfield, 1995; Smyth and Trapani, 1995; Heusel et al., 1994; 
Shresta et al. , 1995). There have been conflicting reports on the entry of granzyme B into 
the target cell. Shi and co-workers (1997), report that granzyme B is able to enter the cell 
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cytoplasm in the absence of perforin. Froelich et al. (1996), however, state that in the 
absence of perforin, granzyme B is unable to enter the cytoplasm. Shi et al. , (1997) report 
that granzyme B remains inactive unless perforin is present, as perforin is necessary for 
apoptosis and translocation of the granzyme B to the nucleus. 
Cytoplasmic granules in NK cells were seen to be positioned near susceptible target cells 
after conjugation. The exocytosis of granule contents, including perforin, has been found in 
the space between the killer and target cell membra,,e. Release of granule contents, such 
as serine esterases and proteoglycans was detected on conjugation (Yagita et al. , 1992). By 
the use of protease inhibitors, cytotoxicity can be completely abrogated, thus postulating a 
role for granzymes in cytotoxicity, although granzymes on their own are unable to cause 
cytolysis. If target cells were treated with a sub-lytic concentration of perforin, together with 
granzyme B, it was found that granzyme B had DNA-fragmenting activity. If granzyme B acts 
on a cytoplasmic substrate, it could possibly release a DNase from actin, thus allowing the 
DNase to enter the nucleus and cause DNA degradation. Thus, although DNA fragmentation 
is not necessarily required for cell death, it occurs rapidly during perforin and granzyme 
mediated cell death. It has also been shown that if perforin and granzyme A are both added 
to target cells, DNA fragmentation can be induced. Perforin thus provides access for 
granzymes into target cells, but it appears that perforin also contributes in some way to 
apoptosis (Griffiths and Argon, 1995; Smyth and Trapani , 1995; Greenberg and Litchfield, 
1995). Nucleolin has been identified as a possible intracellular target for granzyme A, as it 
binds the protease and it could serve as a shuttle to transport this granzyme to the nucleus of 
the target cell. Granzymes could possibly affect the cytoskeleton of the target cell , or could 
increase the damage caused by perforin without itself causing damage to the membrane, by 
increasing Ca2+ levels within the cell, or by preventing repair mechanisms. Granzymes 
could, on the other hand, have no affect on the membrane at all , but merely serve as a 
necessary component for perforin processing (Greenberg and Litchfield, 1995). Ebnet and 
co-workers (1995), showed, using granzyme A-deficient mice, that granzyme A does not play 
a primary role in cell-mediated cytotoxicity by NK cells, as was previously thought. 
Mantel and co-workers (1995-a}, have reported that a human NK-like cell line (YT-INDY}, as 
well as purified fresh human NK cells utilised the Fas lytic pathway and the granule-mediated 
pathway. Fas-mediated cytotoxicity is Ca2+ independent, unlike the perforin/granule model 
and utilises the interaction of Fas antigen (AP0-1 or CD95) on the target cell with Fas ligand 
on the cytotoxic cell , triggering apoptosis. This Fas-mediated cytotoxicity could be partially 
inhibited by blocking with anti-Fas monoclonal antibody, whereas inhibition of granzyme B or 
perforin had no effect on this cytolytic pathway (Mantel et al. , 1995-a; Mantel et al., 1995-b). 
Although Oshimi and co-workers (1996), found Fas ligand expression on freshly isolated 
human NK cells, Eischen and Leibson (1997) feel that this finding may be incorrect, due to 
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technical methods employed. Eischen and Leibson (1997) report that human NK cells 
require activation for Fasl expression. Oshimi and co-workers (1996) further report that in 
the presence of Ca2+ , the percentage of apoptotic cells is profoundly reduced by anti-Fas 
mAb. This would suggest that the Fas-mediated pathway as well as the perforinlgranzyme 
pathway is significant in NK mediated cytotoxicity. Vujanovic and co-authors (1996), also 
report that nonactivated NK cells are capable of killing via necrosis (secretory) and apoptosis 
(non-secretory). These authors state that the two methods of cytotoxicity are mutually 
exclusive and complementary. Smyth and co-authors feel that p&rforin-mediated cytotoxicity 
appears to be the primary method of target cell lysis by NK cells (Smyth et al., 1994). 
Lymphokine activated killer (LAK) cells (NK cells cultured with IL-2 in vitro are called LAK 
cells), apparently lyse target cells without granule exocytosis, resulting in controversy as to 
the key role of perforin in cytotoxicity, although it must be borne in mind that this is an in vitro 
observation only (Yagita et al. , 1992). LAK cells have been shown to express low level of 
Fasl (Eischen and Leibson, 1997). LAK cells generated from perforin and Fas ligand 
deficient mice indicated that these were the only molecules important in short term 
cytotoxicity assays. In long term cytotoxicity assays (16-24 hours), these LAK cells 
generated from knockout mice had significant cytotoxicity which could be attributed to TNF. 
TNF is both membrane bound and soluble and constitutively expressed by LAK cells. With 
the addition of anti-TNF antibodies this LAK mediated cytotoxicity is completely inhibited. 
LAK cells are armed with at least three cytotoxic molecules:- perforin, Fas ligand and TNF 
(Lee et al. , 1996). 
Peripheral blood NK cells expressed perforin mRNA in both stimulated and unstimulated 
cells (Yagita et al., 1992). Active granzyme Band granzyme A are present in the nuclei of 
LAK cells, but perforin on the other hand, was not detected (Smyth et al., 1994). 
Radosevic and co-workers, (1995-b) found that the intracellular concentration of calcium 
increases in target cells that are attacked by cytotoxic cells and was sometimes found to be 
essential for effective cytolysis. Calcium, at a high enough concentration, may trigger a 
destructive pathway in the target cell. Changes in membrane potential of target cells have 
previously been found to be associated with the killing mechanism. These authors found that 
target cells under attack by cytotoxic cells responded in one of two ways. Target cells either 
die immediately (on average within 3 minutes), as a result of the membrane impermeability 
breaking down, or target cells appear to repair the initial membrane damage and survive. 
These two reactions may correlate with two separate methods of cytolysis utilised by NK 
cells. It is possible that these two different responses correspond to a greater susceptibility 
of target cells, or differing killing capacity of NK cells. The action of perforin probably 
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accounts for target cells that die immediately, resembling the colloid osmosis theory 
(Radosevic et al., 1995-b). Clearly there is no consensus of opinion. 
In a recent review article, by Kagi and co-workers (1996), it was stated that NK cells utilise 
the perforin-mediated cytotoxicity pathway exclusively. NK cells form conjugates with target 
cells and cytolytic granules are excreted during this interaction, inducing the formation of lytic 
pores in the target cell membrane. This has led to the formation of the granule exocytosis 
model for NK cytotoxicity, which is further confirmed by the isolation and clor,ing of perforin 
from cytolytic lymphocytes. Perforin is incapable of causing DNA fragmentation, but 
granzymes entering target cells through pores caused by perforin, trigger an internal 
disintegration pathway resulting in DNA fragmentation. Kagi and colleagues (1996), state 
that the mechanisms of lymphocyte-mediated cytotoxicity has been elucidated by the use of 
perforin-deficient mice and state that NK cells utilise the perforin-mediated pathway of 
cytotoxicity exclusively. 
There now follows a model of NK cytotoxicity which incorporates evidence from several 
authors. When an NK cell recognises a target cell , such as a tumour cell , and binds the cell , 
this stimulates reorganisation of the NK cell cytoskeleton and secretory apparatus. Within 
approximately five minutes, the microtubule organising centre and the golgi complex 
rearrange such that the lytic granules concentrate at the site near the bound target cell. The 
granules move along microtubules using a kinesin-like motor, thereby concentrating at the 
area of conjugation (Griffiths and Argon, 1995; Berke, 1994). Thereafter, in the presence of 
Ca2• , granules fuse with the plasma membrane, releasing the granule contents into the 
space between target and NK cell , thereby delivering the "lethal hit". It has been suggested 
that perforin polymerises in the presence of calcium to form transmembrane pores, which 
appear as ring-like tubular lesions, with an inner diameter of approximately 16 nm (ranges 5-
20 nm) in the target cell membrane. It has been suggested however, that the functional 
diameter is approximately 50 angstrom units. It is unclear whether perforin plays a direct 
lytic role in cytolysis, or whether it functions in a more indirect manner by serving as a 
conduit for other granule mediators. It appears that perforin is involved in the indirect 
manner, but these methods are not necessarily mutually exclusive. The pores allow the 
release of cytoplasmic molecules from the target cell and the influx of ions, water and 
cytoplasmic granule contents such as serine esterases from the NK cell , causing membrane 
blebbing, DNA fragmentation and apoptotic nuclear morphology within minutes (Radosevic et 
al. , 1995-a; DeBlaker-Hohe et al. , 1995; Yagita et al. , 1992; Berke G, 1994; Konjevic et al. , 
1995; Smyth and Trapani , 1995; Greenberg and Litchfield, 1995; Smyth et al., 1994; Liu et 
al., 1995). The pores are of sufficient size to allow the passage of dyes and even large 
proteins into the target cell (Lowin et al., 1994). Apoptotic bodies are rapidly phagocytosed 
by adjacent cells. DNA fragmentation is visible on agarose gels as the so-called DNA ladder. 
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The target cell undergoes osmotic changes as a result of membrane damage (Lowin et al. , 
1994). 
Killer lymphocytes need some innate mechanism of protection against perforin-mediated 
cytolysis. Liu and co-workers (1995), describe protein present on the surface of cytotoxic 
lymphocytes, called 'protectin', which may protect these cells from perforin-mediated 
cytolysis. These authors found however, that some killer lymphocytes lacking protectin were 
still resistant to perforin-mediated cytolysis. It is possible that these cells undergo membra11e 
repair, or that some other intracellular mechanism (as yet unidentified) is playing a role (Liu 
et al. , 1995). 
Results of studies undertaken indicate conclusively that perforin is involved in lymphocyte-
mediated cytolysis in vivo (Liu et al. , 1995). 
Radosevic et al., (1995-a) have shown that NK cells may penetrate into the cytoplasm of the 
target cell , a phenomenon entitled in-conjugation, when the killer cell has penetrated 
completely or partly into the target cell. When the entire cell has penetrated into the target 
cell it is called emperipolesis. This phenomenon has also been observed in vivo on biopsy 
samples (Garcia-Periarrubia et al. , 1992). 
An increase in F-actin has beer. found in conjugated NK cells in particular at the site of 
conjugation with target K562 cells. A similar increase in F-actin concentration was found in 
the conjugated K562 cells, coinciding with the appearance of filamentous actin structures, 
occurring at the point of contact. These alterations occurred after the increase in F-actin 
content of the NK cells, which was accompanied by increasing cytotoxic activity. The results 
observed were probably due to the interaction between activated NK cell and K562 target 
cell. The changes of F-actin organisation could be either as a result of cell damage caused 
by the NK cells, or a strengthening of the cell membrane in an attempt to resist the attack 








FIGURE 4. A diagrammatic representation of the perforin/granule exocytosis model of cytotoxicity. 
1. Recognition and target-effector cell conjugation. 
2. Cytoplasmic granule contents containing perforin, granzymes, calreticulin, TIA (a RNA-binding 
protein) and proteoglycans, are exocytosed into the intercellular space. 
3. Perforin binds to target cell membrane and forms transmembrane lesions. 
4. Access of granzymes and calreticulin into cytoplasm of target cell inducing apoptosis. The 
exocytosed proteins or intragranular vesicles (IGV) are possibly endocytosed and then translocated 
into the cytoplasm (Lowin et al., 1994). 
1.2.10. MEASUREMENT OF NK ACTIVITY 
Natural killer activity (NKA) can be measured as percentage cytotoxicity, using a 4 hour 
chromium release assay, which is the most widely used assay to quantify this (for more detail 
as to methodology, see chapter on Materials and Methods). 
In normal healthy individuals NKA does not appear to correlate with the number of circulating 
NK cells. As a result of this, it is necessary to perform NKA assays as well as enumeration of 
NK cells, when evaluating patients for defects in natural immunity (Whiteside, 1991 ). 
It has been found that relatively pure populations of CD16 +ve cells lyse K562 targets 
efficiently without the need of any accessory cells (Reynolds and Wiltrout, 1989). 
It is important to use fresh NK cells rather than cryopreserved cells, as cryopreservation 
sometimes decreases NKA. It is also imperative that medium contains foetal calf serum 
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rather than human serum, as human immunoglobulin has been shown to inhibit NKA 
(Whiteside et al. , 1990). 
1.2.11. FACTORS AFFECTING NKA 
NKA appears to remain relatively stable over time, although there may be a degree of 
biologic variability in the same individuals measured over time. It is thus recommended that 
serial monitorir ,g of NKA is undertaken to detect outliers which may occur. The variability in 
NKA in normal controls has been shown to be 15% above and below the mean for that 
person. Only changes in patients NKA above this variable change can be considered as 
significant. NKA demonstrates circadian as well as circannual rhythms and it is important to 
bleed patients at the same time of day, usually the morning or early afternoon as these are 
times when NKA is maximal (Whiteside, 1991 ; Whiteside and Herberman, 1989; Urba et al. , 
1987). 
Illness e.g. infection, continued stress, or drugs e.g. corticosteroids, hormones, biological 
response modifiers or chemotherapy will alter NKA. NKA is also influenced by age, sex and 
exercise (Whiteside, 1991 ; Whiteside and Herberman, 1989; Kurago et al., 1995; Whiteside 
et al. , 1990). NKA is increased with exercise, although overtraining causes suppression of 
immune function (Shepard and Shek, 1995). 
1.2.12. NK CELLS AND T CELLS 
The functional and phenotypic differences between B cells and NK cells are apparent, but 
the distinction between CTL's and NK cells has been the cause of much controversy. Both 
NK cells and T cells display phenotypic and functional similarities (Lanier et al. , 1986). CD56 
has also been found on a small portion of T cells, but CD16, is not typically present on these 
cells. By using dual markers, it is possible to distinguish between these two populations. NK 
cells are CD3- CD56+, whereas T cells are CD3+ CD56+ (Lotzova, 1991 ). 
To date no cell surface markers have been found definitively distinguishing T and NK cell 
progenitors (Spits et al., 1995). Both NK and T cells that have been activated with IL-2 are 
able to kill tumour cells independent of MHC. These MHC-nonrestricted (MHC-NR) CTL 
display similar LGL morphology to NK cells and they are able to lyse K562. MHC-NR 
restricted CTL account for 1-2% of PBMC's and have less cytolytic activity than NK cells 
(Lanier et al. , 1986). There are, however, distinct differences between these two 
populations. T cells are thymus dependant for both differentiation and function, while NK 
cells are thymus-independant as NK cells are fully functional in athymic mice (Lotzova et al., 
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1978). NK cells have the ability to kill tumour cells without prior activation, but MHC-NR T 
cells cannot (Lotzova, 1991 ). 
NK cells and T cells complement each other in their surveillance against tumour cells. 
Target cells that escape T cell recognition due to lack of or suboptimal levels of class I 
antigens (often a result of tumourigenesis), become susceptible to NK cells (see the following 
section on NK cells and MHC class I) (Moretta et al. , 1994-b; Kos and Engleman, 1996). 
1.2.13. NK CELLS AND MHC CLASS I 
As NK cells are able to lyse cells that express allogeneic MHC antigen and also cells lacking 
MHC, the activity has been referred to as non-MHC-restricted. Progress has been made in 
understanding why NK cells may lyse one target and fail to lyse another target cell. An 
inverse correlation was found between MHC class I expression on target cells and their 
susceptibility to NK-mediated cytotoxicity. Either a lack of expression of MHC molecules, or 
a masking of these molecules would render these cells sensitive to NK cytolysis, which was 
proposed by Karre and co-workers in the "missing self' hypothesis. NK cells therefore play a 
vital role in eliminating cells that do not express MHC class I molecules. Target cells become 
susceptible to NK cytotoxicity if expression of one or more MHC class I alleles are defective 
(Moretta et al., 1996; Moretta et al., 1997). Colonna (1996), states that NK cells have the 
ability to recognise the loss of even a single class I alloty:ie and not necessarily all class I 
molecules. Target cell lysis by NK cells appears to be regulated by specific activating 
signals (positive signals) that initiate cytolytic response and inhibitory receptors (negative 
signals) that down-regulate cytolysis. There is presently a limited understanding in the 
processes of molecules responsible for positive signalling in NK cells, but it is probable that 
the interaction of different receptors occurs, (e.g. CO2, CD16 and CD69) depending on the 
activation state of the NK cell. These receptors have been termed killer-cell activatory 
receptors (KAR) or natural killer cell activatory receptors (NKAR}, with a molecular mass of 
50 kDa. The involvement of receptors in negative signalling is well defined - the presence of 
MHC class I on target cells prevent NK cell-mediated cytotoxicity. NK cells express 
receptors for polymorphic MHC class I molecules that inhibit killing of target cell bearing 
appropriate alleles. These receptors have been termed killer-cell inhibitory receptors (KIR) 
or natural killer cell inhibitory receptors (NKIR) with a molecular mass of 58 kDa. The 
inhibitory receptors prevent the killing of normal cells and focus cytolytic activity towards cells 
with reduced MHC class I. Presently more is known about the prevention of NK activation 
than what causes this activation. KIR's are characterised by the ability to interact with a 
large panel of MHC class I allele products (termed promiscuous recognition). KIR's have the 
ability to transduce a negative signal which causes inhibition of natural cytotoxicity as well as 
ADCC. KIR's serve as receptors for MHC class I molecules and transduce inhibitory signals 
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in NK cells when engagement with their ligands takes place. KAR's expressed on NK cells 
are always co-expressed with at least one KIR. Furthermore, KIR inhibitory functions always 
predominate over KAR triggering of cell lysis. This may be important in the prevention of 
autologous cells from lysis (Yokoyama and Seaman, 1993; Kurago et al., 1995; Raulet and 
Held, 1995; Lanier and Phillips, 1996; Spits et al. , 1995; Lopez-Botet et al., 1996; Yokoyama 
1995; Colonna, 1996; Peria and Solana, 1992; Kagi et al. , 1995; Raulet, 1996; Warren, 
1996; Long et al., 1997; Long and Wagtmann, 1997; Renard et al., 1997; Cantoni and 
Biassoni, 1997; Cambiaggi et al., 1997). In summary therefore, NK cells express both 
activating and inhibitory receptors. Engagement of the activating receptor (the lysis receptor) 
results in either granule exocytosis and/or activation of the Fas/FasL pathway causing 
destruction of the target cell. Presently the identity of the lysis receptor remains uncertain. 
Engagement of the inhibitory receptor by class I MHC molecules on the target cell abrogates 
this lytic process (Reyburn et al., 1997.) 
The presence of MHC class I on target cells affects T cells and NK cells in opposite ways, 
although they use it to distinguish self from non-self. NK cells are not MHC restricted i.e. 
they are inhibited by self MHC class I, therefore they will kill cells lacking MHC class I. The 
presence of MHC class I on target cells inhibits killing by NK cells, i.e. NK cells kill all cells 
not recognised as self. T cells are MHC restricted i.e. they only kill targets expressing self 
MHC but containing foreign peptides in the groove. T cell recognition of target cell MHC 
allows killing, but NK recognition of target cell MHC prevents the killiny by NK cells. In the 
recognition of "missing self', NK cells complement the cytotoxic response mediated by CTL. 
Due to the fact that some virus-infected cells or tumour cells have a down-regulation of the 
expression of MHC class I molecules, they would escape the CTL-mediated lysis. NK cells 
would be important in the elimination of these MHC-negative cells (Yokoyama and Seaman, 
1993; Kurago et al. , 1995; Raulet and Held, 1995; Lanier and Phillips, 1996; Spits et al., 
1995; Lopez-Botet et al. , 1996; Yokoyama 1995; Colonna, 1996; Peria and Solana, 1992; 
Kagi et al., 1995; Raulet, 1996; Moretta et al., 1996). 
Lobo and Patel (1994) have found that MHC class II molecules also serve a protective role 
for some 8-lymphoid tumour cells against both NK and LAK - mediated cytolysis. 
Mixed lymphocyte reaction activated NK cells (CD3 depleted) can lyse PHA induced blasts 
from normal allogeneic donors, but not autologous donors. (Moretta et al., 1994-a; Ciccone 
et al. , 1992). 
K562, which is MHC class I negative is highly susceptible to NK cells, but it was found that 
on induction of class I expression, these cells became NK resistant (Gronberg et al. , 1988). 
The above holds true for autologous cells, when MHC class I molecules are lost or masked, 
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they become NK-sensitive (Moretta et al., 1994-b). Two theories have been proposed to 
account for this phenomenon (1) The effector inhibition hypothesis: presence of MHC class I 
on target cells sends a negative signal to NK cells preventing cytotoxicity, (the presence of 
MHC class I molecules may form the protective element against NK lysis (Moretta et al., 
1994-b)) or (2) The target interference hypothesis: MHC class I antigens on target cells mask 
the recognition by NK cells of NK target structures. Evidence appears to favour the former 
theory (Yokoyama and Seaman, 1993; Trinchieri , 1994; Kurago et al. , 1995). 
Some target cells expressing MHC class I antigens are susceptible to NK lysis, but it is 
possible that the tumour cells may lack expression of single class I alleles which are 
functioning as protective elements (Versteeg et al., 1989). By using allele-specific reagents, 
it was found that the loss of a single allele appears to be relatively common in some tumours 
(Moretta et al. , 1994-b). 
It is possible that NK cells are advanced in their recognition of targets to enable them to 
distinguish self from non-self, NK-sensitive targets and different targets for LAK cells (Lanier 
and Phillips, 1992). 
1.2.14. NK CELL ACTIVATION AND CYTOKINE PRODUCTION 
Much of the evidence for cytokine production by NK cells has been obtained from in vitro 
experiments and it is difficult to directly compare this to an in vivo situation. Many 
experiments are unreliable, due to the presence of contaminating cells in NK enriched 
populations. Bearing this limitation in mind, it is clear that NK cells are capable of producing 
cytokines (Perussia, 1991 ; Naume and Espevik, 1994 ). Production of cytokines by NK cells 
possibly forms one of their essential biological functions. Cytokines are important in self-
renewal , activation, cytotoxic function and in regulation of haemopoietic and lymphoid 
compartments (Lotzova, 1993). Activation of NK cells in response to various stimulatory 
factors, causes secretion of IL-1 , IL-2, IL-3, IL-4, IL-6, IL-7, IL-8, IL-12, IFN-y, 
granulocyte/macrophage colony-stimulating factor (GM-CSF) and TNF alpha and beta and 
chemotactic factors (Trinchieri, 1994; Lotzova, 1993; Perussia, 1991 ; Naume and Espevik, 
1994 ). Results of different studies have been contradictory as to the exact profile as given 
above, but this is probably due to the reasons mentioned previously. Studies appear to 
agree that resting NK cells are unable to secrete IL-2. TNF is secreted by NK cells in 
response to IL-2 and both TNF-a and TNF-P can be detected in the supematants. This 
endogenous TNF production appears to be important in LAK activity and NK proliferation. 
Neutralising antibodies to TNF inhibit the IL-2 induced cytotoxicity and proliferation (Naume 
and Espevik, 1994). Due to the fact that NK cells produce y-lFN, TNF and GM-CSF, it is 
clear that NK cells cause either negative or positive regulatory signals for haemopoiesis. NK 
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cells are thus able to modulate the activities of other leukocytes or leukocyte precursors 
(Naume and Espevik, 1994). Different cytokines have unique effects on NK cells, thus NK 
cells in vivo are able to affect immune reactions and haemopoiesis differently depending on 
the cytokine profile present (Naume and Espevik, 1994 ). 
NK cells enriched from the peripheral blood were found to lyse freshly explanted autologous 
and allogeneic tumour cells as well as K562 (a NK sensitive cell line) and to release a 
functiondlly defined lymphokine called LGL-derived cytotoxic factor. LGL-derived cytotox c 
factor was produced as a result of co-culturing PBMC with autologous tumour cells. Other 
cytokines may lyse tumour cell lines, but this factor is novel in that it has been found to lyse 
fresh human tumour cells. This factor was also found to spare nonmalignant cells (Uchida 
and Fukata, 1993). 
1.2.15. NK CELL RESPONSE TO CYTOKINES 
IL-2 is a cytokine with potent stimulatory properties and was the first immunological agent 
which demonstrated an anti-tumour effect by activating immune effectors. IL-2 also causes 
lymphoid proliferation (both in vitro and in vivo) , cytokine production, increase in the cytotoxic 
granule content, enhancement of adhesion molecule expression and increased cytotoxic 
activity (Tartour et al., 1992; Naume and Espevik, 1994; Lotzova, 1993; Foon, 1989). NK 
cells cultured with IL-2 in vitro i.e. LAK cells show enhanced cytolytic capabilities and 
increased their antitumour activity to both NK-susceptible as well as NK-resistant tumour 
target cells in vitro. LAK effectors generated from CD3- cells are usually found to be positive 
for CD16 and CD56 markers. LAK cells are able to kill their targets in an MHC non-restricted 
manner i.e. LAK cells, have the ability to kill tumour cells expressing MHC class I or MHC 
negative cells (Grimm et al. , 1982; Hercend et al. , 1983; Perussia, 1991 ; Lanier and Phillips, 
1992; Pross and Lotzova, 1993). LAK cells can be regarded as a function rather than a cell 
type or lineage (Foon, 1989; Shau et al. , 1993; Lotzova, 1993). LAK cells are able to lyse a 
greater selection of freshly explanted tumour cells than unactivated NK cells (Moretta et al., 
1994-b; Perussia, 1991 ). LAK cells have shown cytolytic activity towards autologous tumour 
cells in a short-term 51 Cr release assay (Reynolds and Wiltrout, 1989). The enhanced 
cytotoxicity of LAK cells is not due to an increase in the perforin content, but is probably due 
to increased expansion of adhesion molecules, allowing easier attachment to target cells. 
Two subsets of CD56+ cells have been stained, CD56 bright and dim. When these subsets 
are incubated in vitro with IL-2, it was found that the CD56 bright subset was stimulated with 
up to 100 times lower doses of IL-2 than the dim set. At the completion of the 7 day 
incubation period it was found that the bright population proliferated faster and 97% of the 
population consisted of this subset. This phenomenon is possibly due to the fact that CD56 
bright cells express more of the high affinity IL-2R and its beta chain (Konjevic et al., 1995). 
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In a study conducted by Caldera and co-workers (1992), LAK cells generated from normal 
controls and NHL patients were found to produce comparable levels of cytotoxicity. No 
correlation was found between the stage of lymphoma and the in vitro response of NK cells to 
IL-2 (Caldera et al. , 1992). 
Zamkoff and co-authors (1990) conducted a study using PBMC samples from patients with 
relapsed or unresponsive NHL to see whether it was possible to generate in vitro LAK activity 
by using the NK resistant but LAK sensitive cell line, Daudi . All patients were able to 
generate LAK activity. In one third of these patients LAK activity was found to be less than 
normal controls and two thirds of them had LAK activity greater than or equal to that of the 
normal controls. There was no correlation of LAK activity to either histological subtype or 
amount of prior chemotherapy. The amount of LAK activity generated by either patient or 
normal control tended to remain stable over time. 
NK cells are usually described as being nonadherent. This is only true for resting NK cells, 
but not for activated NK cells. NK cells that have been activated by IL-2 can adhere to 
plastic and have been termed adherent LAK cells (Lotzova, 1993). 
IL-6 enhances NK, but not LAK activity, whereas IL-7 has been found to cause high levels of 
LAK activity in 5 day NK purified cultures (Naume and Espevik, 1994; Spits et al. , 1995). 
TNF alone cannot influence NK activities, but when incubated with low concentrations of IL-
2, it is found to cause proliferation, induce IL-2R alpha expression and LAK activity in NK 
cells (Naume and Espevik, 1994). Transforming growth factor-beta (TGF-13) inhibits NK 
functions. Incubation of IL-2 and anti-TGF-13 was found to enhance LAK activity compared to 
IL-2 alone, thus signifying an endogenous regulatory role of TGF-13 (Naume and Espevik, 
1994). 
1.2.16. NK CELL ACTIVATION BY a-lFN 
NK cells that have been stimulated with a-lFN in vitro are found to have a greater spectrum 
of cytolytic activity against most tumours and possibly even some normal tissue (Lanier and 
Phillips, 1992; Lotzova et al. , 1993). a.-lFN, however, does not cause NK cell proliferation 
(Naume and Espevik, 1994). 
The enhanced cytotoxic activity of NK cells treated with a.-lFN in vitro was not accompanied 
by a new recruitment of NK-target binder cells but by an increase in the frequency of killer 
cells in the conjugate fraction (i.e. nonlytic conjugate-forming cells or binders) (Lebow et al. , 
1993; Jewett and Bonavida, 1995). NK cells produce a-lFN when they bind to target cells 
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and this could serve as a positive feedback mechanism regulating their lytic potential. The 
a-lFN can be detected by the use of anti-a.-lFN antibody (Raitt et al., 1987; Lebow et al. , 
1993). 
Jewett and Bonavida (1995) also observed that in vitro incubation of PBMC's with a-lFN 
resulted in a much higher cytotoxic function than NK enriched cells, suggesting a role of 
other cells in activation. Ozer and co-workers (1983) report an enhancement of 20-200% in 
NK assays in vitro following preincubation of PBMC with a-lFN at doses of 10-1000 
international units/millilitre (IU/ml). These investigators found that there was no correlation 
between clinical response and in vitro enhancement of NKA. cx-lFN causes similar 
augmentation of NKA in both normal controls and NHL patients (Mehta, et al., 1989-a). 
Draca (1993) contradicts this by stating that in most patients with disseminated tumours, the 
NK cells cannot respond to a-lFN stimulation. 
1.2.17. EFFECTS OF IN VIVO a-lFN TREATMENT ON IMMUNE FUNCTION 
Patients' proliferative response to phytohaemagglutinin (PHA) and streptokinase-
streptodornase (SK-SD) was profoundly suppressed at a high a-lFN dosage of 100 x 106 IU 
in a study conducted by Ozer and co-workers (1983). This suppression was found to return 
to the baseline levels after 1 month. The response to PHA was reported as being unaffected 
by other authors (Urba and Baseler, 1988). A depression in NKA was also observed at high 
a-lFN doses, with enhancement of NKA seen in only a few patients at low dosage. Neither of 
these results could be correlated with clinical responses. It has been noted that in cancer 
patients, the first a-lFN injection served to boost NKA, but subsequent treatment caused no 
response. Thereafter, continued frequent a-lFN treatment was found to often cause a 
decline in NKA (Reynolds and Wiltrout, 1989; Ozer et al. , 1983; Maluish et al. , 1983). NHL 
patients frequently exhibit depressed immunologic function and an explanation for those 
patients responding to a-lFN, could be that their cytotoxic function remained relatively intact. 
When a-lFN is used at high doses, the antiproliferative effects outweigh any immuno-
enhancing effects (Ozer et al. , 1983). 
It is possible that if a treatment regimen using a-lFN, which resulted in boosted NKA was 
used, a greater clinical benefit would be demonstrated for cancer patients (Maluish et al., 
1983). Whiteside and Herberman (1989) state that when high doses of a-lFN cause a 
depression of NKA, this is a form of toxicity and should be avoided, hence it is important that 
serial measurements of NKA are carried out to avoid this phenomenon (Ozer et al., 1983). It 
is possible that a considerable difference exists between the maximum tolerated dose of a-
lFN and the optimally effective dosage (Urba et al. , 1987). 
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Both T and B lymphocyte populations appeared to be unaffected by a.-lFN treatment. The 
CD4+ and CD8+ populations, as well as the ratio between them, appeared almost 
unchanged at a range of a.-lFN doses, which held true even if there was significant 
leukopenia. The relative monocyte counts were occasionally found to be elevated 24 hours 
after a.-lFN administration (Ozer et al., 1983). Urba and co-workers (1987) however, report 
an increase in CD8+ and HLA-DR+ cells and a decrease in CD4+ PBMC as result of a.-lFN 
treatment. An increase in NKA was also reported, and the increase in these parameters 
correlated with the tumour response. These same authors report on another trial , by other 
researchers who found no alteration in either total lymphocyte counts or any subsets during 
a.-lFN treatment but did find depression in NKA. Clearly there is no consensus of opinion. 
The different findings reported by the various authors could possibly be related to the use of 
either recombinant or non-recombinant a.-lFN. 
One of the major difficulties in evaluating a.-lFN treatment is that by assessing the functions 
of cells present in the peripheral blood this does not truly reflect the immune status of a 
patient. Cells present in the blood are in constant motion and these cells may not be the 
ones requiring change (Urba et al. , 1987). 
a.-lFN affects the NKA of patients by vastly different amounts, even at the same dose and 
route of administration. This poses a problem as to correlation of changes at a particular 
dose or administration site (Urba et al. , 1987). 
Serum levels during a.-lFN treatment were measurable using a bioassay, indicating that a-
lFN retains biologic activity in vivo (Ozer et al., 1983). The measurement of serum a.-lFN 
levels is however not a true reflection of a fully biologically active drug. The induction of the 
intracellular enzyme 2',5'-oligoadenylate synthetase in PBMC is recommended by some as a 
more sensitive indicator of a.-lFN treatment. This enzyme is induced by a.-lFN in a wide 
variety of cells. Others, however, have found that it does not correlate well with dosage and 
routes of administration (Urba and Baseler, 1988). 
Problems arise in interpretation of immune changes resulting from a.-lFN treatment, as some 
functions may appear enhanced, others depressed and others unaffected. For a meaningful 
comparison to be made, a large patient sample should be utilised to enable valid 
interpretation of resulting immune function (Urba and Baseler, 1988). 
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1.2.18. THE EFFECT OF IFN ON TARGET CELLS 
If NK susceptible target cells are exposed in vitro to IFN (alpha, beta or gamma) prior to NK 
cell addition, the lysis of these target cells is often markedly diminished. IFN treatment 
neither affects the conjugate formation between the target cell and the NK cell , nor the 
susceptibility of the target cells to NK cytotoxic factor, released by the effector cells. IFN 
does however appear to reduce the capacity of target cells lo induce activation of conjugated 
NK cells (Reiter, 1993). 
a-lFN has antitumour activity, not only by stimulating cytolytic activity, but also by a direct 
action on the tumour cells (Shephard and Shek, 1995). Urba and co-authors (1987) found 
that the in vitro antiproliferative effects of a-lFN on the patients' own tumour was related to an 
in vivo tumour response. 
1.3.0. IMMUNE DEFECTS IN NHL . 
Although NHL patients are generally accepted as having impaired humeral immunity, studies 
on B and T cell numbers in the peripheral blood has been conflicting. It appears that a 
drastic reduction in numbers of mature B-cells present in the peripheral blood is one of the 
important abnormalities in NHL (Janowska-Wieczorek et al. , 1987). Murray and co-workers 
(1980), report a reduction in absolute C03+ cells as well as total lymphocytes in NHL 
patients with advanced disease (stage Ill and IV), when compared to NHL patients with 
localised disease (stage I and II). Lindemalm et al. (1983), found a reduction in absolute 
C03+ and C04+ cells in the peripheral blood. Absolute numbers of COB+ cells were normal, 
giving a low C04+ to COB+ ratio. A relative reduction in C04+ and COB+ cells was also 
observed in the lymph node, but the ratio between these two subsets was comparable to 
normal patients. In a small study conducted by Balasem and Barker (1984) on untreated 
NHL patients, percentages of COB+ cells was significantly increased and the C04+ to COB+ 
ratio decreased compared to normal controls. Buchi and co-workers (1984), found a 
reduction in absolute numbers of circulating C03+ and C04+ cells in low-grade NHL 
(according to the Kiel classification) and decreased C03+, C04+ and COB+ cells in high-
grade NHL patients. These same authors found normal numbers of circulating B cells. 
Bergmann et al. (1985), report a reduction of C03+, CD4+ and COB+ lymphocytes in NHL 
patients, which was further found to be stage dependent. The reduction in T cell subsets 
was found to be unrelated to histological grade, according to the Kiel classification. B 
lymphocyte numbers remained within normal limits at all disease stages. Previously treated 
NHL patients showed a more profound reduction of CD4+ cells causing a decline in the 
C04+ to COB+ ratio. COB+ lymphocytes in previously treated NHL patients did not differ 
65 
significantly from other untreated patients or normal controls. In a study conducted by 
Janowska-Wieczorek et al. (1987) on NHL patients of various histological grades, a 
reduction in percentages of CD3+ and CD4+ cells, but not CD8+ cells was found. Burger 
and colleagues (1990) conducted studies on both high-grade and low-grade NHL patients. 
The number of CD3+, CD4+ and Leu-7+ and NK cells were found to be decreased in the 
lymph node, depending on the pathological state. This also held true for NKA. There was no 
change in the number of CD8+ lymphocytes. Datta and co-workers (1992) in their study of 
untreated NHL patients, found a significant decrease in absolute lymphucyte number, both T 
and B cell subsets, as well as the CD4+ subset. The low numbers of circulating B cells in the 
peripheral blood could be attributed to a block in B cell differentiation.· These authors state 
that the functional abnormalities of blood lymphocytes in NHL appear to be related to the 
presence of active disease. The authors further postulate that this functional impairment may 
predict relapse in these patients. 
Frydecka and co-authors (1992) found statistically significant depressed NKA in all NHL 
patients studied. This was also found to be true in the different categories of NHL, namely, 
low, intermediate and high-grade. This finding was markedly increased in patients in 
remission after either chemotherapy or radiotherapy treatment. The mean NKA reached 
normal limits in high-grade NHL and was found to be raised in intermediate and low-grade 
patients as compared to normal controls. Contradictory to this, Mehta and colleagues (1989-
b) found NHL patients had depressed NKA prior to treatment which returned to normal 
following treatment. In another study, it was reported that NHL patients demonstrated NKA 
and NK cell number comparable to normal controls (Caldera et al., 1992). Mehta and co-
workers (1989-a) on the other hand reported depressed NKA in NHL patients at diagnosis 
which returned to normal limits after treatment. These authors found that the impaired 
function in these patients occurred after conjugation, which was enhanced after treatment. 
The apparent contradiction in results obtained could be related to the different histological 
types of NHL (i .e. low, intermediate or high grade), as many researchers did not limit their 
study to any particular grade. 
Datta and co-workers (1992), report an impaired DNA synthesis following PHA stimulation in 
NHL patients. Noguchi et al. (1976), in a small study of only 16 patients, found a reduction in 
the PHA response at diagnosis, but normal percentages of T cells. King and co-workers 
(1976), found that both Hodgkin's disease and NHL patients (12 and 5 patients respectively) 
showed an impaired response to the mitogens PHA, pokeweed and concanavalin-A in vitro, 
as a result of radiotherapy or chemotherapy. 
IL-10, IL-6, IL-2 and TNF-a are produced in vivo by NHL patients at the site of the tumour. 
The presence of IL-2 at the site of the tumour may be related to tumour-infiltrating cells rather 
66 
than being produced by tumour cells. Furthermore, in NHL patients, circulating IL-6, IL-10 
and TNF-a have been found in vivo in serum and also to correlate with survival in patients 
with active NHL. IL-10, IL-6 ,IL-2 and TNF-a each stimulated proliferation of NHL tumour 
cells. A combination of all these cytokines caused the greatest level of proliferation of NHL 
tumour cells. These cytokines appear therefore to be important in promoting proliferation of 
tumour cells in vivo (Voorzanger et al., 1996). 
1.4.0. a.-lFN PRODUCTION BY PERIPHERAL BLOOD MONONUCLEAR CELLS FROM 
NHL PATIENTS 
Ho and co-workers (1992) report a deficiency in the production of a.-lFN by the PBMC's of 
low and high-grade NHL patients after stimulation with Newcastle disease virus and 
Corynebacterium parvum. When stimulated with PHA the IFN response was within the 
normal range, with the exception of LG-NHL. As Newcastle disease virus and 
Corynebacterium parvum induce mainly a.-lFN, and PHA mainly IFN-y, it would suggest that 
a deficiency exists in the a.-lFN response of NHL patients. 
1.5.0. NK CELLS AND PRIMARY TUMOUR CELLS 
Most of the evidence on NK cell function in antitumour immunity has been gained from 
experimental animals. In mice it was found that NK cells were able to inhibit NK sensitive 
tumour cells in vivo. In vivo depletion of NK cells in experimental animals has resulted in 
depressed immunity against tumours (Kos and Engleman, 1996). Data also indicates that 
NK cell anti-tumour activity is highly expressed in the blood stream against a variety of 
tumour cells including some NK resistant tumours. This data highlights the importance of NK 
cells in the control of metastatic spread and the growth of primary tumours. NK cells have 
been found to accumulate at the sites of inflammation in both primary and transplanted 
tumours (Reynolds and Wiltrout, 1989). Kurago and co-workers (1995), report that NK cells 
are only able to control small numbers of injected tumour cells, whereas CTL are able to 
eliminate large numbers of immunogenic tumour cells. These cells therefore perform 
complementary functions to each other. Circumstantial evidence suggests a role of NK cells 
in the prevention of the initial development of tumours, as humans and experimental animals 
with depressed NKA have a higher incidence of tumours. Patients on immunosuppressive 
therapy who were found to have low NKA are at high risk of developing tumours, both 
lymphoproliferative and also carcinomas. An early and profound depression of NKA is 
related to tumour incidence, suggesting an interference with natural resistance mechanisms. 
All of the above confirms the immune surveillance theory - that tumour development is 
associated with, and in fact preceded by depressed immunity. Studies have been conducted 
with the bias that NKA is the major contributing mechanism. The possibility that this activity 
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is controlled by soluble factors in vivo must be borne in mind (Reynolds and Wiltrout, 1989). 
There appears to be a correlation between low NKA and incidence of familial cancers, 
therefore a genetic deficiency in NKA may be a predisposing factor to cancer (Strayer et al. , 
1984). Draca (1993) states that there is clearly a correlation between clinical stage and 
progression of malignant disease and that in most patients with disseminated tumours, NK 
cells are not cytolytic and cannot respond to IFN stimulation. Evidence appears to be 
contradictory, with some researchers claiming low NKA to be a predisposing factor or a 
prognos.ic indicator in cancer, while other researchers feel that there is no evidence to prove 
that NK cells prevent the development of tumours (Klein and Mantovani, 1993). This is not 
surprising, given the wide range for NKA among normal donors. It remains unclear whether 
low NKA is as a result of the cancer or a contributing factor to the disease (Pross and 
Lotzova, 1993). Mehta and colleagues (1989-a) report that all NHL patients, irrespective of 
their histological type, showed significant depression in NKA and NK cytotoxic factor, when 
compared to normal controls. The ability of NK cells to recycle from one target to another, 
known as the maximal recycling capacity, was found to be depressed in some malignancies. 
Freshly explanted tumour cells are usually found to be resistant to cytolysis by NK cells, 
however, when cultured they were found to become sensitive. This cytotoxicity could be 
mediated by CTL and not as a result of NK cells at all (Klein and Mantovani, 1993). It is 
therefore important to use fresh tumour cells to measure cytotoxicity (Uchida and Fukata, 
1993). In cancer patients, it was found that NK enriched cell populations demonstrated a 
lower NKA than in normal controls, although the yield and number of NK cells was the same 
in both groups. This could possibly demonstrate a defect in kill ing activity in patients (Satam 
et al., 1986). 
In vitro resistant tumour cells (as measured by sodium chromate 51 (51Cr) release assays) 
which are inoculated intravascularly into laboratory animals, then become susceptible to 
cytolysis by NK cells in the bloodstream. It is possible that in vivo destruction by NK cells is 
more efficient than that detected by the in vitro assay and other cells, or humeral factors may 
also play a role in vivo (Reynolds and Wiltrout, 1989). It seems probable, that the avoidance 
by tumour cells of NK cytotoxicity is only a part of a complex sequence of events prior to the 
formation of a primary tumour. NK cells possibly mediate their tumouricidal effects through 
soluble factors (Reynolds and Wiltrout, 1989). 
Given the wide range of activities of NK cells, it appears that they may play an important role 
in host defence, particularly against abnormal cells early in their generation. Beige mice, 
with an NK defect, appear to be prone to the development of lymphoma, suggesting an 
important role of immune surveillance for NK cells. This NKA is non-specific (Krzanowski , 
1991 ). 
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In experiments with perforin-deficient mice, it was found that perforin-dependent cytotoxicity 
of CTL's as well as NK cells are crucial in the control of tumour cell growth (Kagi et al. , 
1995). 
1.6.0. NK CELLS AND METASTATIC SPREAD 
Investigations involv.ng experimental animals has contributed to the understanding of 
mechanisms involved in the intravascular killing of tumour cells. NK cells were found to play 
a vital role in the removal of tumour cells in the blood stream, thus preventing metastasis 
formation, although other factors such as neutrophils, monocytes, natural antibodies or 
complement cannot be excluded. Tumours may evade the NKA in the bloodstream by 
utilising the lymphatics for metastasising, as NK cell number is low in lymph nodes (Reynolds 
and Wiltrout, 1989). Augmentation of NKA could thus increase the rate of tumour cell 
elimination and metastasis formation, although data seems to indicate that stimulation of 
NKA is more effective for prevention rather than eradication of tumour metastases (Reynolds 
and Wiltrout, 1989). 
It has been proposed that NK cells recognise and kill tumour cells during the blood-borne 
phase of the metastatic cascade, however when there is a large tumour burden NK cells are 
not as competent. This is possibly due to the fact thdt their lytic capacity is overwhelmed or 
depressed due to tumour release of prostaglandins (Shepard and Shek, 1995; Reynolds and 
Wiltrout, 1989). 
NK cells are able to recognise and lyse a wide selection of tumour cells suggesting that 
these cells may be important in controlling proliferation and metastatic spread of 
heterogenous tumour cell types (Lotzova, 1993). 
1.7.0. NK ACTIVITY AS A PROGNOSTIC ROLE IN CANCER 
Evidence for NKA as a prognostic factor appears to be contradictory, with some researchers 
claiming cancer patients usually exhibit low NKA and others reporting that there was no 
difference between normal controls and patients. In a study involving NHL patients, NKA 
was found to be depressed, but this did not correlate with either stage or prognosis (Mehta et 
al. , 1989-a). Kedar and Klein, (1992), report that cancer patients do not usually demonstrate 
either impaired NK or LAK activity, nor does it correlate with clinical response. Lotzova 
(1991 ), on the other hand, feels that there is a correlation between low NKA and a higher 
incidence, progression or dissemination of cancer. This seems to be particularly true of the 
incidence of leukaemia (Lotzova, 1991 ). A genetic deficiency of NKA seems to be 
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associated with familial cancers (Strayer et al. , 1984). NKA is possibly important in 
identifying people at greater risk of cancer, particularly in the close relatives of cancer 
patients (Whiteside and Herberman, 1989). The NK cytotoxicity assay has been suggested 
as a tool for the identification of persons at a greater risk of development of cancer, or in the 
prognostic assessment of cancer patients to attempt to predict progression and 
dissemination so that early treatment can be instituted. Low NKA might be important in 
predicting poor response to treatment and shorter survival time. NKA could be important in 
the monitoring of immunotherapy (Whiteside and Herberman, 1989; Lotzova et al. , 1991 ; 
Lotzova, 1991 ; Whiteside et al., 1990). Pross and Lotzova (1993), however, feel that as a 
result of the wide range of NKA in normal controls, the use of this assay in either identifying 
patients at risk of developing cancer, monitoring of treatment or as a prognostic indicator, 
appears to be very limited. 
1.8.0. TUMOUR-INFILTRATING LYMPHOCYTES 
Tumour-infiltrating lymphocytes (TIL) are lymphocytes found within the tumour. Freshly 
harvested TIL's seem functionally "inert" in vitro compared to normal T cells, by appearing 
relatively immuno-incompetent, unless activated by IL-2. It is possible that either the 
separation techniques, or the enzymatic treatment used to isolate TIL's might result in the 
functional impairment of these cells. TIL's often express activation antigens. TIL's are 
activated and expanded from the tumour, by the in vitro incubati 1n of these lymphocytes in 
the presence of IL-2 (Tartour et al., 1992; Lotzova, 1991 ; Kradin and Bhan,1993; Whiteside 
and Parmiani , 1994). 
TIL's have been found to demonstrate good cytolytic activity after activation with IL-2, more 
so even than PBMC with LAK activity. TIL's were found to be 50 to 100 times more efficient 
at killing targets than LAK cells, and were found to be tumour specific (Rosenberg et al., 
1986; Duckett and Belldegrun, 1992). 
Unstimulated NKA present in TIL's is low compared to the NKA of PBMC's. It was found that 
in NHL, NK cells were seldom present as TIL's (Pross and Lotzova, 1993). 
In some cancers, TIL's were more difficult to culture than in others, thus it may not be 
possible to cultivate TIL's from all tumours. The observation was made, that TIL's may have 
harmful effects on normal bone marrow (Lotzova, 1991 ). 
The number, type, activation state and memory status of T -cells present as TIL's in 8-cell 
lymphoma has been suggested as predictors of clinical outcome (Grogan and Miller, 1993). 
In a study conducted by Strickler and co-workers in 1988, it was found that spontaneous 
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lymphoma regressions were more likely to occur in untreated LG-NHL patients with extensive 
helper T-cell infiltration into the lymph node. Untreated LG-NHL patients with progressive 
disease were found to have fewer T-cells as well as significantly less helper T -cells than 
patients demonstrating spontaneous regressions. The number of cytotoxic/suppressor T-
cells and NK cells was found to be the same in both groups of patients. These findings were 
confirmed in a study conducted by Medeiros and co-workers in 1989. 
Diaz and co-authors (1996), report on the pre3ence of tumour infiltrating T lymphocytes in 
NHL. A progressive increase in both memory and total T cells from LG-NHL to intermediate 
grade NHL and high grade NHL and a correspondingly decreased naTve T cell population 
was noted. These authors recommend that studies be undertaken to determine whether in 
vitro expansion and adoptive transfer of the memory T cell subset would result in tumour 
cytolysis. 
The aims of this current study were as follows:- (1) To identify patients at diagnosis who 
would respond to in vivo cx-lFN treatment. (2) To predict at diagnosis patients' response to 
cyclophosphamide. (3) To predict relapse prior to the appearance of overt symptoms. (4) To 
identify a quantifiable level of immune status that is related to a decreased risk of relapse. 
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2. MATERIALS AND METHODS 
2.1.0. PATIENTS 
A total of 32 low grade (according to the Working Formulation) NHL patients were included in 
this study, (see Figures 6 to 10 for a breakdown of all the relevant parameters). All patients 
had histologically documented NHL from excised lymph node tissue not related to the human 
immunodeficiency virus. Prior to the commencement of medication, baseline blood samples 
were received. Patients then followed a course of chemotherapy, consisting of:-
cyclophosphamide, oncovin (vincristine) and prednisone (COP) for a period of approximately 
6 weeks and blood samples were again received and analysed (postcop). Patients who 
responded to treatment were then selected to either follow a course of oral 
cyclophosphamide or subcutaneous injections of a.-lFN2b (3 x 10
6 U) three times per week; 
lntron A, Schering-Plough (PTY) LTD, lsando, RSA), for two years, according to the 
availability of a.-lFN treatment. Figure 5 summarises the treatment and indicates at which 
time points patients were bled. All patients selected for the trial , were informed and gave 
written consent. The research was approved by the ethics board. Blood samples were 
ideally received at three monthly intervals, but were not always received on schedule. 
Normal controls were run in parallel on every occasion. A total of 38 different normal 






~----------... • I Bleed patient ~-----Diagnosis 
Cop Treatment.± 6 weeks 
~----------.... 1 Bleed patient .__ ___ _. Post Cop 
Bleed patient a-lFN H Bleed patient 
Thereafter bleed patients at 3 monthly intervals or upon relapse. 
A diagrammatic representation of patient treatment and bleeding time points. 
cyclophosphamide 
cyclophosphamide, oncovin (vincristine) and prednisone 
2.2.0. PERIPHERAL BLOOD MONONUCLEAR CELL ISOLATION 
PBMC were isolated as previously described (Ratcliffe et al., 1994) - 50 ml of fresh venous 
blood from NHL patients, or 20 ml from normal controls was collected in heparinised tubes 
(Novo Nordisk (Pty) ltd, Johannesburg, RSA; 5 U/ml blood) (cell recovery was suboptimal in 
patients due to treatment, thus requiring a larger volume of blood). The blood was 
centrifuged for 12 minutes at 300 x gravitational attraction (g) and the plasma removed 
immediately and stored at -20°C for cytokine analysis. The buffy layer was removed and 
diluted with an equal volume of phosphate buffered saline (PBS; Dulbecco 'A', Oxoid, 
Unipath ltd, Hampshire, UK) and gently layered onto Ficoll-Hypaque (Lymphaprep -
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Nycomed, Oslo, Norway) for PBMC isolation by density gradient separation. The gradient 
was then centrifuged for 30 minutes at 600 x g, the PBMC layer removed and washed 3 times 
by resuspending in PBS and centrifuging for 10 minutes at 200 x g. Cells were counted, 
using Turk's solution, (which stains the leukocytes, but lyses red blood cells) and then 
resuspended in tissue culture medium consisting of, Roswell Park Medical Institute media 
(RPMI 1640; Flow, ICN Biomedicals, Aurora, Ohio) containing 100 U/ml penicillin G and 100 
µg/ml streptomycin sulfate (Sigma Chemical Company, St Louis, USA), 20mM HEPES 
(~igma Chemical Company, St. Louis, USA) supplemented with 10% heat inactivatea pooled 
human AB serum for proliferation assays, or in 10% heat inactivated foetal calf serum (FCS; 
Delta bioproducts, Kempton Park, RSA) for both the NK and LAK assays. 
2.3.0. PHENOTYPIC ANALYSIS 
Flow cytometric analysis of PBMC was performed on an Epics Profile II (Coulter Electronics, 
Hialeah, Florida). Monoclonal antibodies used were CD3-FITC, CD4-RD1 , CD8-RD1 , NKH1-
R01 (anti-CD56) and when there appeared to be malignant B-cell spill-over into the blood, 
B4-FITC (anti-CD19) (Coulter Immunology, Hialeah, Florida). For determination of 
percentage NK cells present in peripheral blood, dual parameter flow cytometric analysis was 
performed using both CD3-FITC and NKH1-RD1 monoclonal antibodies. Similarly for 
determination of both CD4+ cells and CDS+ cells, dual parameter flow cytometric analysis 
was conducted using CD3-FITC and either CD4-RD1 or CD8-RD1 . Non-specific antibody 
binding was evaluated by using the relevant mouse isotopic controls, to allow 2% false 
positives. Antibodies were used at concentrations suggested by the manufacturer. 
Lymphocytes were bitmapped to visually exclude monocytes and debris. Histogram data 
were generated for 104 events. In this way the percentage of cells positive for a particular 
surface marker was determined. 
The full blood count and differential counts were determined by the Haematology Laboratory, 
Groote Schuur Hospital , enabling the determination of absolute lymphocytes and absolute 
leukocytes. 
2.4.0. MITOGEN AND ANTIGEN PROLIFERATION 
PBMC proliferation in response to mitogen and antigen was analysed in microculture as 
previously described (Ratcliffe et al. , 1994). PBMC obtained from both NHL patients and 
normal controls, were resuspended at 1 x 106/ml in tissue culture medium, supplemented with 
10% AB human serum. Mitogenic stimulation was monitored in response to 5.75 x 10·3 
mitogenic units/ml PHA (Wellcome Research Laboratories, Beckenham, UK). Antigenic 
stimulation in response to purified protein derivative of Mycobacterium tuberculosis (PPD; 
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Central Veterinary Laboratory, Weybridge, UK) at 3 µg/ml and SK-SD (Lederle Laboratory, 
Wayne, NJ; 250 U/ml streptokinase; 62.5 U/ml streptodornase) at a final dilution of 1 :40 
(following dialysis to remove preservatives}, was also monitored. The SK-SD was heated at 
56°C for 1 hour to inactivate the enzymatic activity, which was damaging to the cells, while 
retaining the antigenicity. These concentrations were found previously to elicit maximal 
thymidine uptake. PBMC were plated in triplicate in sterile 96-well u-bottom m!crotitre plates 
(Greiner GmbH, Frickenhausen, Germany) at 106 cells/ml and incubated at 37°C in a 
humidified atmosphere containing 5% CO2 for 3 days (mitogens) or 6 days (antigens). For 
both day 3 and day 6 proliferation, triplicate wells were included, consisting of PBMC without 
mitogen or antigen for determining background (unstimulated) proliferation. Tritiated 
thymidine (Amersham International, Buckinghamshire, UK, specific activity 185 MBq/mmol) 
was added (2µci/well) on day 3 of mitogen stimulation and day 6 of antigen stimulation for a 
further 18 hours, to allow incorporation of the radiolabel into the proliferating cells. The cells 
were harvested onto titertek filter paper (Flow, ICN Biomedicals. Inc. Costa Mesa, CA), using 
an automated cell harvester (Titertek cell harvester, Flow Laboratories). The filter paper was 
air dried and the circular discs removed and placed into disposable plastic tubes (Zinsser 
Analytic, Frankfurt, Germany). Scintillation fluid was added (lnsta-Gel II , Packard, Meriden, 
U.S.A.) and tritiated thymidine incorporation was measured in a beta counter (Tricarb liquid 
scintillation analyzer 1900CA, Packard) as counts per minute (cpm). Results are expressed 
as a stimulation index (SI}, where SI = mean cpm's in stimulated wells/mean cpm's in 
unstimulated wells (background). 
2.5.0. CYTOKINE ANALYSIS 
2.5.1. PREPARATION OF SUPERNATANTS FOR CYTOKINE ANALYSIS 
PBMC (3 x 106/ml/well) were cultured in tissue culture medium supplemented with 10% 
pooled human AB serum in 24 well tissue culture plates (Falcon, Becton Dickinson and 
company, Lincoln Park, New Jersey) and stimulated by PHA (5.75 x 10-3 mitogenic units/ml; 
Wellcome Research Laboratories, Beckenham, UK). The supernatants were collected after 
24 hours and stored at - 20°C. If sufficient cells were isolated, an unstimulated well was also 
included, consisting of PBMC (3 x 106/ml/well) cultured in 10% pooled human AB serum in 
RPMI. 
2.5.2. CYTOKINE ASSAYS 
A commercial immunoradiometric assay (IL-2 IRMA, Medgenix Diagnostics, Fleurus, 
Belgium) was used to measure IL-2 concentration in the PBMC supernatants and plasma 
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samples according to the manufacturers' directions. A selection of patients from the various 
response groups and normal controls were analysed for IL-2. 
2.6.0. MAINTENANCE OF TISSUE CULTURE CELL LINES 
K562, the NK sensitive cell line, was established by Lozzio and Lozzio (1975) from the 
pleural effusion of a 53 year old female with chronic myelogenous leukemia in terminal blast 
crisis. This cell line has atlained widespread use as a highly sensitive in vitro target for the 
NK assay (Lozzio and Lozzio, 1975). 
Daudi , the NK resistant, but LAK sensitive cell line was derived from a 16 year old Black 
male with Burkitt's lymphoma by Klein and Klein in May 1967. This is a well characterized B 
lymphoblast cell line. Daudi should be handled as potentially biohazardous material under at 
least Biosafety Level 2 containment (Klein et al., 1968). 
The culture medium used for propagation of both K562 and Daudi cell lines, consisted of, 
RPMI (Flow, ICN Biomedicals, Aurora, Ohio) containing 100 Ulml penicillin G and 100 µglml 
streptomycin sulfate (Sigma Chemical Company, St Louis, USA), 20mM HEPES (Sigma 
Chemical Company, St. Louis, USA) supplemented with 10% FCS (Delta bioproducts, 
Kempton Park, RSA). Cell lines were passaged and fresh medium added every 72 hours 
with cells resuspended at 1 x 105 cells/ml in 25 cm2 tissue culture flasks (Nunc A/S, Inter 
Med, Roskilde, Denmark) and incubated at 37°C in a humidified atmosphere containing 5% 
CO2. Cells were routinely checked for Mycoplasma contamination, using an enzyme 
immunoassay Mycoplasma detection kit (Boehringer Mannheim GmbH, Mannheim, 
Germany) according to the manufacturers' directions. Cells were also routinely checked for 
purity using the Epics Profile II (Coulter Electronics, Hialeah, Florida) flow cytometer and a 
DNA propidium iodide stain (Coulter Immunology, Hialeah, Florida). 
2.7.0. NATURAL KILLER ACTIVITY 
Fresh NKA of PBMC from NHL patients and normal controls were evaluated in a standard 4 
hour sodium chromate 51 (51Cr) release cytotoxicity assay against the NK sensitive 
erythroleukaemic cell line K562, as previously described (Ratcliffe et al., 1994). It is of 
utmost importance that target cells are utilised while in the log growth phase, to ensure high 
viability and good uniform uptake of the radioisotope (Whiteside et al., 1990). K562 cells (1 x 
106) were labelled with 250 µci 51 Cr (specific activity 370 MBq/mg, Amersham International, 
Buckinghamshire, UK) for 1 hour and incubated at 37°C in a humidified atmosphere 
containing 5% CO2. The cells were then washed 3 times in cold PBS, supplemented with 
10% FCS. Three thousand targets were added to each well of a 96-well u-bottom microtitre 
76 
plate (Greiner GmbH, Frickenhausen, Germany) in 100 µI 10% FCS in RPMI. PBMC were 
serially diluted in 10% FCS in RPMI to give final effector to target ratios of 90: 1, 30: 1, 10: 1 
and 3: 1 in triplicate. It is imperative that medium contains FCS rather than human serum, as 
human lgG has been shown to inhibit NKA (Whiteside et al, 1990). Maximum 51Cr release 
was determined by the addition of 100µ1 of 5% triton-X 100 (BDH Chemicals Ltd, Poole, 
England) to target cells alone. Spontaneous 51 Cr release was measured in the absence of 
effector cells. Plates were centrifuged at 50 x g for 5 minutes · and incubated at 37°C in a 
humidified atmosphere containing 5% CO2 for 4 hours. The assay was terminated by 
centrifugation at 200 x g for 10 minutes. From each well , 130µ1 of supernatant was removed 
and transferred to disposable counting tubes (Greiner, GmbH, Frickenhausen, Germany). 
Radioactivity of samples was measured in a gamma counter (Auto-gamma, scintillation 
spectrometer 5260, Packard). To avoid circadian variation all NK assays were performed at 
the same time of day. Percentage cytotoxicity was calculated as follows: (E-S)/(M-S) x 100, 
where E is mean cpm of experimental wells, S is the mean cpm for spontaneous release and 
M is the mean cpm for maximal release. 
2.8.0. MICROSCOPIC ANALYSIS OF CYTOTOXICITY 
A 4 hour cytotoxicity assay was carried out as described above without the addition of 51 Cr. 
At the termination of the 4 hour period and after the plate had been centrifuged at 200 x g for 
10 minutes, 100 µI of supernatant was removed and 100 µI of Trypan blue added. The 
sample was well mixed and 100 µI subjected to cytospin centrifugation (Shandon Elliot, 
Shandon Southern Instruments Ltd., Camberley, Surrey, UK). The slide was air dried and 
counterstained with 0.5% carbol fuchsin. Slides were examined under a light microscope 
(Zeiss Axioskop 20, Carl Zeiss, Oberkochen, Germany) and photographed with a microscope 
camera (Zeiss MC80, Carl Zeiss, Oberkochen, Germany). 
2.9.0. ALPHA INTERFERON ENHANCED NKA 
a-lFN (lntron A, Schering-Plough (PTY) LTD, lsando, RSA - kindly provided by Schering-
Plough (PTY) LTD) was prepared by resuspending in bacteriostatic water (Bactstat; 
Schering-Plough (PTY) LTD, lsando, RSA) at a concentration of 1 x 106 U/ml. This was 
aliquoted and immediately snap frozen, using liquid nitrogen. Immediately before use, 
aliquots were gradually thawed by placing in the refrigerator. Any unused a-lFN was 
discarded. a-lFN (1 x 104 U/ml concentration, as recommended by the suppliers) was 
incorporated into the NK assay. 
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2.10.0. LYMPHOKINE-ACTIVATED KILLER ASSAY 
For measurement of LAK activity, as previously described, (Ratcliffe et al. , 1994), effector 
cells were generated by culturing 6-10 x 106 PBMC at 106/ml in 10% human AB serum in 
RPMI, supplemented with 100 U/ml recombinant human IL-2 (Cetus Corporation, Emeryville, 
CA - kindly provided by Dr Eli Kedar, Hadassah Medical School, Jerusalem, Israel) in 25 cm2 
tissue culture flasks (Nunc A/S, Inter Med, Roskilde, Denmark). The cells were incubated at 
37°C in a humidified atmosphere containing 5% CO2 for 7 days. LAK cells were pelleted at 
200 x g and viable cells were counted using a vitally excluded stain, Trypan blue (0.02% 
aqueous solution}, and resuspended in 10% FCS in RPMI , to give effector to target ratios of 
90:1, 30:1, 10:1, 3:1, 1:1, 0.3:1, 0.1:1 and 0.03:1. Thereafter, the assay was performed in 
exactly the same way as for NKA described above, with the additional inclusion of the NK-
resistant but LAK-sensitive Daudi cell line as a second target cell. Percentage cytotoxicity 
was calculated as previously described. 
2.11.0. STATISTICAL ANALYSIS USED IN THE STUDY 
The statistical program Sigma Plot (Jandel Scientific Corporation, USA) has been utilised in 
the compilation of the box and whisker graphs. A box and whisker plot is a graphical display 
that shows a measure of location (the median}, a measure of dispersion (the interquartile 
range}, and the presence of possible outliers and also gives an indication of the symmetry or 
skewness of the distribution. The box and whisker plot is made up of:- (1) Horizontal lines 
drawn at the median and at the upper and lower quartiles which are joined by vertical lines to 
produce the box; (2) A vertical line is drawn from both the upper and lower quartiles to the 
most extreme data points. In this way 90% of the data points are included. Short horizontal 
lines are added to mark the ends of these vertical lines; (3) Each data point beyond the ends 
of these vertical lines is marked with a dot (Rice, 1988). 
The software program Statgraphics (STSC Inc., Rockville, MD) was utilised in the 
determination of p-values by the Mann-Whitney U-test and, where appropriate, the Wilcoxon 




3.1.1. EXCLUSION CRITERIA AND DIFFERENT TREATMENTS 
Thirty two patients were available for evaluation, with some being excluded after the first few 
visits due to a change in treatment protocol. Patient samples should ideally have been 
received at three monthly intervals, but were not always received on schedule. Due to the 
fact that cell recovery was often suboptimal in patients, as a result of treatment, it was not 
always possible to perform all the tests required leading to incomplete data on some 
patients. The time points indicated in the figures are given as ranges, rather than definite 
points to overcome the above-mentioned difficulties. Ideally the patients in the two different 
treatment regimens should consist of equal numbers, but due to a delay in the supply of a-
lFN, more patients were treated with cyclophosphamide than with a-lFN. Twelve patients 
were treated with cyclophosphamide and eight patients with a-lFN and twelve patients with 
regimens that differed from the protocol and have been referred to as "miscellaneous 
patients". The miscellaneous group of patients were included in the study until the treatment 
differed from the stipulated protocol. Normal controls were run in parallel on every occasion. 
A total of 38 different controls were used, with a large proportion being utilised on more than 
one occasion. On repeated testing of normal controls no significant inter-assay variation was 
found. 
3.1.2.0. DISTRIBUTION OF NHL PATIENTS IN THIS STUDY 
3.1.2.1. PATIENT CLASSIFICATION 
Category C, according to the Working Formulation, accounted for the majority of patients in 
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FIGURE 6. Patient Classification distribution. 
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An indication of the distribution of NHL patients according to the Working Formulation 
Classification. 
3.1.2.2. PATIENT STAGING 
The vast majority of patients in this trial were already at stage IV, according to the Ann Arbor 
staging method, when diagnosed (Figure 7). As previously mentioned in the Introduction, the 
majority of LG-NHL are at stage Ill or IV when detected, with only 15-20% being diagnosed at 
stages I and II. This trend was substantiated in the current study, although no patients were 
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FIGURE 7. Patient stage distribution. 
An indication of the Ann Arbor stage distribution of NHL patients. 
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3.1.2.3. PATIENT AGE DISTRIBUTION 
The majority of patients in this trial were between 51-70 years of age (Figure 8). The finding 
that LG-NHL is more common in the elderly was confirmed in the current study. It was found 
that 22% of the patients were > 64 years of age; 72% were 35-64 years of age and 6% were 
< 35 years of age. This study was limited to adults which may result in the moderate 
discrepancy in percentages of patients found in the different age groups as discussed in the 
Introduction (Table 1 ). 
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FIGURE 8. Patient age distribution. 
An indication of the age distribution of NHL patients. 
3.1.2.4. PATIENT SEX DISTRIBUTION 
The male to female ratio of this trial was assessed and found to be 7:9 (Figure 9) which is 
different from that reported by Hancock (1995). Hancock was discussing all NHL's and not 
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FIGURE 9. Patient sex distribution. 
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An indication of the sex distribution of NHL patients. 
3.1.2.5. PATIENT RACE DISTRIBUTION 
I 
50 60 
It was found that most patients in this study were white, with fewer coloured patients and only 
1 black patient (Figure 10). This confirms the report by Greiner and co-workers (1995), 
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3.2.0. IMMUNE STUDIES PERFORMED ON PATIENT BLOOD SAMPLES 
3.2.1. ANALYSIS OF NKA AND a-lFN ENHANCED NKA 
Whiteside and co-authors (1990) recommend the use of lytic units in the estimation of NK 
cytotoxicity. In the determination of lytic units, the percentage cytotoxicity at all the effector 
to target ratios should fall in the linear portion of the graph. In this study however all the 
effector to target ratio cytotoxicity values did not satisfy this requirement. The use of lytic 
units did not accurately reflect the cytolytic potential of the cells and was not suitable in this 
study for comparative purposes. It was decided therefore to rather compare percentage 
cytotoxicity at a specific effector to target ratio, which was more representative of the results. 
An indication of NKA is shown as a box and whisker plot (Figure 11-A). On the Y-axis the 
percentage cytotoxicity is shown at the effector to target ratio of 10: 1. It should be noted that 
all other effector to target ratios gave similar trends. On the X-axis, the normal controls are 
indicated first, with patients' baseline results next (at diagnosis and prior to the 
commencement of treatment). Thereafter the patients' results are given for postcop (after 
completion of COP treatment) and at various intervals until >100 weeks after the 
commencement of treatment. The mean of NKA for controls (18.43 ± 10.11) (mean ± 
standard deviation) was found to be lower than that of patients at diagnosis (24.57 ± 15.94) , 
although this difference was not statistically significant. The NKA was found to decrease 
after the commencement of treatment. The mean for post cop was ( 17. 76 ± 10.12) and this 
diminished even further until it reached the lowest level at 51-70 weeks (11 .5 ± 9.32). At 71-
100 weeks it increased slightly (12.39 ± 5.57) until >100 weeks (16.03 ± 10.61 ). It must be 
borne in mind that the median rather than the mean is indicated in box and whisker plots. 
The difference in this cytotoxicity between patients and controls was found to be statistically 
significant at 30-50 weeks with a p value of <0.05. The difference between patients' baseline 
results and 30-50 weeks (p<0.05) and 51-70 weeks (p<0.05) was found to be statistically 
significant. In all the findings that are found to be statistically significant, sample size has 
been taken into account, but it must be pointed out that with time, the sample size in all 
assays undertaken was decreased. 
Results of studies investigating the NKA of NHL patients have been contradictory. Frydecka 
and co-authors (1992), found statistically significant depressed NKA in all NHL patients 
studied, as well as in the different categories of: low, intermediate and high-grade. Contrary 
to this, Mehta and colleagues (1989-b), found NHL patients had depressed NKA prior to 
treatment which returned to normal following therapy. In another study, it was reported that 
NHL patients demonstrated NKA and NK cell numbers comparable to normal controls 
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(Caldera et al. , 1992). The apparent contradiction in results obtained could be related to the 
different histological types of NHL i.e. low, intermediate or high grade. 
The reason for the finding of a decrease in NKA until 51-70 weeks and then an increase is 
probably due to chemotherapy. It has been established that NKA is diminished in patients 
treated with chemotherapy (Whiteside et al. , 1990). This finding is confirmed in the current 
study. 
a.-lFN augmented NKA (NKA + a.-lFN) using 1 x 104 U/ml is shown in Figure 11-B. A very 
similar trend in results with a.-lFN was detected as that obtained in the NKA results (Figure 
11-A). The patients' baseline NKA + a.-lFN (33.89 ± 18.68) was found to be higher than that 
of the normal controls (26.89 ± 10.08). It is a well established fact that a.-lFN enhances the 
cytolysis of mature PBMC derived NK cells in vitro (Kedar and Klein, 1992; Pollack, 1993). 
This was confirmed in the present study. Controversy exists as to the possible enhancement 
of patients' NKA after in vitro a.-lFN incubation. Mehta and co-workers (1989-a) report similar 
augmentation in both NHL patients and controls. Once again the study by Mehta and co-
workers was not limited to LG-NHL, hence the possible slight discrepancy. Draca (1993) 
contradicts this by stating that in most patients with disseminated tumours, the NK cells 
cannot respond to a.-lFN stimulation. 
Although the postcop results (33.02 ± 12.12) were similar to baseline, NKA + a.-lFN was 
depressed at 30-50 weeks ( 18.25 ± 16.49}, which is probably an indication of the effects of 
chemotherapy. Thereafter the activity rose steadily, until 71-100 weeks (27.32 ± 7.03) at 
which point the mean of the patients' NKA + a.-lFN were similar to controls (26.89 ± 10.08). 
The difference between the controls and patients NKA + a.-lFN results was found to be 
statistically significant after 30-50 weeks, with p<0.01 . Patients' baseline and 30-50 week 
results were also statistically significantly different with p=0.01 , as was the difference 
between postcop and 30-50 weeks with p<0.05. The majority of both patients and controls 
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FIGURE 11. NKA and a-lFN enhanced NKA in controls and patients over time. 
NKA (A) and a-lFN enhanced NKA of PBMC (B) from LG-NHL patients was evaluated in a 
standard 4 hour 51 chromium release assay against K562. a-lFN (1 X 104 U/ml) was 
incorporated into the NK assay (B). On the Y-axis percentage cytotoxicity can be seen at an 
effector to target ratio of 1 O to 1. On the X-axis, the normal controls are indicated first, with 
patients' baseline results next (at diagnosis and prior to the commencement of treatment). 
Thereafter the patients' results are given for postcop and at various time intervals until >100 
weeks after the commencement of treatment. 
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3.2.2. INDIRECT CALCULATION OF NK CELLS REQUIRED TO KILL ONE K562 
TARGET CELL 
By utilising the phenotypic analysis in determining the percentage of NK cells (CD56+) 
present in the peripheral blood, and with the addition of a known number of lymphocytes in 
the NK assay, it was possible to determine the number of NK cells present. The number of 
KS62 cells added was also known, therefore it was possible to determine the number of NK 
cells that were required to kill 1 KS62 target cell (Figure 12-A), and similarly, after boosting 
with a-lFN (Figure 12-B). The number of patients in this graph is different to that in Figure 11 
A and B, due to the fact that not all patients had both NKA and percentage NK cells assayed 
on every sample submitted, as a result of insufficient cell recovery. It was found that the 
patients' baseline results indicated that more NK cells were required to kill 1 target K562 cell 
(10.76 ± 8.2) than in normal controls (8.28 ± 4.94) (Figure 12-A), although this difference did 
not reach statistical significance. Fewer NK cells were required to kill a K562 target cell at 
postcop (7.98 ± 3.46), but by 30-50 weeks (15.66 ± 6.27), this number had increased 
dramatically, the difference being statistically significant with p<0.05. This finding is possibly 
as a result of the diminished NKA or alterations in distribution of NK subsets, due to 
chemotherapy. The difference between the NK cell number required to kill 1 target cell in 
controls and patients at 30-50 weeks is significant with p<0.01 . 
NKA was enhanced by a-lFN (Figure 12-B) and the trend of these results resembles those in 
Figure 12-A, except that the difference between controls (5.16 ± 4.02) and patients at 
baseline (6. 77 ± 4.82) does not appear to be as marked. Initially at postcop (5.16 ± 2.49), 
there appears to be some improvement in that fewer NK cells boosted by a-lFN are required 
to kill the 1 K562 target cell. By 30-50 weeks (12.99 ± 5.62) however, the number of cells 
required has increased significantly between baseline values (p<0.05) and controls (p<0.01 ). 
This is once again thought to be as a result of chemotherapy. 
Several factors would limit the confidence with which one can interpret the results obtained, 
using this indirect calculation of lytic activity. These include the heterogeneity of NK subsets, 
and the use here of only one NK cell marker (CD56). Afify and co-workers (1990), reported 
that CD56+ cells mediate the most NKA in the peripheral blood. However, LeFever and 
Funahashi (1991), state that CD56+CD16+ NK cells are the most lytic subpopulation. Srour 
et al. (1990), state that CD3-(CD16+CD56+)CD57-CD8+ cells were most effective in 
mediating cytolysis against KS62 cells. It is therefore possible that alterations in NK subsets, 
as a result of the disease or chemotherapy, may have impacted on the level of cytotoxicity 
obtained. Given these limitations the results need to be interpreted with caution. However, 
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the data would support reduced lytic activity of NK cells in LG-NHL patients at diagnosis and 
following chemotherapy as being either due to :-
1. Reduced lytic activity of CD56+ NK cells, as was found in CD56+ sorted cells in acute 
lymphoblastic leukaemia patients at diagnosis (Afify et al., 1990). 
2. Selective expansion of CD56+CD16- NK cells, the least lytic subset, which has been 
described in patients with bronchogenic carcinoma (LeFever and Funahashi, 1991 ). 
Dual fluorescent staining using both CD56 and CD16 antibodies would have been 
necessary to more definitively resolve the mechanism accounting for the findings 
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FIGURE 12. Effectivity of NK cells and effectivity of a-lFN enhanced NK cells in controls 
and patients over time. 
NKA of PBMC from LG-NHL patients was evaluated in a standard 4 hour 51 chromium release assay against K562. By utilising the phenotypic analysis in determining the % NK cells present in the peripheral blood, and with the addition of a known number of lymphocytes in the NK assay, it was possible to determine the number of NK cells required to kill 1 K562 
target cell (A). This figure is indicated on the Y-axis (A). In a similar manner the a-lFN 
enhanced NKA of PBMC from LG-NHL patients was evaluated with a-lFN (1 X 104 U/ml) 
incorporated into the NK assay. The effectivity of a-lFN enhanced NK cells was determined (B). This figure is indicated on the Y-axis (B). On the X-axis, the normal controls are indicated first, with patients' baseline results next (at diagnosis and prior to the commencement of treatment). Thereafter the patients' results are given for postcop and 30-50 weeks after the commencement of treatment. Less patients are indicated in Figure 12 as compared to Figure 11 , due to the fact that not all patients had both NKA and % NK cell number assessed due to insufficient cell recovery from peripheral blood samples. 
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3.2.3. MORPHOLOGICAL FEATURES OF NK CYTOTOXICITY 
In an attempt to validate the standard chromium release cytotoxicity assay, the 
morphological features of NK cytotoxicity against K562 (Figure 13) and Daudi (Figure 14) at 
the termination of a four hour NKA assay (without the addition of 51 Cr) were examined 
microscopically. Trypan blue was added and cells counterstained with 0.5% carbol fuchsin. 
Although NK cells make contact and are interacting with the Daudi target cells, these target 
cells are not lysed (Figure 14). This can be compared to Figure 13, where the NK cells are 
both interacting with and lysing the K562 target cells. 
FIGURE 13. Morphological features of NK cytotoxicity assay against K562. 
A 4 hour cytotoxicity assay was carried out as usual , but without the addition of sodium 
chromate. At the termination of the 4 hour period, 100 µI of supernatant was removed and 
100 µI of trypan blue added. 100 µI of this sample was then subjected to cytospin slide 
centrifugation, air dried and counterstained with 0.05% carbol fuchsin. Viable cells are 
stained reddish-pink and non-viable cells blue-black, due to the uptake of trypan blue. A 
non-viable K562 cell can be seen in close contact with NK cells. Magnification X 1000. 
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FIGURE 14. Morphological features of NK cytotoxicity against Daudi. 
A 4 hour cytotoxicity assay was carried out as usual, but without the addition of sodium 
chromate. At the termination of the 4 hour period, 100 µI of supernatant was removed and 
100 µI of trypan blue added. 100 µI of this sample was then subjected to cytospin slide 
centrifugation, air dried and counterstained with 0.05% carbol fuchsin. Viable cells are 
stained reddish-pink and non-viable cells would have stained blue-black, due to the uptake 
of trypan blue. Viable Daudi cells are in close contact with NK cells. Magnification X 1000. 
3.2.4. ANALYSIS OF LAK AGAINST K562 AND DAUDI 
LAK against K562 and Daudi is indicated in Figure 15 A and B respectively. Although only 
the percentage cytotoxicity at an effector to target ratio of 3 to 1 has been shown, it should 
be emphasised that all other effector to target ratios gave similar trends. LAK against K562 
at baseline was found to produce comparable levels of cytotoxicity in both the patient (41 .07 
± 20.93) and control groups (45.47 ± 17.73). These findings confirm those of Caldera and 
co-workers (1992), who reported that generation of LAK activity against K562 and Daudi was 
both possible and comparable in both responsive and unresponsive patients. No 
conclusions can be drawn from the LAK activity over time due to a wide spread of data and 
relatively few patient numbers, although the general trend appears to be an increase in the 
LAK against K562 up until 70 weeks after which there is a decline. No differences in any of 
the results were found to be statistically significant. 
LAK against Daudi (Figure 15-8) was slightly depressed in patients at diagnosis (24.45 ± 
17.15) compared to controls (32. 7 4 ± 16.26). All patients tested were able to generate LAK 
activity against the NK resistant but LAK sensitive cell line Daudi . This confirmed the 
findings of Zamkoff and co-workers (1990), as discussed in the Introduction, where it was 
stated that LAK against Daudi was slightly depressed compared to controls, but not 
significantly so. Due to insufficient lymphocyte recovery in some patients, LAK against Daudi 
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was not performed, resulting in fewer patients in Figure 15-B than in Figure 15-A. As a 
result of this, only three patients are available at 30-50 weeks (27.28 ± 9.4) and the spread is 
quite large making any accurate observations impossible. It would be unwise therefore to 
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FIGURE 15. LAK against KS62 and Daudi in controls and patients over time. 
LAK cells were generated by culturing 6-10 X 106 PBMC at 106/ml in 10% human AB serum 
in RPMI, supplemented with 100 U/ml recombinant human IL-2 for 7 days. LAK activity was 
evaluated in a standard 4 hour 51 chromium release assay against KS62 (A) and Daudi (8). 
On the Y-axis percentage cytotoxicity can be seen at an effector to target ratio of 3 to 1. On 
the X-axis, the normal controls are indicated first, with patients' baseline results next (at 
diagnosis and prior to the commencement of treatment). Thereafter the patients' results are 
given for postcop and at various time intervals until 71-100 weeks after the commencement 
of treatment. The LAK against Daudi is only indicated for baseline and 30-50 weeks after 
treatment due to insufficient lymphocyte recovery in many patients. 
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3.2.5. PHENOTYPIC EVALUATION OF BLOOD SAMPLES 
The percentage of circulating CD3+ cells present in the peripheral blood of patients prior to 
the commencement of treatment (Figure 16) (57.25 ± 18.45) is statistically significantly lower 
than controls (73.69 ± 8.91) (p<0.01 ). Patients' percentage CD3+ cells are found to reduce 
at paste.op and then increase until 51-70 weeks (78.93 ± 9.69), after which there is a 
reduction (65.67 ± 12.61 ). The percentage of CD3+ cells in patients at baseline are 
statistically significantly different from 30-50 weeks (p<0.01) and 51-70 weeks (p=0.01 ). The 
difference between postcop and 30-50 weeks is also significant (p<0.05), as well as the 
difference between postcop and 51-70 weeks (p<0.05). The difference between 30-50 
weeks (p<0.05) and 71-100 weeks is also significant (p<0.05) as is the difference between 
51-70 and 71-100 weeks (p<0.05). The difference between controls and postcop is also 
significant (p<0.05) . Possible reasons for these important findings are discussed after the 
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FIGURE 16. Percentage circulating CD3+ cells present in PBMC of controls and patients 
over time. 
Flow cytometric analysis of PBMC was performed enabling the determination of % CD3+ 
cells present in the peripheral blood. On the Y-axis percentage CD3+ cells can be seen. On 
the X-axis, the normal controls are indicated first, with patients' baseline results next (at 
diagnosis and prior to the commencement of treatment). Thereafter the patients' results are 
given for postcop and at various time intervals until 71-100 weeks after the commencement 
of treatment. 
The percentage of CD4+ cells present in the peripheral blood of patients at baseline (Figure 
17) (36.28 ± 14.7) is lower than normal controls (43.36 ± 7.31 }, although not significantly so. 
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A very slight reduction in percentage CD4+ cells is found at postcop (34.05 ± 3.64) and then 
an increase at 30-50 weeks ( 41 . 33 ± 11 .12) until 51-70 weeks ( 48. 77 ± 11 .88), after which at 
71-100 weeks (31 .8 ± 8.77), the percentage of CD4+ cells decreases. The percentage of 
CD4+ cells between controls and patients at postcop (p<0.01 ) and 71-100 weeks (p<0.01) 
are significantly different. The difference between patients' percentage CD4+ cells at 
postcop and 51-70 weeks is significant (p<0.01), as to is 51-70 and 71 -100 weeks (p<0.05). 
Bergmann et al. (1985) report a dramatic reduction in CD4+ cells following either 
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FIGURE 17. Percentage circulating CD4+ cells present in PBMC of controls and patients 
over time. 
Flow cytometric analysis of PBMC was performed enabling the determination of % CD4+ 
cells present in the peripheral blood. On the Y-axis percentage CD4+ cells can be seen. On 
the X-axis, the normal controls are indicated first, with patients' baseline results next (at 
diagnosis and prior to the commencement of treatment). Thereafter the patients' results are 
given for postcop and at various time intervals until 71-100 weeks after the commencement 
of treatment. 
Patients at diagnosis have significantly less percentage COB+ cells present in the peripheral 
blood (Figure 18) (16.74 ± 8.98) as compared to controls (24.18 ± 5.75) (p<0.05). The 
circulating percentage CD8+ cells are found to increase at postcop (22.73 ± 14.14) until 30-
50 weeks (30.58 ± 9.88) after which a reduction at 51-70 weeks (28.13 ± 8.66) and slight 
increase at 71-100 weeks is then found (28.93 ± 9.81). The difference between the baseline 
results and 30-50 weeks, 51-70 weeks and 71-100 weeks is significant with p values of 
0.005; 0.04 and 0.02 respectively. 
94 
100 




!I! 60 - -s 
,0 ..... 
50 - n=9 1: 
n=6 n=6 " n=6 e
~ ~ 





30 .... g 20 t-
10 t-
0 ' ' ' ' I I 
Control Baseline Postcop 30-50 51-70 71 -1 00 
Weeks Weeks Weeks 
FIGURE 18. Percentage circulating COB+ cells present in PBMC of controls and patients 
over time. 
Flow cytometric analysis of PBMC was performed enabling the determination of % COB+ 
cells present in the peripheral blood. On the Y-axis percentage COB+ cells can be seen. On 
the X-axis, the normal controls are indicated first, with patients' baseline results next (at 
diagnosis and prior to the commencement of treatment). Thereafter the patients' results are 
given for postcop and at various time intervals until 71-100 weeks after the commencement 
of treatment. 
As discussed in the Introduction, Burger and colleagues (1990), concluded that in both high 
and low grade NHL, patients were found to have a decrease in C03+, C04+, Leu-7 (an NK 
and T-cell subset marker) and NK cells, with no difference in COB+ cells. These findings 
were dependent on the pathological state of the patient. The results in this study appear to 
partially confirm those of Burger and co-workers, however COB+ cells were also markedly 
reduced. 
95 
It must be emphasised that the changes in lymphocyte subsets are relative changes only, as 
the percentages of these cells and not absolute numbers were determined. It must be bone 
in mind that as the percentage of one cell subset increases, this would inevitably cause a 
reduction in another subset. Given these limitations, the possible reasons for reduced T 
cells and their subsets at diagnosis could be that:-
1. The cells are not present in the peripheral blood as they have translocated to the site of 
pathology. 
2. The occurrence of bulk disease in the bone marrow i.e. the malignant clone resulting in 
marrow replacement. This would result in less precursor T cells and consequently fewer 
percentages of CD3+, CD4+ and COB+ cells. 
3. As mentioned in the Introduction, depending on the type and stage of evolution of NHL, 
malignant cells may be present in the peripheral blood, similar to the lymphocyte 
leukaemic picture (Babior and Stossel , 1994). If this is the case, the reduction in 
percentages of CD3+ cells present in the peripheral blood may be as a result of the 
malignant spill-over into the peripheral blood resulting in a reduction of percentage CD3+ 
cells. The leukaemic picture is often present in NHL patients classified as Category A of 
the Working Formulation, which accounts for only approximately 10% of patients in this 
study. As the majority of patients are Category B and C, this explanation is not as valid as 
previous ones discussed. 
The general trend for the percentage of circulating CD3+, CD4+ and COB+ cells is found to 
increase until approximately 51-70 weeks after which time there is a substantial decrease in 
the percentage of CD3+ and CD4+ cells. The percentage of COB+ cells is found to plateau 
off after 51-100 weeks. The reason for the reduction in the percentage CD3+ cells at 
postcop is undoubtedly due to chemotherapy. The increase in percentage CD3+ after 
postcop and percentage CD4+ and COB+ cells after baseline, may be due to a reduction in 
the malignant cells in the bone marrow allowing for more precursor lymphocytes. More 
precursor cells in the bone marrow would result in more T cells being present in the 
peripheral blood. This finding would be largely dependent on the amount of 
myelosuppression caused by the chemotherapy. It is important to remember that changes in 
the peripheral blood cell counts lag behind changes in the bone marrow production pools as 
previously mentioned (Bodensteiner and Doolittle, 1993; Dorr and Fritz, 1982). Another 
possibility is that as the chemotherapy begins to control the lymphoma cells at the site of 
pathology, there is no longer a need for these cells to leave the peripheral blood and 
translocate to the site of pathology. This would result in the presence of more T cells in the 
peripheral blood which was seen after postcop. A further explanation could be that as the 
chemotherapy begins to control the number of malignant cells present in the peripheral 
blood, this would allow the T cell numbers to stabilise. 
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It must be emphasised that the reduction in the percentage of circulating C03+ and COB+ 
cells at diagnosis is not due to the fact that these patients are lymphopenic, as only five of 
thirty patients tested demonstrated reduced absolute lymphocytes (Table 12, 13 and 14), 
which would not account for the statistically significant differences that were obtained. Of the 
two lymphopenic patents on whom T -cell subsets were analysed, one patient had a reduction 
in the percentages of C03+, C04+ and COB+ cells and the other a reduction in percentage 
COB+ cells. One patient who was both lymphopenic and leukopenic had normal percentages 
of C03+, C04+ and COB+ cells. Three of the patients presenting with normal numbers of 
both lymphocytes and leukocytes had a reduction in the percentages of C04+ cells, another 
three a reduction in the percentages of COB+ cells and one patient a reduction in 
percentages of C03+, C04+ and COB+ cells. One patient with normal absolute leukocytes 
and lymphocytes had increased percentages of C03+ cells. The most interesting finding, 
was that four patients with increased lymphocytes and leukocytes had reduced percentages 
of C03+, C04+ and COB+ cells. It is unfortunate that a full blood count and a differential 
count were not performed simultaneously with phenotypic evaluation, which would have 
enabled a more conclusive assessment of absolute cell numbers as well as percentages of 
cells, especially in the light of these above-mentioned findings. Although full blood count, 
differential count and phenotypic evaluation was undertaken in most of the patients, these 
were performed at different times, making an accurate evaluation of absolute numbers of T-
eed subsets impossible. 
The ratio between the percentage of circulating C04+ and COB+ (C04:C08) (Figure 19) 
between patients' baseline results (2 .82 ± 1.95) and controls (1 .94 ± 0.64) is found to be 
higher, although not significantly so. The ratio has diminished by postcop (2.09 ± 1.34) and 
more so by 30-50 weeks (1 .57 ± 0.92). There is a slight increase in the mean at 51-70 
weeks (1 .89 ± 0.81) and a reduction in this value at 71-100 weeks (1.48 ± 0.61). The 
difference between the C04:C08 ratio from baseline and 30-50 (p<0.05) and 71-100 weeks 
(p<0.05) is significant. The difference between the control results and patient results at 71-
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FIGURE 19. The ratio of% CD4+ cells to% CD8+ cells present in PBMC of controls and 
patients over time. 
Flow cytometric analysis of PBMC was performed enabling the determination of % CD4+ 
cells present and % CD8+ cells present in the peripheral blood. The ratio of % CD4+ cells to 
% CD8+ cells was determined. On the Y-axis the ratio of CD4:CD8 cells can be seen. On 
the X-axis, the normal controls are indicated first, with patients' baseline results next (at 
diagnosis and prior to the commencement of treatment). Thereafter the patients' results are 
given for postcop and at various time intervals until 71-100 weeks after the commencement 
of treatment. 
There are significantly more percentage NK cells present at baseline in the patients (Figure 
20) (20.65 ± 12.08) when compared to controls (11 .59 ± 5.77) (p=0.01), as determined by 
staining CD56+ which is a known NK cell marker. A reduction is found in this value at 30-50 
weeks (11 .79 ± 6.75) by which time the result is very similar to that of normal controls. There 
is a steady increase in the percentage of NK cells until 71-100 weeks (21 .31 ± 7.64). The 
difference between patients' baseline results and 30-50 weeks is significant, with p<0.05. It 
is intriguing to note that a similar statistically significant reduction in percentage NK cells and 
NKA is seen at 30-50 weeks. This finding is possibly as a result of chemotherapy causing a 
reduction in the percentage of circulating NK cells, which would further result in reduced 
NKA. The difference between 30-50 weeks and 71-100 weeks (21 .31 ± 7.64) is also 
significant (p<0.05). The difference between controls (11 .59 ± 5.77) and postcop patients 
(21 .24 ± 11.27) as well as patients at 71-100 weeks (21 .31 ± 7.64) after the commencement 
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FIGURE 20. Percentage circulating NK cells present in PBMC of controls and patients 
over time. 
Dual parameter flow cytometric analysis of PBMC was performed enabling the determination 
of % CD56+ (NK) and % CD3- cells present in the peripheral blood. On the Y-axis 
percentage NK cells can be seen. On the X-axis, the normal controls are indicated first, with 
patients' baseline results next (at diagnosis and prior to the commencement of treatment). 
Thereafter the patients' results are given for postcop and at various time intervals until 71-
100 weeks after the commencement of treatment. 
NK cells have been proposed as the first line of defence against tumour cells (Caldera et al. , 
1992). Data indicates that NK cell anti-tumour activity is highly expressed in the blood 
stream thus preventing metastasis via this route. This highlights the importance of NK cells 
in the control of metastasis and the growth of primary tumours (Reynolds and Wiltrout, 1989). 
It has been proposed that NK cells recognise and kill tumour cells during the blood-borne 
phase of metastasis, but when there is a large tumour burden, NK cells are not as 
competent. This is possibly due to the fact that their lytic capacity is overwhelmed, or 
depressed due to tumour release of prostaglandins (Shepard and Shek, 1995; Reynolds and 
Wiltrout, 1989). The increase in the percentage of NK cells in the peripheral blood at 
diagnosis of patients in this study when compared to normal controls, is possibly an attempt 
by NK cells to overcome the tumour burden. 
Most of the evidence on NK cell function in antitumour immunity has been gained from 
experimental animals. In mice, it was found that NK cells were able to inhibit NK sensitive 
tumour cells in vivo. In vivo depletion of NK cells in experimental animals has resulted in 
depressed immunity against tumours (Kos and Engleman, 1996). NK cells have been found 
to accumulate at the sites of inflammation in both primary and transplanted tumours 
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(Reynolds and Wiltrout, 1989). 'Beige' mice with an NK defect, appear to be prone to the 
development of lymphoma, suggesting an important role of immune surveillance for NK cells 
(Krzanowski, 1991 ). In this study, the increase in percentage of NK cells in the peripheral 
blood could be an attempt by the host to overcome the malignant cells. It is dissappointing 
that staining was only undertaken on a single NK cell marker (CD56). Had dual staining 
been carried out on both CD56 and CD16 markers, more information could have been gained 
on the lytic ability of these cells. As previously mentioned, the CD56+CD16+ NK cells are 
more lyti,; than CD56+CD16- NK cells (LeFever and Funahashi , 1991 ). The finding of a 
particular cell phenotype however does not imply fully functional activity as indicated by Urba 
and co-workers (1987). Kurago and co-workers (1995) report that NK cells are only able to 
control small numbers of injected tumour cells, whereas CTL are able to eliminate large 
numbers of immunogenic tumour cells. These cells therefore appear to perform 
complementary functions to each other. Although in this study the percentage of NK cells 
was increased in the bloodstream, the percentage of CD8+ cells was depressed. Possibly 
this complementary function was not working as effectively as it should have been (Moretta 
et al., 1996). 
The decrease in percentage CD3+ cells and the increase in percentage NK cells of patients 
at diagnosis when compared to normal controls could also be attributed to secondary 
reciprocal changes in the cell types sharing the common peripheral blood compartment. 
A comparison was made between percent NK cells and cytotoxicity in both controls and 
patients and no correlation was found (data not shown). Whiteside (1991), concluded that in 
normal healthy individuals, NKA did not appear to correlate with the number of circulating NK 
cells. This finding is confirmed in this current study. 
3.2.6. MITOGEN AND ANTIGEN PROLIFERATION 
The mean of the PHA stimulation index (SI) [a ratio of PHA counts per minute (cpm's) to 
background cpm's] for patients at diagnosis (349.74 ± 233.68) and prior to the 
commencement of treatment is similar to that of normal controls (340.64 ± 362.67) (Figure 
21 ). This is a highly relevant finding especially in the light of the fact that percentage CD3+ 
cells are decreased at diagnosis in the patient group. There is a dramatic reduction in PHA 
SI until 51-70 weeks (62.03 ± 40.63), after which there is a slight increase in this value at 71-
100 weeks (198.8 ± 161 .39). The baseline results and 51-70 week results are significantly 
different (p<0.05), as too are the control and 51-70 week results (p<0.01 ). As the percentage 
CD3+ cells increase after postcop, it is possible that this reduction in PHA SI could reflect a 
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FIGURE 21. PHA stimulation of PBMC in controls and patients over time. 
PBMC were resuspended at 1 X 106/ml in RPMI supplemented with 10% AB human serum. 
Mitogenic stimulation was assessed in response to 5. 75 X 10-3 mitogenic units/ml of PHA 
after 3 days incubation. Thereafter tritiated thymidine incorporation was measured in a beta 
counter. On the Y-axis the ratio of PHA cpm's to background cpm's (PHA SI) are given. On 
the X-axis, the normal controls are indicated first, with patients' baseline results next (at 
diagnosis and prior to the commencement of treatment). Thereafter the patients' results are 
given for postcop and at various time intervals until 71-100 weeks after the commencement 
of treatment. 
The PPD SI of controls (66.4 ± 73.3) (Figure 22) is significantly higher than the patients' 
baseline results (64.2 ± 166.2) (p<0.01). Patients' results drop dramatically at postcop (2.6 ± 
3.34) and remain low until 51-70 weeks (4.7 ± 5.4) after which there is an increase in the 
mean PPD SI at 71-100 weeks (22 ± 47.15). The difference between controls and patients at 
the following time points are significant :- postcop (p<0.001 ); 30-50 weeks (p<0.01 ); 51 -70 
weeks (p<0.01) and 71-100 weeks (p<0.05). It is interesting to note that this PPD antigen-
specific proliferation is profoundly depressed in patients at diagnosis and remains inhibited 
at all time points. This could possibly indicate a defect in either the responding cells or the 
antigen presenting cells, or both. 
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FIGURE 22. PPD stimulation of PBMC in controls and patients over time. 
PBMC were resuspended at 1 X 106/ml in RPMI supplemented with 10% AB human serum. 
Antigenic stimulation was assessed in response to 3 µg/ml of PPD after 6 days incubation. 
Thereafter tritiated thymidine incorporation was measured in a beta counter. On the Y-axis 
the ratio of PPD cpm's to background cpm's (PPD SI) are given. On the X-axis, the normal 
controls are indicated first, with patients' baseline results next (at diagnosis and prior to the 
commencement of treatment). Thereafter the patients' results are given for postcop and at 
various time intervals until 71-100 weeks after the commencement of treatment. 
The SK-SD SI for controls (71 .75 ± 104.2) is slightly higher than that of patients at baseline 
(40.3 ± 52.64) though not significantly so (Figure 23). There are no significant differences 
obtained between controls and patients at any of the different time points. The patient 
number for the measurement of SK-SD proliferation is greatly reduced at diagnosis, as 
compared to PHA or PPD proliferation, due to the fact that there was insufficient cell recovery 
in some patients. This fact alone may account for the finding that SK-SD is very similar in 
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FIGURE 23. SK-SD stimulation of PBMC in controls and patients over time. 
PBMC were resuspended at 1 X 106/ml in RPMI supplemented with 10% AB human serum. 
Antigenic stimulation was assessed in response to heat treated 250 U/ml streptokinase; 62.5 
U/ml streptodornase after 6 days incubation. Thereafter tritiated thymidine incorporation 
was measured in a beta counter. On the Y-axis the ratio of SK-SD cpm's to background 
cpm's (SK-SD SI) are given. On the X-axis, the normal controls are indicated first, with 
patients' baseline results next (at diagnosis and prior to the commencement of treatment). 
Thereafter the patients' results are given for postcop and at various time intervals until 51-70 
weeks after the commencement of treatment. 
3.2.7. ANALYIS OF THE EFFECT OF TREATMENT ON NKA AND a-lFN ENHANCED 
NKA 
NKA of patients at baseline and prior to the commencement of a-lFN treatment (26.9 ± 
19. 14) are compared with the same patients 34-4 7 weeks after the commencement of 
treatment (12.98 ± 6.28) (Figure 24-A). These patients are compared to baseline results of 
untreated patients who are subsequently treated with cyclophosphamide (16.39 ± 8.67) and 
the same patients 34-47 weeks into treatment (14.89 ± 14.29). It must be borne in mind that 
a-lFN and cyclophosphamide treatment commenced at approximately 6 weeks. NKA of 
normal controls (18.43 ± 10.25) are also indicated. The NKA of patients at 34-47 weeks 
treated with a-lFN is found to be depressed compared to baseline, although this difference is 
not statistically significant. These results confirm that of other researchers who report that 
the continued and frequent use of in vivo a-lFN treatment often causes a decline in NKA 
(Reynolds and Wiltrout, 1989; Ozer et al. , 1983; Maluish et al. , 1983). Patients treated with 
cyclophosphamide, on the other hand show very similar NKA at baseline and 34-47 weeks. 
The same patient groups as well as time points are compared as in Figure 24-A, but with a-
lFN enhanced NKA. Patients that have been treated with a-lFN have been found to have 
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severely depressed NKA boosted by cx-lFN (12.55 ± 7.28) when compared to their own 
baseline results (39.97 ± 24.97) (Figure 24-8). Using the Wilcoxon signed-ranks test for 
paired data, this difference was found to be significant with p<0.05. This is an extremely 
interesting finding and may indicate that the in vivo administration of cx-lFN has rendered the 
NK cell insensitive to further stimulation by cx-lFN in vitro. NK cells appear to be maximally 
boosted in vivo. This may imply that down-regulation of cx-lFN receptors has occurred 
resulting in a decrease of cx-lFN augmented NKA. Cyclophosphamide patients were found to 
have very similar results at both baseline (23.5 ± 10.05) and 34-47 weeks after the 
commencement of treatment (23.42 ± 19.08). Control results (26.89 ± 10.08) have also been 
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FIGURE 24-A. A comparison of NKA in controls and patients at diagnosis and 34-47 weeks 
after treatment. 
FIGURE 24-B. A comparison of cx.-lFN enhanced NKA in controls and patients at diagnosis 
and 34-47 weeks after treatment. 
NKA (A) or cx.-lFN enhanced NKA (B) of PBMC from LG-NHL patients was evaluated in a 
standard 4 hour 51 chromium release assay against K562 at diagnosis and prior to the 
commencement of treatment. cx.-lFN (1 X 104 U/ml) was incorporated into the NK assay for cx.-
lFN enhanced NKA (Figure 24-8). These same patients were then analysed 34-47 weeks 
after the commencement of treatment. On the Y-axis percentage cytotoxicity can be seen at 
an effector to target ratio of 10 to 1. On the X-axis, cx.-lFN (A-IFN) patients at diagnosis is 
shown, followed by the same patients 34-47 weeks after the commencement of cx.-lFN 
treatment. Similarly cyclophosphamide patients at diagnosis is shown, followed by the same 
patients 34-47 weeks after the commencement of cyclophosphamide treatment. The controls 
NKA (Figure 24-A) or cx.-lFN enhanced NKA (Figure 24-B) is indicated last on the X-axis. 
Blue bars are baseline results and yellow bars indicate the NKA after 34-47 weeks of 
treatment (Figure 24-A). Red bars are basel ine results and green bars indicate the NKA 
after 34-47 weeks of treatment (Figure 24-8). Standard deviation is indicated as error bars. 
Stars indicate statistically significant differences (p<0.05). 
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3.2.8. PHENOTYPIC ANALYSIS AND ITS COMPARISON TO TREATMENT RESPONSES 
A bar graph of percentage CD3+, CD4+, CDS+ and NK cells present in the peripheral blood 
of all patients compared to normal controls is shown in Figure 25. The difference between 
the percentage of circulating CD3+ in patients at diagnosis (57.25 ± 18.45) and controls 
(73.69 ± 8.91) is found to be statistically significant (p<0.01 }, as also the percentage CDS+ in 
patients at diagnosis (16.74 ± 8.99) and controls (24.18 ± 5.75 (p<0.05). Similarly the 
percentage circulating NK cells in patients at diagnosis (20.65 ± 12.08) and percentage NK 
cells in normal controls (11 .59 ± 5.77) is also significant (p<0.05). The percentage of CD4+ 
cells is also decreased in patients (36.28 ± 14.7) as compared to normal controls (43.36 ± 
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FIGURE 25. A comparison of% CD3+, CD4+, CDS+ and NK cells present in the 
peripheral blood of controls compared to all patients. 
Flow cytometric analysis of PBMC was performed enabling the determination of % CD3+, 
CD4+, CDS+ and NK cells present in the peripheral blood at diagnosis and prior to the 
commencement of treatment. On the Y-axis the percentage of cells positive for the different 
phenotype is indicated. On the X-axis, CD3, CD4, CDS and NK cells are indicated, with 
controls first, followed by patients. Stars indicate a statistically significant difference. The 
difference between % CD3+ in controls and patients is significant (p<0.01 }, as is the % CDS+ 
in patients at diagnosis (p<0.05). Similarly the percentage circulating NK cells in patients at 
diagnosis is also significant (p<0.05). Turquoise bars represent controls and magenta bars 
patients. Standard deviation is indicated as error bars. 
Figure 26 A-D is a bar graph of the above-mentioned parameters, but in this case the 
patients have been divided into the different treatment schedules of cyclophosphamide, a.-
lFN and miscellaneous patients (those not treated according to protocol}. Patients are then 
further classified as responding patients (this includes partial and complete response) and 
non-responding patients (this includes minimal response, progressive disease, 
transformation to a higher grade of NHL and relapsing patients) (Czader et al., 1996). The 
mean percentage circulating CD3+ cells in controls (7 4 ± 9) is significantly more than either 
cyclophosphamide non-responding patients (35 ± 0) (p<0.05) or miscellaneous non-
responding patients (46 ± 21) (p=0.01) (Figure 26-A). Cyclophosphamide responding 
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patients (72 ± 19), cx-lFN non-responding patients (69 ± 7) and miscellaneous responding 
patients (66 ± 4) gave comparable results. The mean percentage circulating CD4+ cells in 
controls (43 ± 7) is significantly more than in cyclophosphamide non-responding patients (21 
± 1) (p<0.05) and significantly less than miscellaneous responding patients (55 ± 4) (p=0.05) 
(Figure 26-B). Cyclophosphamide non-responding patients have an increase in percentage 
CD4+ cells (53 ± 13) and cx-lFN non-responding patients (34 ± 8) and miscellaneous non-
responding patients (27 ± 10) less when compared to normal controls, although none of 
these differences reached statistical significance. Cyclophospham,de non-responding 
patients (12 ± 1) (p<0.05) and miscellaneous responding patients (9 ± 1) (p<0.05) had 
significantly fewer percentage CD8+ cells in the peripheral blood than normal controls (24 ± 
6) (Figure 26-C). Cyclophosphamide responding patients (19 ± 10) and miscellaneous non-
responding patients ( 15 ± 11) had less percentage CD8+ cells and cx-lFN non-responding 
patients (26 ± 5) more than normal controls. Both cyclophosphamide (30 ± 15) and cx-lFN 
(30 ± 6) responding patients had significantly more percentage circulating NK cells than 
controls (12 ± 6), with p<0.05 and p<0.01 respectively (Figure 26-D). Cyclophosphamide 
non-responding patients (18 ± 4) , cx-lFN non-responding patients (17 ± 11 }, miscellaneous 
responding patients ( 18 ± 2) and miscellaneous non-responding patients ( 12 ± 9) presented 
with comparable percentages of circulating NK cells present at diagnosis. Due to the fact 
that patient numbers in these subgroups are small , it would be unwise to speculate on the 
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A comparison of% T-cell subsets and% NK cells present in the periphera 
blood at diagnosis in the different patient treatment schedules and their 
responses. 
Flow cytometric analysis of PBMC was performed enabling the determination of % CD3+ (A), 
% CD4+ (B), % CD8+ (C) and % NK cells (D) present in the peripheral blood at diagnosis 
and prior to the commencement of treatment. On the Y-axes the percentage of cells positive 
for the different phenotype is indicated. On the X-axes the controls are indicated first, 
followed by cyclophosphamide responding patients (C Res), cyclophosphamide non-
responding patients (C Non), a.-lFN responding patients (A Res), a.-lFN non-responding 
patients (A Non), miscellaneous responding patients (M Res) and miscellaneous non-
responding patients (M Non). Responding patients include both a partial and complete 
response. Non-responding patients include minimal response, progressive disease, 
transformation to a higher grade of NHL and relapsing patients. a.-lFN treated responding 
patients were only ascertained for percentage NK cells present at diagnosis due to 
insufficient cell recovery. Statistically significant differences have been indicated by stars. 
Standard deviation is shown as error bars. 
3.2.9. PHENOTYPIC TRENDS OVER TIME IN RESPONDING AND NON-RESPONDING 
PATIENTS 
A comparison was made between responding and non-responding patients over time in all 
treatment schedules for the following:- percentages CD3+, CD4+, CD8+ and NK cells 
present in the peripheral blood, the ratio of CD3+ to CD4+ cells and NKA. This was 
undertaken to ascertain whether a different trend could be detected between the different 
responses. Hernberg and co-workers (1997), found an increase in the CD4+ to CD8+ cell 
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ratio to be a good prognostic indicator and a reduction in this value a poor prognostic 
indicator in a.-lFN treated renal cell carcinoma patients. In this current study, similar trends 
were detected for all the above-mentioned parameters (data not shown), except for 
percentage NK cells present in the peripheral blood. Responding patients showed a 
dramatic reduction in percentage NK cells over time, whereas non-responding patients had a 
gradual increase in this percentage (Figure 27). Although r2 = 0.59 for responding patients 
and r2 = 0.21 for non-responding patients, this trend may be an important indicator of 
response over time, if confirmed in a larger trial. This phenomenon could be explained by 
the fact that in responding patients, the NK cells have translocated to the site of pathology, 
whereas in non-responding patients this has not taken place. Literature appears to be 
contradictory in this regard, as Trinchieri (1992), states that following in vivo activation, NK 
cells migrate to affected areas and draining lymph nodes. Reynolds and Wiltrout (1989), 
state that NK cell number in the lymph nodes is low. Warren ( 1996) on the other hand report 
that NK cells do not circulate between the peripheral blood and lymph nodes. Pross and 
Lotzova (1993), state that NK cells are seldom present as tumour-infiltrating lymphocytes. 
40 ,-----~.-----r.========::.-. 
I 
--- Non-responding I 
---- - Responding 
30 -
---- ··- . .!!! ······--- -......-----····· · ····· · · 








0 - ·- ... _ -
-10 '------~------'------'--' - --' 
0 20 40 60 
Weeks Since Diagnosis 
FIGURE 27. A comparison between% NK cells over time in responding and non-
responding patients. 
Flow cytometric analysis of PBMC was performed enabling the determination of% NK cells 
at diagnosis and prior to the commencement of treatment and this parameter was measured 
serially over time. Patients in all the different treatment schedules were included and 
responding patients were compared to non-responding patients. 95% confidence intervals 
are indicated. In the equation Y = mx + c, for responding patients, m = -0.26965 and c = 
23.435 and n = 16. For non-responding patients, m = 0.070425 and c = 16.602 and n = 11. 
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3.2.10. CYTOKINE ANALYSIS 
Only cyclophosphamide treated patients will be analysed for IL-2 levels, due to the fact that 
insufficient a-lFN treated patients were assessed for this parameter. Figure 28 is an 
indication of the amount of IL-2 present in plasma and Figure 29, the amount of IL-2 present 
in the supernatant fluid of PBMC after stimulation with the mitogen PHA (5.75 x 10-3 
mitoge_nic units/ml). Both of these parameters were measured at diagnosis and prior to the 
commencement of any treatment. Random selection of patients from each treatmer,t group 
was undertaken for IL-2 analysis. Very little IL-2 was found in the supernatant fluids and 
even less in the plasma. With such low values it is difficult to interpret any differences at al l. 
In the PHA supernatants, the mean for IL-2 levels in normal controls (4.65 ± 2.6) was similar 
to that of cyclophosphamide responding patients (6.88 ± 5.58). The cyclophosphamide non-
responding patients are found to have an increase in the mean of IL-2 levels (25.77 ± 43.34), 
but the range is too great to enable any relevant conclusions to be made. Whiteside (1994), 
discussed whether plasma or serum was more valuable for determining the amount of 
cytokine present. This author concluded that leukocytes including immune cells were 
activated during the clotting process and may release cytokines. As an alternative to 
plasma, it was recommended that cytokine analysis of supernatant fluid be performed after 
PHA stimulation of PBMC cells. In this study supernatant fluids were analysed in this way. A 
possible flaw in the method used in this study, was that the cells were not irradiated prior to 
PHA addition which would have prevented utilisation of IL-2. Alternatively, the IL-2 receptor 
could have been blocked with anti-lL-2 receptor antibody prior to the addition of PHA. If 
either of these two steps had been undertaken, more free IL-2 would possibly have been 
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FIGURE 28. Concentration of IL-2 present in the plasma of controls and 
cyclophosphamide treated patients. 
IL-2 concentrations were measured in the plasma of cyclophosphamide treated patients at 
diagnosis and prior to the commencement of treatment using a commercial 
immunoradiometric assay. IL-2 concentration is indicated as IU/ml on the Y-axis. On the X-
axis, controls are indicated first, then cyclophosphamide responding patients (respond) and 
lastly cyclophosphamide non-responding patients (relapse). 
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FIGURE 29. Concentration of IL-2 present in the supernatant of PHA treated PBMC in 
controls and cyclophosphamide treated patients. 
PBMC (3 X 106/ml/well) at diagnosis and prior to the commencement of treatment were 
cultured in 10% human AB serum in RPMI and stimulated by 5.75 X 10-3 mitogenic units/ml of 
PHA for 24 hours. Supernatant fluids were then removed and IL-2 concentrations were then 
measured using a commercial immunoradiometric assay. IL-2 levels are indicated as IU/ml 
on the Y-axis. On the X-axis, controls are indicated first, then cyclophosphamide responding 
patients (respond) and lastly cyclophosphamide non-responding patients (relapse). 
3.3.0. ANALYSIS OF PATIENTS ACCORDING TO TREATMENT SCHEDULES 
3.3.1. ANALYSIS OF CYCLOPHOSPHAMIDE TREATED PATIENTS 
Table 12 summarises the different parameters of category according to the Working 
Formulation, stage, age and sex of cyclophosphamide treated patients and their subsequent 
response. It was possible to adequately assess cyclophosphamide response in twelve 
patients. Fifty eight percent (7 patients) had a complete response and 42% (5 patients) a 
partial response following treatment (2 of which suffered a relapse). Seventeen percent of 
patients (2) who had previously demonstrated a partial response suffered a relapse. All of 
the cyclophosphamide treated patients were diagnosed as being at stage IV. Greater than 
60-70 years is also used as a poor prognostic indicator in other trials, but 57% (4) of patients 
with a complete response and 14% (1) with a partial response were between 60-70 years of 
age. One of the two patients who relapsed was 40 years of age and the other 63 years of 
age . Male gender is also used as an unfavourable prognosis. In the seven complete 
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responding patients, three were male (43%}, and four female (57%) and two of three partial 
responders was female and one male. Of the relapsing patients, one was male and one 
female. These above-mentioned factors were therefore not accurate as prognostic indicators 
in this group of patients. Table 12 indicates that absolute white cell count as well as 
absolute lymphocyte count was not a useful prognostic indicator in this group of patients, as 
two complete responding patients were found to be lymphopenic. One relapsing patient and 
one partial responder had an increase in both the leukocyte and lymphocyte count. It is 
unfortunate that the full blood count and differential count were not performed simultaneously 
with the T -cell subsets. Had all these tests been performed concurrently, absolute T cell 
numbers could be compared as well as percentages of cells. Parker and co-workers (1994), 
found that LG-NHL patients with lymphocyte counts below 1 x 109/1 prior to the 
commencement of treatment demonstrated worse survival than patients with higher counts. 
The majority of patients in the study undertaken by Parker and his co-workers, presented 
with lymphocyte counts between 1-3 x 109/1 , however patients with lymphocyte counts of 
greater than 3 x 109/1 showed similar survival. The present study identified two lymphopenic 
patients, both of whom demonstrated a complete response. This factor therefore did not 
serve as a prognostic indicator in this trial. 
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TABLE 12. ANALYSIS OF DIFFERENT PARAMETERS IN CYCLOPHOSPHAMIDE 
TREATED PATIENTS 
Response Category Stage Age Sex Absolute leukocytes Absolute lymphocytes 
Normal 4000-11000 Normal 1200-4000 
CR C IV 67 F 7530 ND 
CR B IV 52 F 8700 1044-
CR B IV 69 M 6600 746-
CR C IV 65 M 8800 2526 
CR C IV 63 F 5500 1540 
CR C IV 55 M 7900 3160 
CR C IV 59 F 4000 ND 
PR C IV 39 F 5900 1475 
PR A IV 46 M 8100 2673 
PR A IV 64 F 35640+ 25304+ 
Relapse C IV 40 F 15800+ 11534+ 
Relapse C IV 63 M 6790 2037 
+ indicates results above normal values - indicates results below normal values ND = test not done CR = complete response PR = partially response 
3.3.2. ANALYSIS OF a-lFN TREATED PATIENTS 
Table 13 summarises all patients treated with a-lFN and the different parameters of category 
according to the Working Formulation, stage, age and sex and their subsequent response. It 
was possible to adequately assess a-lFN treatment in 8 patients. Thirty-eight percent (3 
patients) showed a complete response, fifty percent (4 patients) a partial response and 
thirteen percent (1 patient) progressive disease. The patient with progressive disease 
subsequently transformed to a higher grade of NHL. Of the patients that demonstrated a 
complete response, one patient transformed to a higher grade of NHL and one patient 
relapsed and died (of their disease) after 156 weeks. Of the patients with a partial response, 
one patient subsequently relapsed and another patient had a reduction and ultimate 
discontinuation in the a-lFN treatment, due to toxic side-effects. The side effects consisted 
of severe lack of concentration. Absolute leukocyte and lymphocyte counts at diagnosis are 
also included. One a-lFN relapsing patient was found to be both leukopenic and 
lymphopenic, while the other relapsing and one partially responsive patient were 
lymphopenic. One a-lFN transforming patient was found to have lymphocytosis. All patients 
were younger than 60 years of age, except for one relapsing patient, who was 60 years old. 
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TABLE 13. ANALYSIS OF DIFFERENT PARAMETERS IN a-lFN TREATED PATIENTS 
Response Category Stage Age Sex Absolute leukocytes Absolute lymphocytes 
Normal 4000-11000 Normal 1200-4000 
CR Unclassified IV 40 F 10300 1308 
PR C Ill 46 M 6300 2186 
PR C Ill 28 F 8200 1263 
PR C IV 30 M 8600 384-
Relapse C IV 51 M 9300 856-
Relapse - T-cell IV 60 F 1400- 434-
died 
Transform B IV 57 F 8400 1344 
Transform C Ill 50 M 5630 9001+ 
+ indicates results above normal values - indicates results below normal values 
CR = complete response PR = partially response 
3.3.3. ANALYSIS OF MISCELLANEOUS TREATED PATIENTS 
Table 14 summarises all patients treated off protocol and the different parameters of 
category according to the Working Formulation, stage, age and sex and their subsequent 
response. Absolute leukocyte and lymphocyte counts at diagnosis are also included. 
TABLE ·14. ANALYSIS OF DIFFERENT PARAMETERS IN MISCELLANEOUS 
TREATED PATIENTS 
Response Category Stage Age 
CR C IV 58 
CR C I 77 
CR C I 74 
CR B I 54 
CR B IV 37 
PR C IV 40 
MR A IV 70 
MR - C IV 64 
died 
PD C IV 44 
PD B IV 60 
No change - C IV 64 
died 
Relapse Unclassified IV 70 
+ 1nd1cates results above normal values 
CR = complete response 
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3.3.4. ANALYSIS OF a-lFN TREATED PATIENTS AND THEIR RESPONSE 
Using the baseline NKA and NKA + a-lFN and expressing the in vitro a-lFN enhancement as 
percentage a-lFN stimulation (NKA/NKA + a-lFN x 100) in patients treated with a-lFN in vivo 
(Figure 30), there appeared to be an inverse correlation between in vitro and in vivo a-lFN 
response. The percentage stimulation was found to be the highest in a-lFN transforming 
then relapsing and lowest in responding patients. This finding may be useful in predicting an 
in vivo response from an in vitro a-lFN response and would disagree with Ozer and co-
workers (1983) who report that there was no correlation between clinical response and in 
vitro enhancement of NKA. 
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FIGURE 30. A comparison between the NKA, NKA + a-lFN and percentage of stimulation 
by a-lFN in patients treated with a-lFN in vivo. 
In an attempt to predict an in vivo response to a-lFN, the basel ine NKA, NKA + a-lFN and 
percentage stimulation by a-lFN (NKA/NKA + a-lFN x 100) were compared in all a-lFN 
treated patients. a-lFN responding patients are referred to as responders and are indicated 
by blue bars, a-lFN relapsing patients are referred to as relapsors and indicated by green 
bars and a-lFN transforming patients are called transformers and red bars are used. 
3.4.0. MULTIVARIATE DISCRIMINANT ANALYSIS 
A multivariate discriminant analysis software program, Statgraphics (STSC Inc., Rockville, 
MD) was used to analyse all 32 patients in all three different treatment schedules using 
response as the classification factor. For the purposes of this analysis all patients were 
either regarded as responding patients (this included complete and partial response) or non 
responding patients. Patients with progressing disease, patients transforming to a higher 
grade of NHL, relapsing patients and patients with a minimal response were all regarded as 
non responders (Czader et al., 1996). Variables for entering into the discriminant function 
were selected as follows:-A correlation matrix of the immunological parameters at diagnosis 
was generated and where variables correlated significantly only one (that made the best 
biological sense) of the set was entered into the discriminant function. If the variable added 
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"noise" as judged by a decrease in the magnitude of / then the variable was removed. A 
linear discriminant function was generated and the magnitude of the standardised 
coefficients were used to compare the relative importance of the immunological parameters. 
The best linear discriminant function with unstandardised coefficients was generated and for 
practical purposes the midpoint between the two centroids was taken as the cutt-off point for 
predicting responders and non responders. Thus by making use of the generated 
discriminant function, it is possible to predict with varying degrees of accuracy whether a 
patient will or will not respond to a particular form of treatment (Afifi and Clark, ·1990). 
3.4.1. ALL PATIENTS 
In the multivariate discriminant analysis, percentages of circulating CD3+, CD4+ and CD8+ 
were found to be predictive for treatment response when all patients were compared 
(p<0.005). Due to the fact that this is a combination of all the treatment regimens, patients 
were divided into cyclophosphamide treated patients, a-lFN treated patients and the patients 
that were treated with other forms of treatment not on the study protocol were kept in a 
separate group. 
3.4.2. CYCLOPHOSPHAMIDE TREATED PATIENTS 
In this group of patients, if the percentage of CD3+, CD4+ and CD8+ is compared in a 
multivariate discriminant analysis, the unstandardized discriminant function coefficients are 




The constant is 81 .6385. 
The formula making use of all these coefficients is derived enabling a prediction of response 
or non-response to cyclophosphamide treatment. For this formula to be significant, p must 
be< 0.05, in this case p=0.01, therefore this finding is statistically significant. 
Formula:-
-(%CD3 X-4.20901) + (%CD4 X 1.67926) + (%COB X 5.76613) + 81 .6385 = A 
If A <11.966, then the patient will respond to cyclophosphamide. 
If A> 11 .966, then the patient will not respond to cyclophosphamide. 
Twelve patients in this study were treated with cyclophosphamide, but in only five patients 
was the percentages of CD3+, CD4+ and COB+ ascertained. Although in cyclophosphamide 
treated patients, the response of all five patients in whom the above-mentioned tests were 
performed was correctly determined by the use of this formula, it is recommended that this 
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finding is confirmed in a much larger study. This formula should therefore be used with 
caution. 
3.4.3. a-lFN TREATED PATIENTS 
In this group of patients, it was found by the same multivariate discriminant analysis that the 
percentage of NK and CD3+ cells as well as the ratio of percentage CD4+ to CDS+ cells 
could be used in predicting the response or non-response of a-lFN. The p value in this case 
is <0.05. 
The formula is as follows:-
·(NK% X 0.88770) - (%CD3 X 1.13259) + (CD4:CD8 X 9.76602) + 72.0362 = 8. 
If B > 19.41607, then patients will respond to a-lFN. 
If B < 19.41607, then patients will not respond to a-lFN. 
Eight patients in this study were treated with a-lFN, of which five had the above-mentioned 
tests performed. In all these five patients, the response was correctly determined. This 
finding must be interpreted with caution, as it would need further confirmation in a much 
larger trial. 
3.5.0. COMPARISON OF CYCLOPHOSPHAMIDE AND a-lFN TREATED PATIENTS 
A Kaplan-Meier curve was generated to compare cyclophosphamide and a-lFN treated 
patients to ascertain which of the two treatments was more favourable (Figure 31 ). Time to 
treatment failure of the two different treatment regimens was compared (Matthews and 
Farewell , 1985). Treatment failure included both relapse and transformation to a higher 
grade of NHL. Although cyclophosphamide treatment appeared to be far more favourable 
than a-lFN treatment, the difference between these two treatments did not quite reach 
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Kaplan-Meier curve comparing cyclophosphamide and a-lFN treated 
patients. 
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A Kaplan-Meier curve comparing (on the X-axis) time in weeks to treatment failure and on the 
Y-axis, the percentage of non-relapsing patients. Treatment failure included both relapsing 
patients and those that transformed to a hig:1er grade of NHL. The difference between 




Due to the fact that little progress has been made in the treatment of LG-NHL and the 
ultimate prognosis for these patients has remained the same over the past decades, it is 
clear that innovative treatment approaches are necessary (Hiddemann and Unterhalt, 1994). 
A major objective of this trial was to study the ability of a-lFN to increase the duration of 
remission in LG-NHL patients. Of the patients treated with a-lFN, 38% had a complete 
response and 50% of palients a partial response, totalling 88%. Only 13% showed 
progressive disease. These response rates are very encouraging, however 25% of patients 
who had initially responded to treatment relapsed, of which 13% died and 25% transformed 
to a higher grade of NHL. A total of 50% of the patients failed this treatment (i .e. 25% 
relapsed and 25% transformed to a higher grade), although some initially responded. 
Comparing this trial and other trials in the literature, it can be seen that the responses in this 
current trial compare favourably to those in previous studies (Merigen et al. , 1978; Louie et 
al. , 1981 ; Horning, 1994-b; Ozer et al., 1983; Foon et al. , 1984; Van der Molen et al. , 1990; 
Clark et al., 1989; Ozer et al. , 1987; Chisesi et al., 1987; Smalley et al. , 1992). The trial 
conducted by Merigan and co-workers in 1978 using non-recombinant a-lFN, showed a 
partial response rate of 100%. This data was generated from a very small study consisting of 
only three patients. The only other study which displayed a comparable response rate was 
the combination trial by Chisesi and co-workers in 1987 which produced a response of 80%. 
However, attaining a response is not the difficulty in these patients, it is the maintenance of 
that response which is the major obstacle. The use of maintenance a-lFN is reported to 
improve remission duration and hence possibly survival (Rohatiner, 1991 ). This strategy of 
treating the patient with chemotherapy, followed by maintenance a-lFN is felt to maximise the 
effects of a-lFN at a time when the patient has minimal residual disease and biological 
agents would be expected to be most effective. It is also at the stage following 
immunosuppressive therapy when the immune restorative effects of a-lFN would be most 
beneficial. Although a-lFN has an established role and definite therapeutic activity in the 
management of LG-NHL patients (Crowther, 1991 ; Clemens, 1988), a-lFN therapy in this 
study did not appear to be the treatment of choice. The Kaplan-Meier curve indicates that 
cyclophosphamide treatment is more beneficial to the patient than a-lFN treatment, although 
the difference between these two groups did not attain statistical significance (p=0.06). At 
131 weeks, 83.3% of cyclophosphamide patients remained in remission, whereas only 43.3% 
of a-lFN patients were still in remission. Verification of these findings would require a larger 
study. 
As suggested by Maluish and co-workers (1983), it would be further recommended that in 
any future a-lFN trials, NKA be monitored serially in these patients. The therapy should be 
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adjusted to enable in vitro NKA to be enhanced. If a-lFN treatment is adjusted to cause NKA 
enhancement, greater clinical benefit might be demonstrated for LG-NHL patients. It should, 
however be borne in mind that one of the major difficulties in evaluating a-lFN treatment, is 
that assessment of cell functions in the peripheral blood may not accurately reflect the 
immune status of a patient. 
Ho and co-workers (1992) report a deficiency in the stimulation of a-lFN by the PBMC's of 
low and high-grade NHL patients after stimulation. a-lFN treatment in vivo might have 
overcome this defect, but in reviewing patients in this current trial treated with a-lFN and the 
duration of response, this does not appear to be the case. 
The use of the multivariate discriminant analysis in the generation of formulae to predict 
response to the various forms of treatment, was a particularly exciting and apparently novel 
finding. c.:-IFN treatment is extremely expensive and by utilising the flow cytometric analysis 
of lymphocyte subsets at diagnosis and incorporating these into the formula generated via 
the multivariate discriminant analysis {-(NK% X 0.88770) - (%CD3 X 1.13259) + (CD4:CD8 X 
9.76602) + 72.0362 = B. If B > 19.41607, then patients will respond to a-lFN. If B < 
19.41607, then patients will not respond to a-lFN}, it would be possible to identify patients 
most likely to respond to a-lFN treatment. This would prevent patients being treated with a-
lFN who would not respond clinically and would result in enormous cost-saving. It would 
also identify patients unlikely to respond to cyclophosphamide {-(%CD3 X -4.20901) + 
(%CD4 X 1.67926) + (%COB X 5. 76613) + 81 .6385 = A If A <11 .966, then the patient will 
respond to cyclophosphamide. If A > 11 .966, then the patient will not respond to 
cyclophosphamide}, enabling the clinician to institute an alternative form of treatment. This 
finding is invaluable to both patient and clinician, as appropriate therapy could be instituted 
at diagnosis, whether it be cyclophosphamide or a-lFN. It would also possibly identify 
patients who would be highly resistant to either forms of treatment. Patients who are unlikely 
to respond to either of these forms of therapy may be entered into a research treatment 
regimen without compromising the outcome of their disease, as they would not have 
responded to the available therapy. This finding needs confirmation in a larger prospective 
cross-sectional and longitudinal study. 
As a second confirmatory test to establish at diagnosis whether a patient would be likely to 
respond clinically to a-lFN, a low in vitro a-lFN augmented NKA response could be used, as 
those patients were found to respond to a-lFN in vivo. This would further increase the 
chances of detecting the appropriate treatment for all patients. This study has identified both 
a possible positive indicator (the formula generated in the multivariate discriminant analysis 
using the flow cytometric phenotypic analysis) and a negative indicator of a-lFN response (a 
high in vitro a-lFN augmented response) and. It would be highly recommended that these 
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formulae be used at the commencement of any future trial to distinguish putative responding 
or non-responding patients to either cyclophosphamide or a-lFN treatment. In a larger trial 
this would confirm whether these conclusions are valid, and if so would prevent patients 
undergoing unnecessary treatment to which they would not respond. By making use of both 
of these factors, it would increase the chances of patients being selected for appropriate 
forms of treatment and minimising the chances of patients suffering a relapse. A larger 
comparative a-lFN clinical trial would enable valid conclusions to be drawn on whether or not 
cyclophosphamide therapy is preferable to a-lFN treatment. Urba and co-workers (1988) 
recommend that for a meaningful comparison to be made in a-lFN treated patients, not only 
should a large patient sample be utilised, but lengthy follow-up time periods should be 
instituted to enable valid interpretation of resulting immune function. In any future trials with 
a-lFN in vivo therapy, the patient group in each treatment schedule should ideally be much 
larger. This would ensure that there are sufficient numbers of patients in the different 
response categories for valid conclusions to be drawn. Patients should also be evaluated 
and followed up for extensive periods of time, as years of follow-up are necessary to 
accurately assess response to treatment, due to the long natural history of LG-NHL, as well 
as the continual relapsing and remission pattern. 
The statistically significant reduction in the percentage of CD3+ and CD8+ cells and increase 
in percentage NK cells present in the peripheral blood at diagnosis needs further 
investigation. The different trends for percentage of NK cells in the peripheral blood between 
responding patients and non-responding patients also needs to be analysed further. 
Analysis of NK cell numbers present in enlarged lymph nodes could possibly clarify this 
matter, as authors differ in their opinion as to NK involvement in lymph nodes. As there is no 
correlation between patients demonstrating a reduction in the percentage of T -cell subsets 
and either leukopenia or lymphopenia, the question arises as to what comparative analyses 
of absolute numbers of these subsets would have shown. It would be highly recommended 
that absolute numbers rather than subset percentages be determined, in order to reach a 
more valid conclusion. This option is available now on newer flow cytometry instruments. 
Alternatively, it is essential to ensure that full blood counts and differential counts as well as 
phenotypic analyses are conducted simultaneously at each patient visit. 
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5. CONCLUSION 
In this current study much valuable information has been gained which has the potential to 
accurately predict patients' response to treatment at diagnosis and prior to the 
commencement of any form of therapy. Furthermore, this study has identified several pitfalls 
that should be avoided in any future such trial. It would be invaluable therefore, to formulate 
a trial based on the knowledge that has been gained from this study. Prior to the 
commencement of this study, a statistician was consulted to ascertain how many patients 
would need to be enrolled in this trial to ensure valid conclusions. This trial failed to accrue 
sufficient numbers of patients as advised by the statistician. To overcome this problem, all 
hospitals treating LG-NHL patients in close enough proximity to make a future study viable, 
would be notified of the trial and encouraged to participate, making it possible to enrol the 
maximum amount of patients possible in a multi-centre investigation. All patients would have 
the diagnosis confirmed by one pathologist who is a recognised expert in the field. At 
baseline and prior to any form of treatment being instituted, the following tests would be 
undertaken:- full blood count and differential count; percentages of CD3+, CD4+, CDS+, NK 
(dual CDS6 and CD16 markers) and B cells present in the peripheral blood; NKA; a.-lFN 
enhanced NKA. If sufficient material from the lymph node is available, lymphocyte subsets 
should also be evaluated in the lymph node. By using the formulae derived from the 
multivariate discriminant analysis, patients can be selected to receive the appropriate 
medication to which they would respond. As a further confirmatory test, the in vitro a.-lFN 
response can be used to select patients most likely to respond clinically to a.-lFN (i.e. a low in 
vitro a.-lFN augmented NKA response may be suggestive of an in vivo response to a.-lFN). 
All patients that are selected to receive in vivo a.-lFN treatment should be regularly monitored 
for NKA and treatment adjusted to ensure that no depression in NKA is observed. At three 
monthly intervals all the above-mentioned tests should be repeated for at least two years. 
Patients should be monitored for at least five to ten years, due to the long natural history of 
the disease as well as the continuous pattern of remission and relapse. Factors which 
mitigate against successful completion of such a study have been identified and include the 
lengthy duration, cost, number of patients defaulting and the need for a multi-centre study. 
These factors would need to be addressed by the funding agencies, hospital committees, 
and patient support groups. 
A major objective of a new study would be to see if conclusions drawn from retrospective 
analysis would hold true in a prospective randomised study, and to confirm whether the 
formulae derived from the multivariate discriminant analysis are valid. It would also confirm 
whether an inverse relationship exists between the in vitro a.-lFN augmented NKA response 
and the actual in vivo response obtained with a.-lFN therapy. Furthermore, such a study 
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would establish whether cyclophosphamide treatment is preferable to a.-lFN treatment in LG-
NHL patients. If dual markers for NK (CD56 and CD16) are used to determine percentage 
NK cells in the peripheral blood, it would be possible to determine whether the most lytic NK 
subset (CD56+CD16+) or least lytic subset (CD56+CD16-) is increased at diagnosis. If 
phenotypic evaluation is conducted in the lymph node, conclusions could be drawn as to 
whether or not lymphocytes have translocated from the bloodstream to the site of pathology. 
By making use of full blood count and differential counts together with the percentages of 
circulating lymphocytes, absolute cell numbers can be derived which may be nore relevant 
than percentages of lymphocytes. The findings of the current study indicate that immune 
parameters may be invaluable as predictors of response and possibly also prognosis in LG-
NHL The results strongly support conducting another clinical trial as a matter of urgency, 
due to the importance that the outcome would have for both clinician and LG-NHL patient in 
the treatment of this disease. 
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